

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp310

Request ID: cder_mpl1r_wp310

Request Description: In this report, we characterized dispensing and administration patterns of 25 New Molecular Entities (NMEs) approved from January 1, 2020, to June 30, 2020, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on August 8, 2025. We included aggregate results from all 13 data partners in this report. The study period included data from January 1, 2020, to April 30, 2025. Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals initiating any of the 25 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2020, and June 30, 2020, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Overview for Request: cder_mpl1r_wp310

Please refer to Appendices F and G for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

<u>Glossary (CIDA)</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1b</u>	Aggregated Characteristics of Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1c</u>	Aggregated Characteristics of Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1d</u>	Aggregated Characteristics of Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1e</u>	Aggregated Characteristics of Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1f</u>	Aggregated Characteristics of Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1g</u>	Aggregated Characteristics of Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1h</u>	Aggregated Characteristics of Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1i</u>	Aggregated Characteristics of Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1j</u>	Aggregated Characteristics of Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1k</u>	Aggregated Characteristics of Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1l</u>	Aggregated Characteristics of Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1m</u>	Aggregated Characteristics of Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1n</u>	Aggregated Characteristics of Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1o</u>	Aggregated Characteristics of Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1p</u>	Aggregated Characteristics of Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1q</u>	Aggregated Characteristics of Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1r</u>	Aggregated Characteristics of Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1s</u>	Aggregated Characteristics of Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1t</u>	Aggregated Characteristics of Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1u</u>	Aggregated Characteristics of Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1v</u>	Aggregated Characteristics of Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1w</u>	Aggregated Characteristics of Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 1x</u>	Aggregated Characteristics of Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table of Contents

<u>Table 1y</u>	Aggregated Characteristics of Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

Table of Contents

<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1a</u>	Patient Entry into Study by Month for Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1b</u>	Patient Entry into Study by Month for Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1c</u>	Patient Entry into Study by Month for Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1d</u>	Patient Entry into Study by Month for Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1e</u>	Patient Entry into Study by Month for Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1f</u>	Patient Entry into Study by Month for Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1g</u>	Patient Entry into Study by Month for Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1h</u>	Patient Entry into Study by Month for Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1i</u>	Patient Entry into Study by Month for Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Table of Contents

<u>Figure 1j</u>	Patient Entry into Study by Month for Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1k</u>	Patient Entry into Study by Month for Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1l</u>	Patient Entry into Study by Month for Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1m</u>	Patient Entry into Study by Month for Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1n</u>	Patient Entry into Study by Month for Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1o</u>	Patient Entry into Study by Month for Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1p</u>	Patient Entry into Study by Month for Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1q</u>	Patient Entry into Study by Month for Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1r</u>	Patient Entry into Study by Month for Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1s</u>	Patient Entry into Study by Month for Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1t</u>	Patient Entry into Study by Month for Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1u</u>	Patient Entry into Study by Month for Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1v</u>	Patient Entry into Study by Month for Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1w</u>	Patient Entry into Study by Month for Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1x</u>	Patient Entry into Study by Month for Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Figure 1y</u>	Patient Entry into Study by Month for Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date
<u>Appendix B</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
<u>Appendix E</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request
<u>Appendix F.1</u>	Specifications Defining Parameters in this Request
<u>Appendix F.2</u>	Specifications Defining Baseline Characteristics in this Request
<u>Appendix F.3</u>	Specifications Defining Utilization Parameters in this Request
<u>Appendix G</u>	Design Diagrams of Cohort Entry Requirements in this Request

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Avapritinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	664	N/A ²
Demographic Characteristics		
Age (years)	64.0	12.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	56	8.4%
41-64 years	207	31.2%
≥ 65 years	388	58.4%
Sex		
Female	360	54.2%
Male	304	45.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	49	7.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	126	19.0%
White	464	69.9%
Hispanic origin		
Yes	19	2.9%
No	475	71.5%
Unknown	170	25.6%
Year		
2020	*****	*****
2021	98	14.8%
2022	76	11.4%
2023	163	24.5%
2024	264	39.8%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	16	2.4%

Table 1a. Aggregated Characteristics of Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Avapritinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	60	9.0%
Diabetes Mellitus	122	18.4%
Heart Failure	64	9.6%
Hyperlipidemia	212	31.9%
Hypertension	281	42.3%
Depression	159	23.9%
Ischemic Heart Disease	103	15.5%
Rheumatoid Arthritis/Osteoarthritis	128	19.3%
Stroke/TIA ⁴	*****	*****
Breast Cancer	20	3.0%
Colorectal Cancer	41	6.2%
Prostate Cancer	22	3.3%
Lung Cancer	11	1.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	124	18.7%
Anemia	321	48.3%
Asthma	61	9.2%
Benign Prostatic Hyperplasia	58	8.7%
Chronic Kidney Disease	96	14.5%
COPD ⁵ and Bronchiectasis	66	9.9%
Glaucoma	49	7.4%
Osteoporosis	75	11.3%
Obesity: diagnosed or identified by weight management procedures	139	20.9%
Obesity: identified by weight management-related dispensings	17	2.6%
Overweight	56	8.4%
Smoking: diagnosed or identified by smoking cessation procedures	193	29.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	11	1.7%
Drug Abuse or Dependence	32	4.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	25	3.8%
Liver Disease Based on CCW ⁶ Definition	98	14.8%
Liver Disease Extended Definition (CCW + Additional Codes)	98	14.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.6	15.0
Mean number of emergency room encounters	0.6	1.4

Table 1a. Aggregated Characteristics of Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Avapritinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.2	11.7
Mean number of filled prescriptions	21.4	16.7
Mean number of generics dispensed	9.7	6.0
Mean number of unique drug classes dispensed	9.0	5.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Characteristics of Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Teprotumumab-Trbw		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	6,680	N/A ²
Demographic Characteristics		
Age (years)	61.5	11.0
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	629	9.4%
41-64 years	2,472	37.0%
≥ 65 years	3,502	52.4%
Sex		
Female	5,155	77.2%
Male	1,525	22.8%
Race ³		
American Indian or Alaska Native	16	0.2%
Asian	239	3.6%
Black or African American	675	10.1%
Multi-racial	81	1.2%
Native Hawaiian or Other Pacific Islander	17	0.3%
Unknown	1,579	23.6%
White	4,073	61.0%
Hispanic origin		
Yes	231	3.5%
No	4,441	66.5%
Unknown	2,008	30.1%
Year		
2020	1,085	16.2%
2021	1,857	27.8%
2022	1,312	19.6%
2023	1,334	20.0%
2024	1,053	15.8%
2025	39	0.6%
Health Characteristics		
Acute Myocardial Infarction	22	0.3%
Alzheimer's Disease	12	0.2%
Non-Alzheimer's Dementia	67	1.0%

Table 1b. Aggregated Characteristics of Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Teprotumumab-Trbw	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	460	6.9%
Diabetes Mellitus	1,010	15.1%
Heart Failure	421	6.3%
Hyperlipidemia	2,008	30.1%
Hypertension	2,382	35.7%
Depression	1,180	17.7%
Ischemic Heart Disease	723	10.8%
Rheumatoid Arthritis/Osteoarthritis	928	13.9%
Stroke/TIA ⁴	92	1.4%
Breast Cancer	219	3.3%
Colorectal Cancer	30	0.4%
Prostate Cancer	79	1.2%
Lung Cancer	27	0.4%
Endometrial Cancer	12	0.2%
Acquired Hypothyroidism	2,623	39.3%
Anemia	908	13.6%
Asthma	277	4.1%
Benign Prostatic Hyperplasia	136	2.0%
Chronic Kidney Disease	396	5.9%
COPD ⁵ and Bronchiectasis	429	6.4%
Glaucoma	1,389	20.8%
Osteoporosis	440	6.6%
Obesity: diagnosed or identified by weight management procedures	1,323	19.8%
Obesity: identified by weight management-related dispensings	191	2.9%
Overweight	720	10.8%
Smoking: diagnosed or identified by smoking cessation procedures	1,317	19.7%
Smoking: identified by smoking-related dispensings	97	1.5%
Alcohol Abuse or Dependence	106	1.6%
Drug Abuse or Dependence	191	2.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	168	2.5%
Liver Disease Based on CCW ⁶ Definition	159	2.4%
Liver Disease Extended Definition (CCW + Additional Codes)	164	2.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.4	10.9

Table 1b. Aggregated Characteristics of Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Teprotumumab-Trbw	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.8	6.7
Mean number of filled prescriptions	17.6	16.2
Mean number of generics dispensed	7.6	5.3
Mean number of unique drug classes dispensed	7.2	4.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tazemetostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	502	N/A ²
Demographic Characteristics		
Age (years)	63.4	16.5
Age		
0-17 years	21	4.2%
18-24 years	18	3.6%
25-40 years	49	9.8%
41-64 years	101	20.1%
≥ 65 years	313	62.4%
Sex		
Female	230	45.8%
Male	272	54.2%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	35	7.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	99	19.7%
White	348	69.3%
Hispanic origin		
Yes	20	4.0%
No	360	71.7%
Unknown	122	24.3%
Year		
2020	*****	*****
2021	129	25.7%
2022	111	22.1%
2023	84	16.7%
2024	93	18.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1c. Aggregated Characteristics of Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tazemetostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	52	10.4%
Diabetes Mellitus	100	19.9%
Heart Failure	81	16.1%
Hyperlipidemia	150	29.9%
Hypertension	215	42.8%
Depression	105	20.9%
Ischemic Heart Disease	106	21.1%
Rheumatoid Arthritis/Osteoarthritis	57	11.4%
Stroke/TIA ⁴	21	4.2%
Breast Cancer	15	3.0%
Colorectal Cancer	*****	*****
Prostate Cancer	17	3.4%
Lung Cancer	26	5.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	69	13.7%
Anemia	228	45.4%
Asthma	34	6.8%
Benign Prostatic Hyperplasia	36	7.2%
Chronic Kidney Disease	85	16.9%
COPD ⁵ and Bronchiectasis	66	13.1%
Glaucoma	37	7.4%
Osteoporosis	23	4.6%
Obesity: diagnosed or identified by weight management procedures	91	18.1%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	48	9.6%
Smoking: diagnosed or identified by smoking cessation procedures	124	24.7%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	13	2.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	38	7.6%
Liver Disease Based on CCW ⁶ Definition	43	8.6%
Liver Disease Extended Definition (CCW + Additional Codes)	44	8.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.1	16.2

Table 1c. Aggregated Characteristics of Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tazemetostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.8	1.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	10.8	17.8
Mean number of filled prescriptions	23.0	19.0
Mean number of generics dispensed	10.0	6.3
Mean number of unique drug classes dispensed	9.2	5.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lactitol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A ²
Demographic Characteristics		
Age (years)	-	-
Age		
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ³		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Multi-racial	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	-
2023	-	-
2024	-	-
2025	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease	-	-
Non-Alzheimer's Dementia	-	-

Table 1d. Aggregated Characteristics of Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lactitol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA ⁴	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD ⁵ and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related dispensings	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related dispensings	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Liver Disease Based on CCW ⁶ Definition	-	-
Liver Disease Extended Definition (CCW + Additional Codes)	-	-
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	-	-

Table 1d. Aggregated Characteristics of Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lactitol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 1e. Aggregated Characteristics of Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Bempedoic Acid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	64,418	N/A ²
Demographic Characteristics		
Age (years)	68.5	8.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	932	1.4%
41-64 years	18,628	28.9%
≥ 65 years	44,816	69.6%
Sex		
Female	37,906	58.8%
Male	26,512	41.2%
Race ³		
American Indian or Alaska Native	139	0.2%
Asian	1,924	3.0%
Black or African American	5,050	7.8%
Multi-racial	810	1.3%
Native Hawaiian or Other Pacific Islander	100	0.2%
Unknown	11,680	18.1%
White	44,715	69.4%
Hispanic origin		
Yes	1,486	2.3%
No	44,143	68.5%
Unknown	18,789	29.2%
Year		
2020	4,810	7.5%
2021	13,068	20.3%
2022	9,742	15.1%
2023	16,212	25.2%
2024	19,477	30.2%
2025	1,109	1.7%
Health Characteristics		
Acute Myocardial Infarction	812	1.3%
Alzheimer's Disease	369	0.6%
Non-Alzheimer's Dementia	1,119	1.7%

Table 1e. Aggregated Characteristics of Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Bempedoic Acid	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	5,549	8.6%
Diabetes Mellitus	18,934	29.4%
Heart Failure	7,630	11.8%
Hyperlipidemia	49,571	77.0%
Hypertension	39,997	62.1%
Depression	10,789	16.7%
Ischemic Heart Disease	29,887	46.4%
Rheumatoid Arthritis/Osteoarthritis	13,616	21.1%
Stroke/TIA ⁴	2,366	3.7%
Breast Cancer	1,637	2.5%
Colorectal Cancer	333	0.5%
Prostate Cancer	1,434	2.2%
Lung Cancer	375	0.6%
Endometrial Cancer	151	0.2%
Acquired Hypothyroidism	10,374	16.1%
Anemia	11,172	17.3%
Asthma	3,294	5.1%
Benign Prostatic Hyperplasia	3,154	4.9%
Chronic Kidney Disease	7,710	12.0%
COPD ⁵ and Bronchiectasis	4,835	7.5%
Glaucoma	6,410	10.0%
Osteoporosis	3,477	5.4%
Obesity: diagnosed or identified by weight management procedures	16,938	26.3%
Obesity: identified by weight management-related dispensings	4,533	7.0%
Overweight	8,467	13.1%
Smoking: diagnosed or identified by smoking cessation procedures	11,567	18.0%
Smoking: identified by smoking-related dispensings	354	0.5%
Alcohol Abuse or Dependence	877	1.4%
Drug Abuse or Dependence	1,397	2.2%
History of Cardiac Arrest	164	0.3%
History of Coronary Angioplasty or Bypass	8,690	13.5%
Liver Disease Based on CCW ⁶ Definition	2,392	3.7%
Liver Disease Extended Definition (CCW + Additional Codes)	2,469	3.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.3	11.6

Table 1e. Aggregated Characteristics of Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Bempedoic Acid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.1	6.7
Mean number of filled prescriptions	19.9	16.6
Mean number of generics dispensed	8.9	5.4
Mean number of unique drug classes dispensed	8.4	4.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Eptinezumab-jjmr		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	18,234	N/A ²
Demographic Characteristics		
Age (years)	54.4	13.1
Age		
0-17 years	37	0.2%
18-24 years	638	3.5%
25-40 years	3,097	17.0%
41-64 years	8,482	46.5%
≥ 65 years	5,980	32.8%
Sex		
Female	15,341	84.1%
Male	2,893	15.9%
Race ³		
American Indian or Alaska Native	70	0.4%
Asian	133	0.7%
Black or African American	881	4.8%
Multi-racial	289	1.6%
Native Hawaiian or Other Pacific Islander	18	0.1%
Unknown	3,733	20.5%
White	13,110	71.9%
Hispanic origin		
Yes	409	2.2%
No	12,339	67.7%
Unknown	5,486	30.1%
Year		
2020	1,425	7.8%
2021	3,832	21.0%
2022	3,497	19.2%
2023	4,517	24.8%
2024	4,750	26.1%
2025	213	1.2%
Health Characteristics		
Acute Myocardial Infarction	27	0.1%
Alzheimer's Disease	85	0.5%
Non-Alzheimer's Dementia	267	1.5%

Table 1f. Aggregated Characteristics of Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Eptinezumab-jjmr		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	539	3.0%
Diabetes Mellitus	2,353	12.9%
Heart Failure	673	3.7%
Hyperlipidemia	4,745	26.0%
Hypertension	5,347	29.3%
Depression	8,180	44.9%
Ischemic Heart Disease	1,557	8.5%
Rheumatoid Arthritis/Osteoarthritis	5,061	27.8%
Stroke/TIA ⁴	523	2.9%
Breast Cancer	347	1.9%
Colorectal Cancer	44	0.2%
Prostate Cancer	103	0.6%
Lung Cancer	54	0.3%
Endometrial Cancer	25	0.1%
Acquired Hypothyroidism	2,669	14.6%
Anemia	2,913	16.0%
Asthma	1,727	9.5%
Benign Prostatic Hyperplasia	302	1.7%
Chronic Kidney Disease	1,066	5.8%
COPD ⁵ and Bronchiectasis	870	4.8%
Glaucoma	1,073	5.9%
Osteoporosis	1,086	6.0%
Obesity: diagnosed or identified by weight management procedures	4,860	26.7%
Obesity: identified by weight management-related dispensings	1,016	5.6%
Overweight	1,813	9.9%
Smoking: diagnosed or identified by smoking cessation procedures	2,675	14.7%
Smoking: identified by smoking-related dispensings	118	0.6%
Alcohol Abuse or Dependence	243	1.3%
Drug Abuse or Dependence	1,141	6.3%
History of Cardiac Arrest	17	0.1%
History of Coronary Angioplasty or Bypass	319	1.7%
Liver Disease Based on CCW ⁶ Definition	609	3.3%
Liver Disease Extended Definition (CCW + Additional Codes)	619	3.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.4	14.4

Table 1f. Aggregated Characteristics of Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Eptinezumab-jjmr	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	2.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	9.3
Mean number of filled prescriptions	34.0	26.0
Mean number of generics dispensed	13.0	7.6
Mean number of unique drug classes dispensed	11.8	6.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1g. Aggregated Characteristics of Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Amisulpride		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	7,951	N/A ²
Demographic Characteristics		
Age (years)	58.2	13.0
Age		
0-17 years	43	0.5%
18-24 years	204	2.6%
25-40 years	1,258	15.8%
41-64 years	2,849	35.8%
≥ 65 years	3,597	45.2%
Sex		
Female	6,312	79.4%
Male	1,639	20.6%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	200	2.5%
Black or African American	443	5.6%
Multi-racial	208	2.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	2,247	28.3%
White	4,826	60.7%
Hispanic origin		
Yes	285	3.6%
No	4,293	54.0%
Unknown	3,373	42.4%
Year		
2020	*****	*****
2021	*****	*****
2022	479	6.0%
2023	1,690	21.3%
2024	5,378	67.6%
2025	283	3.6%
Health Characteristics		
Acute Myocardial Infarction	21	0.3%
Alzheimer's Disease	14	0.2%
Non-Alzheimer's Dementia	65	0.8%

Table 1g. Aggregated Characteristics of Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Amisulpride		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	419	5.3%
Diabetes Mellitus	1,236	15.5%
Heart Failure	449	5.6%
Hyperlipidemia	2,684	33.8%
Hypertension	3,033	38.1%
Depression	1,651	20.8%
Ischemic Heart Disease	1,016	12.8%
Rheumatoid Arthritis/Osteoarthritis	1,930	24.3%
Stroke/TIA ⁴	110	1.4%
Breast Cancer	1,059	13.3%
Colorectal Cancer	108	1.4%
Prostate Cancer	194	2.4%
Lung Cancer	87	1.1%
Endometrial Cancer	152	1.9%
Acquired Hypothyroidism	1,025	12.9%
Anemia	1,485	18.7%
Asthma	481	6.0%
Benign Prostatic Hyperplasia	240	3.0%
Chronic Kidney Disease	579	7.3%
COPD ⁵ and Bronchiectasis	389	4.9%
Glaucoma	501	6.3%
Osteoporosis	431	5.4%
Obesity: diagnosed or identified by weight management procedures	2,212	27.8%
Obesity: identified by weight management-related dispensings	517	6.5%
Overweight	839	10.6%
Smoking: diagnosed or identified by smoking cessation procedures	1,560	19.6%
Smoking: identified by smoking-related dispensings	29	0.4%
Alcohol Abuse or Dependence	93	1.2%
Drug Abuse or Dependence	191	2.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	273	3.4%
Liver Disease Based on CCW ⁶ Definition	480	6.0%
Liver Disease Extended Definition (CCW + Additional Codes)	484	6.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.7	13.4

Table 1g. Aggregated Characteristics of Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Amisulpride		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	7.0
Mean number of filled prescriptions	15.5	15.2
Mean number of generics dispensed	7.7	5.5
Mean number of unique drug classes dispensed	7.1	4.9

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Rimegepant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	269,018	N/A ²
Demographic Characteristics		
Age (years)	48.4	13.5
Age		
0-17 years	1,686	0.6%
18-24 years	15,447	5.7%
25-40 years	72,809	27.1%
41-64 years	134,194	49.9%
≥ 65 years	44,882	16.7%
Sex		
Female	229,890	85.5%
Male	39,128	14.5%
Race ³		
American Indian or Alaska Native	1,110	0.4%
Asian	4,015	1.5%
Black or African American	17,055	6.3%
Multi-racial	6,625	2.5%
Native Hawaiian or Other Pacific Islander	194	0.1%
Unknown	76,926	28.6%
White	163,093	60.6%
Hispanic origin		
Yes	12,149	4.5%
No	150,996	56.1%
Unknown	105,873	39.4%
Year		
2020	21,242	7.9%
2021	60,968	22.7%
2022	54,424	20.2%
2023	67,867	25.2%
2024	60,473	22.5%
2025	4,044	1.5%
Health Characteristics		
Acute Myocardial Infarction	623	0.2%
Alzheimer's Disease	803	0.3%
Non-Alzheimer's Dementia	3,400	1.3%

Table 1h. Aggregated Characteristics of Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Rimegepant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	6,295	2.3%
Diabetes Mellitus	30,646	11.4%
Heart Failure	9,885	3.7%
Hyperlipidemia	53,459	19.9%
Hypertension	63,900	23.8%
Depression	93,015	34.6%
Ischemic Heart Disease	19,053	7.1%
Rheumatoid Arthritis/Osteoarthritis	48,025	17.9%
Stroke/TIA ⁴	9,373	3.5%
Breast Cancer	3,983	1.5%
Colorectal Cancer	558	0.2%
Prostate Cancer	764	0.3%
Lung Cancer	619	0.2%
Endometrial Cancer	300	0.1%
Acquired Hypothyroidism	27,079	10.1%
Anemia	35,215	13.1%
Asthma	19,491	7.2%
Benign Prostatic Hyperplasia	2,628	1.0%
Chronic Kidney Disease	11,423	4.2%
COPD ⁵ and Bronchiectasis	12,727	4.7%
Glaucoma	10,872	4.0%
Osteoporosis	7,608	2.8%
Obesity: diagnosed or identified by weight management procedures	64,018	23.8%
Obesity: identified by weight management-related dispensings	15,963	5.9%
Overweight	23,670	8.8%
Smoking: diagnosed or identified by smoking cessation procedures	36,562	13.6%
Smoking: identified by smoking-related dispensings	2,847	1.1%
Alcohol Abuse or Dependence	4,079	1.5%
Drug Abuse or Dependence	13,012	4.8%
History of Cardiac Arrest	327	0.1%
History of Coronary Angioplasty or Bypass	4,230	1.6%
Liver Disease Based on CCW ⁶ Definition	6,725	2.5%
Liver Disease Extended Definition (CCW + Additional Codes)	6,857	2.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	12.7

Table 1h. Aggregated Characteristics of Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Rimegepant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	1.6
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.1	10.0
Mean number of filled prescriptions	26.6	23.5
Mean number of generics dispensed	10.4	6.8
Mean number of unique drug classes dispensed	9.6	6.0

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1i. Aggregated Characteristics of Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Isatuximab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	2,843	N/A ²
Demographic Characteristics		
Age (years)	71.3	8.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	568	20.0%
≥ 65 years	2,262	79.6%
Sex		
Female	1,362	47.9%
Male	1,481	52.1%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	59	2.1%
Black or African American	456	16.0%
Multi-racial	21	0.7%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	342	12.0%
White	1,945	68.4%
Hispanic origin		
Yes	95	3.3%
No	2,253	79.2%
Unknown	495	17.4%
Year		
2020	272	9.6%
2021	574	20.2%
2022	633	22.3%
2023	704	24.8%
2024	636	22.4%
2025	24	0.8%
Health Characteristics		
Acute Myocardial Infarction	51	1.8%
Alzheimer's Disease	12	0.4%
Non-Alzheimer's Dementia	76	2.7%

Table 1i. Aggregated Characteristics of Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Isatuximab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	407	14.3%
Diabetes Mellitus	659	23.2%
Heart Failure	573	20.2%
Hyperlipidemia	1,091	38.4%
Hypertension	1,678	59.0%
Depression	606	21.3%
Ischemic Heart Disease	612	21.5%
Rheumatoid Arthritis/Osteoarthritis	574	20.2%
Stroke/TIA ⁴	88	3.1%
Breast Cancer	109	3.8%
Colorectal Cancer	37	1.3%
Prostate Cancer	119	4.2%
Lung Cancer	27	0.9%
Endometrial Cancer	11	0.4%
Acquired Hypothyroidism	423	14.9%
Anemia	1,912	67.3%
Asthma	144	5.1%
Benign Prostatic Hyperplasia	241	8.5%
Chronic Kidney Disease	885	31.1%
COPD ⁵ and Bronchiectasis	277	9.7%
Glaucoma	287	10.1%
Osteoporosis	212	7.5%
Obesity: diagnosed or identified by weight management procedures	503	17.7%
Obesity: identified by weight management-related dispensings	38	1.3%
Overweight	331	11.6%
Smoking: diagnosed or identified by smoking cessation procedures	740	26.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	46	1.6%
Drug Abuse or Dependence	112	3.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	203	7.1%
Liver Disease Based on CCW ⁶ Definition	134	4.7%
Liver Disease Extended Definition (CCW + Additional Codes)	137	4.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	31.6	18.1

Table 1i. Aggregated Characteristics of Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Isatuximab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	12.0	13.6
Mean number of filled prescriptions	27.7	16.1
Mean number of generics dispensed	12.2	5.7
Mean number of unique drug classes dispensed	11.3	5.0

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1j. Aggregated Characteristics of Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Osilodrostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	539	N/A ²
Demographic Characteristics		
Age (years)	56.5	13.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	81	15.0%
41-64 years	221	41.0%
≥ 65 years	214	39.7%
Sex		
Female	413	76.6%
Male	126	23.4%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	35	6.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	115	21.3%
White	372	69.0%
Hispanic origin		
Yes	22	4.1%
No	365	67.7%
Unknown	152	28.2%
Year		
2020	*****	*****
2021	108	20.0%
2022	99	18.4%
2023	117	21.7%
2024	152	28.2%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1j. Aggregated Characteristics of Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Osilodrostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	40	7.4%
Diabetes Mellitus	282	52.3%
Heart Failure	75	13.9%
Hyperlipidemia	249	46.2%
Hypertension	324	60.1%
Depression	145	26.9%
Ischemic Heart Disease	102	18.9%
Rheumatoid Arthritis/Osteoarthritis	72	13.4%
Stroke/TIA ⁴	18	3.3%
Breast Cancer	12	2.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	203	37.7%
Anemia	140	26.0%
Asthma	26	4.8%
Benign Prostatic Hyperplasia	20	3.7%
Chronic Kidney Disease	104	19.3%
COPD ⁵ and Bronchiectasis	35	6.5%
Glaucoma	56	10.4%
Osteoporosis	62	11.5%
Obesity: diagnosed or identified by weight management procedures	226	41.9%
Obesity: identified by weight management-related dispensings	95	17.6%
Overweight	51	9.5%
Smoking: diagnosed or identified by smoking cessation procedures	97	18.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	18	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	37	6.9%
Liver Disease Based on CCW ⁶ Definition	57	10.6%
Liver Disease Extended Definition (CCW + Additional Codes)	57	10.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.5	14.8

Table 1j. Aggregated Characteristics of Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Osilodrostat		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.1	11.9
Mean number of filled prescriptions	28.0	19.5
Mean number of generics dispensed	11.5	6.2
Mean number of unique drug classes dispensed	10.4	5.3

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Characteristics of Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ozanimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	3,587	N/A ²
Demographic Characteristics		
Age (years)	47.8	12.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	1,000	27.9%
41-64 years	1,933	53.9%
≥ 65 years	467	13.0%
Sex		
Female	2,281	63.6%
Male	1,306	36.4%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	74	2.1%
Black or African American	277	7.7%
Multi-racial	105	2.9%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,232	34.3%
White	1,888	52.6%
Hispanic origin		
Yes	128	3.6%
No	1,744	48.6%
Unknown	1,715	47.8%
Year		
2020	152	4.2%
2021	722	20.1%
2022	686	19.1%
2023	1,145	31.9%
2024	835	23.3%
2025	47	1.3%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	31	0.9%

Table 1k. Aggregated Characteristics of Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ozanimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	48	1.3%
Diabetes Mellitus	249	6.9%
Heart Failure	52	1.4%
Hyperlipidemia	529	14.7%
Hypertension	649	18.1%
Depression	791	22.1%
Ischemic Heart Disease	139	3.9%
Rheumatoid Arthritis/Osteoarthritis	314	8.8%
Stroke/TIA ⁴	37	1.0%
Breast Cancer	42	1.2%
Colorectal Cancer	*****	*****
Prostate Cancer	15	0.4%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	200	5.6%
Anemia	603	16.8%
Asthma	113	3.2%
Benign Prostatic Hyperplasia	44	1.2%
Chronic Kidney Disease	75	2.1%
COPD ⁵ and Bronchiectasis	85	2.4%
Glaucoma	175	4.9%
Osteoporosis	96	2.7%
Obesity: diagnosed or identified by weight management procedures	623	17.4%
Obesity: identified by weight management-related dispensings	84	2.3%
Overweight	300	8.4%
Smoking: diagnosed or identified by smoking cessation procedures	466	13.0%
Smoking: identified by smoking-related dispensings	25	0.7%
Alcohol Abuse or Dependence	37	1.0%
Drug Abuse or Dependence	91	2.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	18	0.5%
Liver Disease Based on CCW ⁶ Definition	69	1.9%
Liver Disease Extended Definition (CCW + Additional Codes)	69	1.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.1	9.4

Table 1k. Aggregated Characteristics of Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ozanimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.7	9.4
Mean number of filled prescriptions	16.3	15.8
Mean number of generics dispensed	6.8	5.1
Mean number of unique drug classes dispensed	6.4	4.7

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11. Aggregated Characteristics of Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selumetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	944	N/A ²
Demographic Characteristics		
Age (years)	20.7	12.5
Age		
0-17 years	565	59.9%
18-24 years	138	14.6%
25-40 years	124	13.1%
41-64 years	98	10.4%
≥ 65 years	19	2.0%
Sex		
Female	462	48.9%
Male	482	51.1%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	29	3.1%
Black or African American	100	10.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	379	40.1%
White	407	43.1%
Hispanic origin		
Yes	133	14.1%
No	535	56.7%
Unknown	276	29.2%
Year		
2020	350	37.1%
2021	352	37.3%
2022	77	8.2%
2023	88	9.3%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 11. Aggregated Characteristics of Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selumetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	13	1.4%
Heart Failure	19	2.0%
Hyperlipidemia	41	4.3%
Hypertension	86	9.1%
Depression	128	13.6%
Ischemic Heart Disease	12	1.3%
Rheumatoid Arthritis/Osteoarthritis	15	1.6%
Stroke/TIA ⁴	13	1.4%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	25	2.6%
Anemia	81	8.6%
Asthma	47	5.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	14	1.5%
Glaucoma	30	3.2%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	60	6.4%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	20	2.1%
Smoking: diagnosed or identified by smoking cessation procedures	42	4.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	20	2.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	12.8

Table 1I. Aggregated Characteristics of Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selumetinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.4	1.7
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	10.5	25.7
Mean number of filled prescriptions	13.5	22.1
Mean number of generics dispensed	5.1	5.1
Mean number of unique drug classes dispensed	4.8	4.7

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1m. Aggregated Characteristics of Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tucatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	3,007	N/A ²
Demographic Characteristics		
Age (years)	58.4	11.7
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	1,667	55.4%
≥ 65 years	1,023	34.0%
Sex		
Female	2,863	95.2%
Male	144	4.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	165	5.5%
Black or African American	428	14.2%
Multi-racial	36	1.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	760	25.3%
White	1,591	52.9%
Hispanic origin		
Yes	195	6.5%
No	2,039	67.8%
Unknown	773	25.7%
Year		
2020	733	24.4%
2021	898	29.9%
2022	450	15.0%
2023	476	15.8%
2024	429	14.3%
2025	21	0.7%
Health Characteristics		
Acute Myocardial Infarction	12	0.4%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	41	1.4%

Table 1m. Aggregated Characteristics of Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tucatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	86	2.9%
Diabetes Mellitus	421	14.0%
Heart Failure	455	15.1%
Hyperlipidemia	560	18.6%
Hypertension	968	32.2%
Depression	672	22.3%
Ischemic Heart Disease	220	7.3%
Rheumatoid Arthritis/Osteoarthritis	275	9.1%
Stroke/TIA ⁴	181	6.0%
Breast Cancer	2,801	93.1%
Colorectal Cancer	174	5.8%
Prostate Cancer	*****	*****
Lung Cancer	106	3.5%
Endometrial Cancer	20	0.7%
Acquired Hypothyroidism	313	10.4%
Anemia	1,109	36.9%
Asthma	168	5.6%
Benign Prostatic Hyperplasia	15	0.5%
Chronic Kidney Disease	171	5.7%
COPD ⁵ and Bronchiectasis	150	5.0%
Glaucoma	103	3.4%
Osteoporosis	137	4.6%
Obesity: diagnosed or identified by weight management procedures	433	14.4%
Obesity: identified by weight management-related dispensings	40	1.3%
Overweight	191	6.4%
Smoking: diagnosed or identified by smoking cessation procedures	613	20.4%
Smoking: identified by smoking-related dispensings	23	0.8%
Alcohol Abuse or Dependence	40	1.3%
Drug Abuse or Dependence	106	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	28	0.9%
Liver Disease Based on CCW ⁶ Definition	382	12.7%
Liver Disease Extended Definition (CCW + Additional Codes)	383	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	27.1	13.4

Table 1m. Aggregated Characteristics of Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Tucatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.5	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	10.0	15.3
Mean number of filled prescriptions	21.6	16.8
Mean number of generics dispensed	9.5	5.6
Mean number of unique drug classes dispensed	8.8	5.0

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1n. Aggregated Characteristics of Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pemigatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	551	N/A ²
Demographic Characteristics		
Age (years)	64.1	10.0
Age		
0-17 years	*****	*****
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	190	34.5%
≥ 65 years	326	59.2%
Sex		
Female	324	58.8%
Male	227	41.2%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	18	3.3%
Black or African American	57	10.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	103	18.7%
White	362	65.7%
Hispanic origin		
Yes	15	2.7%
No	408	74.0%
Unknown	128	23.2%
Year		
2020	115	20.9%
2021	161	29.2%
2022	120	21.8%
2023	78	14.2%
2024	*****	*****
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1n. Aggregated Characteristics of Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pemigatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	40	7.3%
Diabetes Mellitus	167	30.3%
Heart Failure	56	10.2%
Hyperlipidemia	213	38.7%
Hypertension	289	52.5%
Depression	112	20.3%
Ischemic Heart Disease	113	20.5%
Rheumatoid Arthritis/Osteoarthritis	86	15.6%
Stroke/TIA ⁴	17	3.1%
Breast Cancer	35	6.4%
Colorectal Cancer	32	5.8%
Prostate Cancer	20	3.6%
Lung Cancer	29	5.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	92	16.7%
Anemia	321	58.3%
Asthma	40	7.3%
Benign Prostatic Hyperplasia	33	6.0%
Chronic Kidney Disease	86	15.6%
COPD ⁵ and Bronchiectasis	54	9.8%
Glaucoma	50	9.1%
Osteoporosis	18	3.3%
Obesity: diagnosed or identified by weight management procedures	117	21.2%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	48	8.7%
Smoking: diagnosed or identified by smoking cessation procedures	172	31.2%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	24	4.4%
Drug Abuse or Dependence	23	4.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	36	6.5%
Liver Disease Based on CCW ⁶ Definition	261	47.4%
Liver Disease Extended Definition (CCW + Additional Codes)	261	47.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	30.9	15.1

Table 1n. Aggregated Characteristics of Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Pemigatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	11.5	14.0
Mean number of filled prescriptions	25.3	18.6
Mean number of generics dispensed	11.4	6.3
Mean number of unique drug classes dispensed	10.3	5.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Sacituzumab Govitecan-hziy		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	9,669	N/A ²
Demographic Characteristics		
Age (years)	65.6	10.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	3,216	33.3%
≥ 65 years	6,017	62.2%
Sex		
Female	8,395	86.8%
Male	1,274	13.2%
Race ³		
American Indian or Alaska Native	24	0.2%
Asian	247	2.6%
Black or African American	1,277	13.2%
Multi-racial	50	0.5%
Native Hawaiian or Other Pacific Islander	11	0.1%
Unknown	1,676	17.3%
White	6,384	66.0%
Hispanic origin		
Yes	272	2.8%
No	7,236	74.8%
Unknown	2,161	22.3%
Year		
2020	515	5.3%
2021	1,860	19.2%
2022	1,926	19.9%
2023	2,879	29.8%
2024	2,405	24.9%
2025	84	0.9%
Health Characteristics		
Acute Myocardial Infarction	82	0.8%
Alzheimer's Disease	13	0.1%
Non-Alzheimer's Dementia	115	1.2%

Table 1o. Aggregated Characteristics of Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Sacituzumab Govitecan-hziy		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	630	6.5%
Diabetes Mellitus	1,949	20.2%
Heart Failure	1,183	12.2%
Hyperlipidemia	2,997	31.0%
Hypertension	4,216	43.6%
Depression	2,286	23.6%
Ischemic Heart Disease	1,413	14.6%
Rheumatoid Arthritis/Osteoarthritis	1,305	13.5%
Stroke/TIA ⁴	270	2.8%
Breast Cancer	7,992	82.7%
Colorectal Cancer	135	1.4%
Prostate Cancer	257	2.7%
Lung Cancer	521	5.4%
Endometrial Cancer	81	0.8%
Acquired Hypothyroidism	1,779	18.4%
Anemia	5,077	52.5%
Asthma	518	5.4%
Benign Prostatic Hyperplasia	214	2.2%
Chronic Kidney Disease	1,453	15.0%
COPD ⁵ and Bronchiectasis	795	8.2%
Glaucoma	647	6.7%
Osteoporosis	610	6.3%
Obesity: diagnosed or identified by weight management procedures	1,584	16.4%
Obesity: identified by weight management-related dispensings	111	1.1%
Overweight	871	9.0%
Smoking: diagnosed or identified by smoking cessation procedures	2,689	27.8%
Smoking: identified by smoking-related dispensings	33	0.3%
Alcohol Abuse or Dependence	132	1.4%
Drug Abuse or Dependence	352	3.6%
History of Cardiac Arrest	18	0.2%
History of Coronary Angioplasty or Bypass	303	3.1%
Liver Disease Based on CCW ⁶ Definition	1,461	15.1%
Liver Disease Extended Definition (CCW + Additional Codes)	1,482	15.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	33.3	14.8

Table 1o. Aggregated Characteristics of Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Patient Characteristics	Sacituzumab Govitecan-hziy	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	9.5	11.2
Mean number of filled prescriptions	22.2	16.1
Mean number of generics dispensed	10.5	5.8
Mean number of unique drug classes dispensed	9.6	5.1

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Opicapone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,543	N/A ²
Demographic Characteristics		
Age (years)	72.8	8.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	632	13.9%
≥ 65 years	3,896	85.8%
Sex		
Female	1,749	38.5%
Male	2,794	61.5%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	201	4.4%
Black or African American	130	2.9%
Multi-racial	24	0.5%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	564	12.4%
White	3,603	79.3%
Hispanic origin		
Yes	110	2.4%
No	3,582	78.8%
Unknown	851	18.7%
Year		
2020	344	7.6%
2021	1,351	29.7%
2022	1,154	25.4%
2023	1,000	22.0%
2024	673	14.8%
2025	21	0.5%
Health Characteristics		
Acute Myocardial Infarction	28	0.6%
Alzheimer's Disease	91	2.0%
Non-Alzheimer's Dementia	677	14.9%

Table 1p. Aggregated Characteristics of Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Opicapone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	396	8.7%
Diabetes Mellitus	740	16.3%
Heart Failure	374	8.2%
Hyperlipidemia	1,648	36.3%
Hypertension	1,958	43.1%
Depression	1,408	31.0%
Ischemic Heart Disease	892	19.6%
Rheumatoid Arthritis/Osteoarthritis	957	21.1%
Stroke/TIA ⁴	178	3.9%
Breast Cancer	98	2.2%
Colorectal Cancer	28	0.6%
Prostate Cancer	180	4.0%
Lung Cancer	26	0.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	493	10.9%
Anemia	941	20.7%
Asthma	126	2.8%
Benign Prostatic Hyperplasia	566	12.5%
Chronic Kidney Disease	371	8.2%
COPD ⁵ and Bronchiectasis	196	4.3%
Glaucoma	460	10.1%
Osteoporosis	300	6.6%
Obesity: diagnosed or identified by weight management procedures	506	11.1%
Obesity: identified by weight management-related dispensings	57	1.3%
Overweight	432	9.5%
Smoking: diagnosed or identified by smoking cessation procedures	570	12.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	43	0.9%
Drug Abuse or Dependence	85	1.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	245	5.4%
Liver Disease Based on CCW ⁶ Definition	71	1.6%
Liver Disease Extended Definition (CCW + Additional Codes)	72	1.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	14.6

Table 1p. Aggregated Characteristics of Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Opicapone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	7.6	15.1
Mean number of filled prescriptions	26.0	20.0
Mean number of generics dispensed	9.5	5.0
Mean number of unique drug classes dispensed	9.0	4.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1q. Aggregated Characteristics of Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Capmatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,700	N/A ²
Demographic Characteristics		
Age (years)	74.9	9.0
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,446	85.1%
Sex		
Female	952	56.0%
Male	748	44.0%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	99	5.8%
Black or African American	134	7.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	227	13.4%
White	1,226	72.1%
Hispanic origin		
Yes	36	2.1%
No	1,325	77.9%
Unknown	339	19.9%
Year		
2020	253	14.9%
2021	381	22.4%
2022	327	19.2%
2023	375	22.1%
2024	350	20.6%
2025	14	0.8%
Health Characteristics		
Acute Myocardial Infarction	30	1.8%
Alzheimer's Disease	18	1.1%
Non-Alzheimer's Dementia	88	5.2%

Table 1q. Aggregated Characteristics of Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Capmatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	275	16.2%
Diabetes Mellitus	361	21.2%
Heart Failure	268	15.8%
Hyperlipidemia	866	50.9%
Hypertension	1,044	61.4%
Depression	327	19.2%
Ischemic Heart Disease	513	30.2%
Rheumatoid Arthritis/Osteoarthritis	359	21.1%
Stroke/TIA ⁴	151	8.9%
Breast Cancer	117	6.9%
Colorectal Cancer	36	2.1%
Prostate Cancer	99	5.8%
Lung Cancer	1,666	98.0%
Endometrial Cancer	15	0.9%
Acquired Hypothyroidism	312	18.4%
Anemia	727	42.8%
Asthma	104	6.1%
Benign Prostatic Hyperplasia	177	10.4%
Chronic Kidney Disease	284	16.7%
COPD ⁵ and Bronchiectasis	442	26.0%
Glaucoma	190	11.2%
Osteoporosis	133	7.8%
Obesity: diagnosed or identified by weight management procedures	220	12.9%
Obesity: identified by weight management-related dispensings	19	1.1%
Overweight	169	9.9%
Smoking: diagnosed or identified by smoking cessation procedures	872	51.3%
Smoking: identified by smoking-related dispensings	18	1.1%
Alcohol Abuse or Dependence	36	2.1%
Drug Abuse or Dependence	59	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	152	8.9%
Liver Disease Based on CCW ⁶ Definition	201	11.8%
Liver Disease Extended Definition (CCW + Additional Codes)	202	11.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.6	13.4

Table 1q. Aggregated Characteristics of Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Capmatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.1	12.9
Mean number of filled prescriptions	22.0	15.5
Mean number of generics dispensed	10.6	5.5
Mean number of unique drug classes dispensed	9.7	4.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1r. Aggregated Characteristics of Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selpercatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	924	N/A ²
Demographic Characteristics		
Age (years)	64.1	12.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	67	7.3%
41-64 years	295	31.9%
≥ 65 years	541	58.5%
Sex		
Female	464	50.2%
Male	460	49.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	57	6.2%
Black or African American	68	7.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	239	25.9%
White	546	59.1%
Hispanic origin		
Yes	40	4.3%
No	605	65.5%
Unknown	279	30.2%
Year		
2020	156	16.9%
2021	214	23.2%
2022	*****	*****
2023	198	21.4%
2024	210	22.7%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	11	1.2%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	24	2.6%

Table 1r. Aggregated Characteristics of Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selpercatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	80	8.7%
Diabetes Mellitus	175	18.9%
Heart Failure	84	9.1%
Hyperlipidemia	330	35.7%
Hypertension	470	50.9%
Depression	175	18.9%
Ischemic Heart Disease	155	16.8%
Rheumatoid Arthritis/Osteoarthritis	118	12.8%
Stroke/TIA ⁴	47	5.1%
Breast Cancer	40	4.3%
Colorectal Cancer	29	3.1%
Prostate Cancer	37	4.0%
Lung Cancer	559	60.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	299	32.4%
Anemia	275	29.8%
Asthma	63	6.8%
Benign Prostatic Hyperplasia	66	7.1%
Chronic Kidney Disease	115	12.4%
COPD ⁵ and Bronchiectasis	122	13.2%
Glaucoma	63	6.8%
Osteoporosis	50	5.4%
Obesity: diagnosed or identified by weight management procedures	134	14.5%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	80	8.7%
Smoking: diagnosed or identified by smoking cessation procedures	268	29.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	18	1.9%
Drug Abuse or Dependence	31	3.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	37	4.0%
Liver Disease Based on CCW ⁶ Definition	119	12.9%
Liver Disease Extended Definition (CCW + Additional Codes)	121	13.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.8	13.5

Table 1r. Aggregated Characteristics of Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Selpercatinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.5	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.6	10.8
Mean number of filled prescriptions	19.1	14.0
Mean number of generics dispensed	9.1	5.7
Mean number of unique drug classes dispensed	8.4	4.9

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1s. Aggregated Characteristics of Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ripretinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	616	N/A ²
Demographic Characteristics		
Age (years)	67.7	10.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	198	32.1%
≥ 65 years	396	64.3%
Sex		
Female	291	47.2%
Male	325	52.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	43	7.0%
Black or African American	89	14.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	123	20.0%
White	347	56.3%
Hispanic origin		
Yes	38	6.2%
No	440	71.4%
Unknown	138	22.4%
Year		
2020	136	22.1%
2021	151	24.5%
2022	111	18.0%
2023	*****	*****
2024	105	17.0%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	16	2.6%

Table 1s. Aggregated Characteristics of Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ripretinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	64	10.4%
Diabetes Mellitus	123	20.0%
Heart Failure	108	17.5%
Hyperlipidemia	211	34.3%
Hypertension	382	62.0%
Depression	103	16.7%
Ischemic Heart Disease	130	21.1%
Rheumatoid Arthritis/Osteoarthritis	71	11.5%
Stroke/TIA ⁴	20	3.2%
Breast Cancer	12	1.9%
Colorectal Cancer	163	26.5%
Prostate Cancer	31	5.0%
Lung Cancer	12	1.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	130	21.1%
Anemia	328	53.2%
Asthma	24	3.9%
Benign Prostatic Hyperplasia	44	7.1%
Chronic Kidney Disease	125	20.3%
COPD ⁵ and Bronchiectasis	58	9.4%
Glaucoma	63	10.2%
Osteoporosis	33	5.4%
Obesity: diagnosed or identified by weight management procedures	104	16.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	62	10.1%
Smoking: diagnosed or identified by smoking cessation procedures	161	26.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	22	3.6%
Drug Abuse or Dependence	26	4.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	30	4.9%
Liver Disease Based on CCW ⁶ Definition	143	23.2%
Liver Disease Extended Definition (CCW + Additional Codes)	143	23.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.7	12.6

Table 1s. Aggregated Characteristics of Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Ripretinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.5	1.0
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	9.4	16.9
Mean number of filled prescriptions	24.5	18.8
Mean number of generics dispensed	10.4	5.5
Mean number of unique drug classes dispensed	9.6	4.8

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Characteristics of Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fluoroestradiol F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,791	N/A ²
Demographic Characteristics		
Age (years)	69.0	10.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	445	24.8%
≥ 65 years	1,304	72.8%
Sex		
Female	1,715	95.8%
Male	76	4.2%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	51	2.8%
Black or African American	112	6.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	247	13.8%
White	1,357	75.8%
Hispanic origin		
Yes	50	2.8%
No	1,296	72.4%
Unknown	445	24.8%
Year		
2020	0	0.0%
2021	61	3.4%
2022	373	20.8%
2023	650	36.3%
2024	671	37.5%
2025	36	2.0%
Health Characteristics		
Acute Myocardial Infarction	11	0.6%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	36	2.0%

Table 1t. Aggregated Characteristics of Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fluoroestradiol F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	121	6.8%
Diabetes Mellitus	318	17.8%
Heart Failure	155	8.7%
Hyperlipidemia	648	36.2%
Hypertension	764	42.7%
Depression	385	21.5%
Ischemic Heart Disease	239	13.3%
Rheumatoid Arthritis/Osteoarthritis	336	18.8%
Stroke/TIA ⁴	46	2.6%
Breast Cancer	1,650	92.1%
Colorectal Cancer	42	2.3%
Prostate Cancer	20	1.1%
Lung Cancer	59	3.3%
Endometrial Cancer	22	1.2%
Acquired Hypothyroidism	293	16.4%
Anemia	506	28.3%
Asthma	101	5.6%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	212	11.8%
COPD ⁵ and Bronchiectasis	134	7.5%
Glaucoma	161	9.0%
Osteoporosis	175	9.8%
Obesity: diagnosed or identified by weight management procedures	375	20.9%
Obesity: identified by weight management-related dispensings	49	2.7%
Overweight	159	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	384	21.4%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	32	1.8%
Drug Abuse or Dependence	48	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	30	1.7%
Liver Disease Based on CCW ⁶ Definition	148	8.3%
Liver Disease Extended Definition (CCW + Additional Codes)	150	8.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.5	12.8

Table 1t. Aggregated Characteristics of Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Fluoroestradiol F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.0	8.3
Mean number of filled prescriptions	16.3	13.2
Mean number of generics dispensed	8.1	5.2
Mean number of unique drug classes dispensed	7.6	4.7

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1u. Aggregated Characteristics of Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Artesunate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A ²
Demographic Characteristics		
Age (years)	58.4	14.0
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2020	0	0.0%
2021	*****	*****
2022	*****	*****
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1u. Aggregated Characteristics of Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Artesunate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ⁴	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	26.9	9.2

Table 1u. Aggregated Characteristics of Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Artesunate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	1.0	0.4
Mean number of inpatient hospital encounters	0.1	0.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	9.9	0.7
Mean number of filled prescriptions	13.1	5.2
Mean number of generics dispensed	7.0	1.5
Mean number of unique drug classes dispensed	6.7	1.5

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1v. Aggregated Characteristics of Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Flortaucipir F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A ²
Demographic Characteristics		
Age (years)	74.4	8.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2020	0	0.0%
2021	0	0.0%
2022	0	0.0%
2023	*****	*****
2024	*****	*****
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1v. Aggregated Characteristics of Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Flortaucipir F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	35.2	15.4

Table 1v. Aggregated Characteristics of Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Flortaucipir F18		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.1	8.5
Mean number of filled prescriptions	15.8	11.4
Mean number of generics dispensed	7.1	4.0
Mean number of unique drug classes dispensed	6.8	3.6

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Characteristics of Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Inebilizumab-cdon		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	471	N/A ²
Demographic Characteristics		
Age (years)	55.9	14.0
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	88	18.7%
41-64 years	187	39.7%
≥ 65 years	184	39.1%
Sex		
Female	404	85.8%
Male	67	14.2%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	22	4.7%
Black or African American	150	31.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	120	25.5%
White	166	35.2%
Hispanic origin		
Yes	33	7.0%
No	303	64.3%
Unknown	135	28.7%
Year		
2020	*****	*****
2021	*****	*****
2022	118	25.1%
2023	135	28.7%
2024	120	25.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	11	2.3%

Table 1w. Aggregated Characteristics of Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Inebilizumab-cdon		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	17	3.6%
Diabetes Mellitus	83	17.6%
Heart Failure	31	6.6%
Hyperlipidemia	136	28.9%
Hypertension	187	39.7%
Depression	141	29.9%
Ischemic Heart Disease	32	6.8%
Rheumatoid Arthritis/Osteoarthritis	111	23.6%
Stroke/TIA ⁴	24	5.1%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	65	13.8%
Anemia	140	29.7%
Asthma	33	7.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	33	7.0%
COPD ⁵ and Bronchiectasis	27	5.7%
Glaucoma	46	9.8%
Osteoporosis	28	5.9%
Obesity: diagnosed or identified by weight management procedures	123	26.1%
Obesity: identified by weight management-related dispensings	18	3.8%
Overweight	44	9.3%
Smoking: diagnosed or identified by smoking cessation procedures	87	18.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	26	5.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	17	3.6%
Liver Disease Extended Definition (CCW + Additional Codes)	17	3.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.6	13.7

Table 1w. Aggregated Characteristics of Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Inebilizumab-cdon		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	0.5	0.8
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	10.5	19.4
Mean number of filled prescriptions	21.7	20.5
Mean number of generics dispensed	9.3	6.3
Mean number of unique drug classes dispensed	8.7	5.7

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1x. Aggregated Characteristics of Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lurbinectedin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	7,968	N/A ²
Demographic Characteristics		
Age (years)	69.5	7.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	1,856	23.3%
≥ 65 years	6,074	76.2%
Sex		
Female	3,988	50.1%
Male	3,980	49.9%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	87	1.1%
Black or African American	505	6.3%
Multi-racial	34	0.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	856	10.7%
White	6,449	80.9%
Hispanic origin		
Yes	74	0.9%
No	6,409	80.4%
Unknown	1,485	18.6%
Year		
2020	143	1.8%
2021	2,476	31.1%
2022	1,746	21.9%
2023	1,939	24.3%
2024	1,617	20.3%
2025	47	0.6%
Health Characteristics		
Acute Myocardial Infarction	102	1.3%
Alzheimer's Disease	21	0.3%
Non-Alzheimer's Dementia	197	2.5%

Table 1x. Aggregated Characteristics of Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lurbinectedin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,020	12.8%
Diabetes Mellitus	2,002	25.1%
Heart Failure	1,104	13.9%
Hyperlipidemia	3,583	45.0%
Hypertension	4,655	58.4%
Depression	1,943	24.4%
Ischemic Heart Disease	2,535	31.8%
Rheumatoid Arthritis/Osteoarthritis	1,294	16.2%
Stroke/TIA ⁴	390	4.9%
Breast Cancer	452	5.7%
Colorectal Cancer	218	2.7%
Prostate Cancer	499	6.3%
Lung Cancer	7,334	92.0%
Endometrial Cancer	47	0.6%
Acquired Hypothyroidism	1,521	19.1%
Anemia	4,628	58.1%
Asthma	320	4.0%
Benign Prostatic Hyperplasia	690	8.7%
Chronic Kidney Disease	1,045	13.1%
COPD ⁵ and Bronchiectasis	3,745	47.0%
Glaucoma	438	5.5%
Osteoporosis	344	4.3%
Obesity: diagnosed or identified by weight management procedures	1,359	17.1%
Obesity: identified by weight management-related dispensings	106	1.3%
Overweight	873	11.0%
Smoking: diagnosed or identified by smoking cessation procedures	5,993	75.2%
Smoking: identified by smoking-related dispensings	194	2.4%
Alcohol Abuse or Dependence	307	3.9%
Drug Abuse or Dependence	457	5.7%
History of Cardiac Arrest	28	0.4%
History of Coronary Angioplasty or Bypass	805	10.1%
Liver Disease Based on CCW ⁶ Definition	1,601	20.1%
Liver Disease Extended Definition (CCW + Additional Codes)	1,615	20.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	36.7	14.1

Table 1x. Aggregated Characteristics of Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Lurbinectedin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	9.6	12.0
Mean number of filled prescriptions	26.4	18.3
Mean number of generics dispensed	11.9	6.2
Mean number of unique drug classes dispensed	10.9	5.4

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1y. Aggregated Characteristics of Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Triheptanoin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	182	N/A ²
Demographic Characteristics		
Age (years)	17.8	12.3
Age		
0-17 years	119	65.4%
18-24 years	24	13.2%
25-40 years	20	11.0%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	91	50.0%
Male	91	50.0%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	14	7.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	63	34.6%
White	93	51.1%
Hispanic origin		
Yes	12	6.6%
No	109	59.9%
Unknown	61	33.5%
Year		
2020	54	29.7%
2021	71	39.0%
2022	20	11.0%
2023	19	10.4%
2024	18	9.9%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1y. Aggregated Characteristics of Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Triheptanoin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	26	14.3%
Hyperlipidemia	*****	*****
Hypertension	17	9.3%
Depression	20	11.0%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	13	7.1%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	19	10.4%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	13	7.1%
Liver Disease Extended Definition (CCW + Additional Codes)	13	7.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.8	26.2

Table 1y. Aggregated Characteristics of Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

Triheptanoin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.4	1.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	22.1	41.9
Mean number of filled prescriptions	12.4	19.1
Mean number of generics dispensed	4.4	5.6
Mean number of unique drug classes dispensed	4.2	5.0

¹Value represents standard deviation where n % follows the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Avapritinib</i>	4,805	4,778	99.4%	*****	*****	*****	*****	0	0.0%
<i>Teprotumumab-Trbw</i>	44,583	44,566	100.0%	*****	*****	*****	*****	*****	*****
<i>Tazemetostat</i>	3,196	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	356,216	232,945	65.4%	9,838	2.8%	113,332	31.8%	101	0.0%
<i>Eptinezumab-jjmr</i>	72,178	67,846	94.0%	*****	*****	4,070	5.6%	*****	*****
<i>Amisulpride</i>	8,170	8,170	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rimegepant</i>	1,481,756	1,404,765	94.8%	64,539	4.4%	12,300	0.8%	152	0.0%
<i>Isatuximab</i>	39,682	39,504	99.6%	*****	*****	*****	*****	0	0.0%
<i>Osilodrostat</i>	5,007	4,699	93.8%	*****	*****	160	3.2%	*****	*****
<i>Ozanimod</i>	34,362	32,168	93.6%	783	2.3%	1,388	4.0%	23	0.1%
<i>Selumetinib</i>	7,896	6,573	83.2%	1,304	16.5%	*****	*****	*****	*****
<i>Tucatinib</i>	19,217	18,179	94.6%	1,023	5.3%	*****	*****	*****	*****
<i>Pemigatinib</i>	4,456	4,437	99.6%	*****	*****	*****	*****	0	0.0%
<i>Sacituzumab Govitecan-hziy</i>	106,585	106,585	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Opicapone</i>	33,733	27,263	80.8%	*****	*****	5,830	17.3%	*****	*****
<i>Capmatinib</i>	10,790	10,629	98.5%	145	1.3%	*****	*****	*****	*****
<i>Selpercatinib</i>	9,172	8,829	96.3%	305	3.3%	*****	*****	*****	*****
<i>Ripretinib</i>	4,192	4,064	96.9%	113	2.7%	*****	*****	*****	*****
<i>Fluoroestradiol F18</i>	2,216	2,216	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Artesunate</i>	14	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Inebilizumab-cdon</i>	1,497	1,388	92.7%	*****	*****	*****	*****	79	5.3%
<i>Lurbinectedin</i>	35,503	35,503	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Triheptanoin</i>	1,901	1,859	97.8%	*****	*****	*****	*****	0	0.0%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	4,805	1	30	30	30	90	28.7	5.7
<i>Teprotumumab-Trbw</i>	44,583	1	1	1	1	210	2.9	6.0
<i>Tazemetostat</i>	3,196	1	30	30	30	78	29.1	4.1
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	356,216	1	30	30	90	210	48.6	28.4
<i>Eptinezumab-jjmr</i>	72,178	1	1	1	1	180	6.3	20.1
<i>Amisulpride</i>	8,170	1	1	1	1	1	1.0	0.0
<i>Rimegepant</i>	1,481,756	1	16	30	30	382	24.3	10.9
<i>Isatuximab</i>	39,682	1	1	1	1	84	1.5	4.5
<i>Osilodrostat</i>	5,007	1	28	30	30	140	30.1	12.6
<i>Ozanimod</i>	34,362	1	30	30	30	300	31.5	13.1
<i>Selumetinib</i>	7,896	1	30	30	30	120	33.6	12.5
<i>Tucatinib</i>	19,217	1	30	30	30	300	30.3	8.3
<i>Pemigatinib</i>	4,456	1	21	21	21	63	19.7	4.5
<i>Sacituzumab Govitecan-hziy</i>	106,585	1	1	1	1	28	1.1	1.3
<i>Opicapone</i>	33,733	1	30	30	30	150	39.0	23.9
<i>Capmatinib</i>	10,790	1	28	28	28	112	27.3	5.2
<i>Selpercatinib</i>	9,172	1	30	30	30	180	29.4	9.4
<i>Ripretinib</i>	4,192	1	30	30	30	300	29.9	7.0
<i>Fluoroestradiol F18</i>	2,216	1	1	1	1	1	1.0	0.0
<i>Artesunate</i>	14	1	1	1	1	42	3.9	11.0
<i>Flortaucipir F18</i>	*****	1	1	1	1	1	1.0	0.0
<i>Inebilizumab-cdon</i>	1,497	1	1	1	1	180	12.1	39.4
<i>Lurbinectedin</i>	35,503	1	1	1	1	21	1.2	1.8
<i>Triheptanoin</i>	1,901	1	29	30	30	90	28.2	5.8

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Avapritinib	4,805	4,778	100.0%	*****	*****	*****	*****	0	NaN
Female	2,745	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,060	*****	*****	*****	*****	0	0.0%	0	NaN
Teprotumumab-Trbw	44,583	44,566	100.0%	*****	*****	*****	*****	*****	*****
Female	34,286	*****	*****	*****	*****	*****	*****	*****	*****
Male	10,297	*****	*****	*****	*****	*****	*****	0	0.0%
Tazemetostat	3,196	*****	*****	*****	*****	*****	*****	0	NaN
Female	1,479	*****	*****	*****	*****	0	0.0%	0	NaN
Male	1,717	*****	*****	*****	*****	*****	*****	0	NaN
Lactitol	0	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-
Bempedoic Acid	356,216	232,945	100.0%	9,838	100.0%	113,332	100.0%	101	100.0%
Female	204,799	134,972	57.9%	5,677	57.7%	64,091	56.6%	59	58.4%
Male	151,417	97,973	42.1%	4,161	42.3%	49,241	43.4%	42	41.6%
Eptinezumab-jjmr	72,178	67,846	100.0%	*****	*****	4,070	100.0%	*****	*****
Female	61,283	57,657	85.0%	*****	*****	3,406	83.7%	*****	*****
Male	10,895	10,189	15.0%	*****	*****	664	16.3%	*****	*****
Amisulpride	8,170	8,170	100.0%	0	NaN	0	NaN	0	NaN
Female	6,504	6,504	79.6%	0	NaN	0	NaN	0	NaN
Male	1,666	1,666	20.4%	0	NaN	0	NaN	0	NaN
Rimegepant	1,481,756	1,404,765	100.0%	64,539	100.0%	12,300	100.0%	152	100.0%
Female	1,285,206	1,219,551	86.8%	55,055	85.3%	10,463	85.1%	137	90.1%
Male	196,550	185,214	13.2%	9,484	14.7%	1,837	14.9%	15	9.9%
Isatuximab	39,682	39,504	100.0%	*****	*****	*****	*****	0	NaN
Female	18,010	17,900	45.3%	110	62.1%	0	0.0%	0	NaN
Male	21,672	21,604	54.7%	*****	*****	*****	*****	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Osilodrostat	5,007	4,699	100.0%	*****	*****	160	100.0%	*****	*****
Female	3,772	3,525	75.0%	*****	*****	131	81.9%	*****	*****
Male	1,235	1,174	25.0%	32	21.8%	29	18.1%	0	0.0%
Ozanimod	34,362	32,168	100.0%	783	100.0%	1,388	100.0%	23	100.0%
Female	22,458	21,029	65.4%	507	64.8%	911	65.6%	11	47.8%
Male	11,904	11,139	34.6%	276	35.2%	477	34.4%	12	52.2%
Selumetinib	7,896	6,573	100.0%	1,304	100.0%	*****	*****	*****	*****
Female	3,707	3,072	46.7%	*****	*****	*****	*****	0	0.0%
Male	4,189	3,501	53.3%	*****	*****	*****	*****	*****	*****
Tucatinib	19,217	18,179	100.0%	1,023	100.0%	*****	*****	*****	*****
Female	18,575	17,564	96.6%	996	97.4%	*****	*****	*****	*****
Male	642	615	3.4%	27	2.6%	0	0.0%	0	0.0%
Pemigatinib	4,456	4,437	100.0%	*****	*****	*****	*****	0	NaN
Female	2,770	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,686	*****	*****	0	0.0%	*****	*****	0	NaN
Sacituzumab Govitecan-hziy	106,585	106,585	100.0%	0	NaN	0	NaN	0	NaN
Female	94,970	94,970	89.1%	0	NaN	0	NaN	0	NaN
Male	11,615	11,615	10.9%	0	NaN	0	NaN	0	NaN
Opicapone	33,733	27,263	100.0%	*****	*****	5,830	100.0%	*****	*****
Female	11,901	9,808	36.0%	*****	*****	1,879	32.2%	*****	*****
Male	21,832	17,455	64.0%	*****	*****	3,951	67.8%	*****	*****
Capmatinib	10,790	10,629	100.0%	145	100.0%	*****	*****	*****	*****
Female	6,307	6,232	58.6%	*****	*****	*****	*****	*****	*****
Male	4,483	4,397	41.4%	*****	*****	*****	*****	*****	*****
Selpercatinib	9,172	8,829	100.0%	305	100.0%	*****	*****	*****	*****
Female	4,501	4,316	48.9%	*****	*****	*****	*****	0	0.0%
Male	4,671	4,513	51.1%	*****	*****	*****	*****	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Ripretinib	4,192	4,064	100.0%	113	100.0%	*****	*****	*****	*****
Female	1,918	1,842	45.3%	*****	*****	*****	*****	*****	*****
Male	2,274	2,222	54.7%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol F18	2,216	2,216	100.0%	0	NaN	0	NaN	0	NaN
Female	2,134	2,134	96.3%	0	NaN	0	NaN	0	NaN
Male	82	82	3.7%	0	NaN	0	NaN	0	NaN
Artesunate	14	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	1,497	1,388	100.0%	*****	*****	*****	*****	79	100.0%
Female	1,276	*****	*****	*****	*****	*****	*****	61	77.2%
Male	221	*****	*****	*****	*****	*****	*****	18	22.8%
Lurbinectedin	35,503	35,503	100.0%	0	NaN	0	NaN	0	NaN
Female	18,546	18,546	52.2%	0	NaN	0	NaN	0	NaN
Male	16,957	16,957	47.8%	0	NaN	0	NaN	0	NaN
Triheptanoin	1,901	1,859	100.0%	*****	*****	*****	*****	0	NaN
Female	893	868	46.7%	*****	*****	*****	*****	0	NaN
Male	1,008	991	53.3%	*****	*****	*****	*****	0	NaN

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	4,805	1	30	30	30	90	28.7	5.7
Female	2,745	1	30	30	30	90	28.9	6.0
Male	2,060	1	30	30	30	60	28.4	5.4
Teprotumumab-Trbw	44,583	1	1	1	1	210	2.9	6.0
Female	34,286	1	1	1	1	210	2.8	5.9
Male	10,297	1	1	1	1	84	3.1	6.4
Tazemetostat	3,196	1	30	30	30	78	29.1	4.1
Female	1,479	1	30	30	30	40	29.1	3.9
Male	1,717	1	30	30	30	78	29.1	4.4
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	356,216	1	30	30	90	210	48.6	28.4
Female	204,799	1	30	30	90	210	48.3	28.3
Male	151,417	1	30	30	90	180	49.0	28.5
Eptinezumab-jjmr	72,178	1	1	1	1	180	6.3	20.1
Female	61,283	1	1	1	1	180	6.3	20.0
Male	10,895	1	1	1	1	112	6.7	20.9
Amisulpride	8,170	1	1	1	1	1	1.0	0.0
Female	6,504	1	1	1	1	1	1.0	0.0
Male	1,666	1	1	1	1	1	1.0	0.0
Rimegepant	1,481,756	1	16	30	30	382	24.3	10.9
Female	1,285,206	1	16	30	30	382	24.3	10.8
Male	196,550	1	16	30	30	150	24.4	11.0
Isatuximab	39,682	1	1	1	1	84	1.5	4.5
Female	18,010	1	1	1	1	58	1.6	4.9
Male	21,672	1	1	1	1	84	1.5	4.1

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Osilodrostat	5,007	1	28	30	30	140	30.1	12.6
Female	3,772	1	28	30	30	140	30.3	13.1
Male	1,235	1	30	30	30	90	29.8	11.0
Ozanimod	34,362	1	30	30	30	300	31.5	13.1
Female	22,458	1	30	30	30	300	31.5	13.0
Male	11,904	1	30	30	30	180	31.4	13.2
Selumetinib	7,896	1	30	30	30	120	33.6	12.5
Female	3,707	1	30	30	30	90	33.6	12.4
Male	4,189	1	30	30	30	120	33.6	12.6
Tucatinib	19,217	1	30	30	30	300	30.3	8.3
Female	18,575	1	30	30	30	300	30.3	8.3
Male	642	1	30	30	30	60	29.7	7.8
Pemigatinib	4,456	1	21	21	21	63	19.7	4.5
Female	2,770	1	21	21	21	63	19.9	4.4
Male	1,686	1	17	21	21	63	19.4	4.6
Sacituzumab Govitecan-hziy	106,585	1	1	1	1	28	1.1	1.3
Female	94,970	1	1	1	1	28	1.1	1.4
Male	11,615	1	1	1	1	21	1.0	0.9
Opicapone	33,733	1	30	30	30	150	39.0	23.9
Female	11,901	1	30	30	30	120	37.9	23.3
Male	21,832	1	30	30	30	150	39.6	24.2
Capmatinib	10,790	1	28	28	28	112	27.3	5.2
Female	6,307	1	28	28	28	93	27.1	5.0
Male	4,483	1	28	28	28	112	27.5	5.5
Selpercatinib	9,172	1	30	30	30	180	29.4	9.4
Female	4,501	1	30	30	30	90	29.3	8.3
Male	4,671	1	30	30	30	180	29.6	10.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ripretinib	4,192	1	30	30	30	300	29.9	7.0
Female	1,918	1	30	30	30	300	30.3	8.9
Male	2,274	1	30	30	30	90	29.6	4.9
Fluoroestradiol F18	2,216	1	1	1	1	1	1.0	0.0
Female	2,134	1	1	1	1	1	1.0	0.0
Male	82	1	1	1	1	1	1.0	0.0
Artesunate	14	1	1	1	1	42	3.9	11.0
Female	*****	1	1	1	1	42	4.7	12.4
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	1,497	1	1	1	1	180	12.1	39.4
Female	1,276	1	1	1	1	180	10.9	37.3
Male	221	1	1	1	1	180	18.6	49.5
Lurbinectedin	35,503	1	1	1	1	21	1.2	1.8
Female	18,546	1	1	1	1	21	1.2	2.1
Male	16,957	1	1	1	1	21	1.1	1.5
Triheptanoin	1,901	1	29	30	30	90	28.2	5.8
Female	893	1	28	30	30	90	27.8	5.9
Male	1,008	1	30	30	30	90	28.5	5.8

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Avapritinib	4,805	4,778	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	19	19	0.4%	0	0.0%	0	0.0%	0	NaN
18-24 years	42	42	0.9%	0	0.0%	0	0.0%	0	NaN
25-40 years	434	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,806	1,789	37.4%	17	73.9%	0	0.0%	0	NaN
≥ 65 years	2,504	*****	*****	*****	*****	*****	*****	0	NaN
Teprotumumab-Trbw	44,583	44,566	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	24	24	0.1%	0	0.0%	0	0.0%	0	0.0%
18-24 years	435	435	1.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	3,756	3,756	8.4%	0	0.0%	0	0.0%	0	0.0%
41-64 years	16,222	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	24,146	*****	*****	*****	*****	*****	*****	0	0.0%
Tazemetostat	3,196	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	105	*****	*****	0	0.0%	*****	*****	0	NaN
18-24 years	106	106	3.3%	0	0.0%	0	0.0%	0	NaN
25-40 years	307	307	9.6%	0	0.0%	0	0.0%	0	NaN
41-64 years	667	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	2,011	*****	*****	*****	*****	0	0.0%	0	NaN
Lactitol	0	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-
Bempedoic Acid	356,216	232,945	100.0%	9,838	100.0%	113,332	100.0%	101	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	5,001	3,853	1.7%	*****	*****	*****	*****	0	0.0%
41-64 years	108,350	76,196	32.7%	2,266	23.0%	29,863	26.4%	25	24.8%
≥ 65 years	242,708	152,802	65.6%	7,487	76.1%	82,343	72.7%	76	75.2%
Eptinezumab-jjmr	72,178	67,846	100.0%	*****	*****	4,070	100.0%	*****	*****
0-17 years	144	144	0.2%	0	0.0%	0	0.0%	0	0.0%
18-24 years	2,160	2,088	3.1%	*****	*****	*****	*****	0	0.0%
25-40 years	11,381	10,744	15.8%	53	20.8%	*****	*****	*****	*****
41-64 years	33,225	30,799	45.4%	*****	*****	2,278	56.0%	*****	*****
≥ 65 years	25,268	24,071	35.5%	*****	*****	1,142	28.1%	*****	*****
Amisulpride	8,170	8,170	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	43	43	0.5%	0	NaN	0	NaN	0	NaN
18-24 years	206	206	2.5%	0	NaN	0	NaN	0	NaN
25-40 years	1,302	1,302	15.9%	0	NaN	0	NaN	0	NaN
41-64 years	2,948	2,948	36.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,671	3,671	44.9%	0	NaN	0	NaN	0	NaN
Rimegepant	1,481,756	1,404,765	100.0%	64,539	100.0%	12,300	100.0%	152	100.0%
0-17 years	7,504	7,021	0.5%	407	0.6%	76	0.6%	0	0.0%
18-24 years	67,283	64,583	4.6%	2,330	3.6%	*****	*****	*****	*****
25-40 years	391,503	376,124	26.8%	13,406	20.8%	*****	*****	*****	*****
41-64 years	808,706	768,336	54.7%	33,997	52.7%	6,273	51.0%	100	65.8%
≥ 65 years	206,760	188,701	13.4%	14,399	22.3%	3,630	29.5%	30	19.7%
Isatuximab	39,682	39,504	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	21	21	0.1%	0	0.0%	0	0.0%	0	NaN
25-40 years	92	92	0.2%	0	0.0%	0	0.0%	0	NaN
41-64 years	7,339	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	32,230	*****	*****	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Osilodrostat	5,007	4,699	100.0%	*****	*****	160	100.0%	*****	*****
0-17 years	27	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	241	241	5.1%	0	0.0%	0	0.0%	0	0.0%
25-40 years	761	699	14.9%	33	22.4%	29	18.1%	0	0.0%
41-64 years	2,011	1,896	40.3%	68	46.3%	47	29.4%	0	0.0%
≥ 65 years	1,967	*****	*****	*****	*****	84	52.5%	*****	*****
Ozanimod	34,362	32,168	100.0%	783	100.0%	1,388	100.0%	23	100.0%
0-17 years	68	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	1,563	*****	*****	*****	*****	41	3.0%	*****	*****
25-40 years	9,167	8,687	27.0%	*****	*****	273	19.7%	*****	*****
41-64 years	19,590	18,401	57.2%	*****	*****	745	53.7%	*****	*****
≥ 65 years	3,974	3,528	11.0%	*****	*****	329	23.7%	*****	*****
Selumetinib	7,896	6,573	100.0%	1,304	100.0%	*****	*****	*****	*****
0-17 years	4,866	4,047	61.6%	*****	*****	*****	*****	*****	*****
18-24 years	1,130	917	14.0%	*****	*****	*****	*****	0	0.0%
25-40 years	1,118	989	15.0%	*****	*****	*****	*****	0	0.0%
41-64 years	690	*****	*****	148	11.3%	*****	*****	0	0.0%
≥ 65 years	92	*****	*****	*****	*****	0	0.0%	0	0.0%
Tucatinib	19,217	18,179	100.0%	1,023	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	11,088	10,495	57.7%	*****	*****	*****	*****	0	0.0%
≥ 65 years	6,193	5,829	32.1%	*****	*****	*****	*****	*****	*****
Pemigatinib	4,456	4,437	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,617	1,617	36.4%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	2,597	2,579	58.1%	*****	*****	*****	*****	0	NaN
Sacituzumab Govitecan-hziy	106,585	106,585	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	19	19	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	4,062	4,062	3.8%	0	NaN	0	NaN	0	NaN
41-64 years	33,785	33,785	31.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	68,719	68,719	64.5%	0	NaN	0	NaN	0	NaN
Opicapone	33,733	27,263	100.0%	*****	*****	5,830	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	5,031	4,146	15.2%	*****	*****	790	13.6%	*****	*****
≥ 65 years	28,562	22,995	84.3%	*****	*****	5,022	86.1%	*****	*****
Capmatinib	10,790	10,629	100.0%	145	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	24	24	0.2%	0	0.0%	0	0.0%	0	0.0%
41-64 years	1,398	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	9,368	*****	*****	*****	*****	*****	*****	*****	*****
Selpercatinib	9,172	8,829	100.0%	305	100.0%	*****	*****	*****	*****
0-17 years	67	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	107	107	1.2%	0	0.0%	0	0.0%	0	0.0%
25-40 years	598	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	3,234	3,130	35.5%	*****	*****	*****	*****	*****	*****
≥ 65 years	5,166	4,944	56.0%	189	62.0%	*****	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Ripretinib	4,192	4,064	100.0%	113	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	1,352	1,317	32.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	2,653	2,568	63.2%	*****	*****	*****	*****	0	0.0%
Fluoroestradiol F18	2,216	2,216	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	540	540	24.4%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,630	1,630	73.6%	0	NaN	0	NaN	0	NaN
Artesunate	14	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	1,497	1,388	100.0%	*****	*****	*****	*****	79	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	244	230	16.6%	*****	*****	*****	*****	*****	*****
41-64 years	628	582	41.9%	*****	*****	*****	*****	*****	*****
≥ 65 years	596	547	39.4%	*****	*****	*****	*****	35	44.3%
Lurbinectedin	35,503	35,503	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	92	92	0.3%	0	NaN	0	NaN	0	NaN
41-64 years	7,874	7,874	22.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	27,525	27,525	77.5%	0	NaN	0	NaN	0	NaN
Triheptanoin	1,901	1,859	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	1,316	1,278	68.7%	*****	*****	*****	*****	0	NaN
18-24 years	206	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	99	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	79	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	201	*****	*****	0	0.0%	*****	*****	0	NaN

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	4,805	1	30	30	30	90	28.7	5.7
0-17 years	19	1	21	30	30	30	24.9	8.2
18-24 years	42	12	30	30	30	30	27.7	5.6
25-40 years	434	1	30	30	30	60	27.1	6.7
41-64 years	1,806	1	30	30	30	60	29.0	5.5
≥ 65 years	2,504	1	30	30	30	90	28.8	5.7
Teprotumumab-Trbw	44,583	1	1	1	1	210	2.9	6.0
0-17 years	24	1	1	1	21	21	8.3	9.7
18-24 years	435	1	1	1	1	21	2.1	4.5
25-40 years	3,756	1	1	1	1	21	1.8	3.9
41-64 years	16,222	1	1	1	1	210	2.5	5.5
≥ 65 years	24,146	1	1	1	1	84	3.4	6.6
Tazemetostat	3,196	1	30	30	30	78	29.1	4.1
0-17 years	105	7	30	30	30	78	29.4	6.3
18-24 years	106	14	30	30	30	30	28.1	5.0
25-40 years	307	4	30	30	30	30	28.8	4.4
41-64 years	667	1	30	30	30	40	28.8	4.3
≥ 65 years	2,011	1	30	30	30	60	29.3	3.8
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	356,216	1	30	30	90	210	48.6	28.4
0-17 years	*****	1	16	30	60	90	37.8	37.4
18-24 years	*****	1	30	30	90	90	51.4	29.7
25-40 years	5,001	1	30	30	30	90	41.9	25.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	108,350	1	30	30	90	180	45.9	27.3
≥ 65 years	242,708	1	30	30	90	210	49.9	28.8
Eptinezumab-jjmr	72,178	1	1	1	1	180	6.3	20.1
0-17 years	144	1	1	1	1	17	1.1	1.3
18-24 years	2,160	1	1	1	1	90	4.0	14.9
25-40 years	11,381	1	1	1	1	91	5.9	19.3
41-64 years	33,225	1	1	1	1	180	7.5	22.1
≥ 65 years	25,268	1	1	1	1	91	5.2	18.1
Amisulpride	8,170	1	1	1	1	1	1.0	0.0
0-17 years	43	1	1	1	1	1	1.0	0.0
18-24 years	206	1	1	1	1	1	1.0	0.0
25-40 years	1,302	1	1	1	1	1	1.0	0.0
41-64 years	2,948	1	1	1	1	1	1.0	0.0
≥ 65 years	3,671	1	1	1	1	1	1.0	0.0
Rimegepant	1,481,756	1	16	30	30	382	24.3	10.9
0-17 years	7,504	1	16	30	30	90	24.3	11.4
18-24 years	67,283	1	16	30	30	277	24.4	10.3
25-40 years	391,503	1	16	30	30	330	24.0	10.3
41-64 years	808,706	1	16	30	30	382	24.3	10.8
≥ 65 years	206,760	1	16	30	30	365	24.9	12.3
Isatuximab	39,682	1	1	1	1	84	1.5	4.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	21	1	1	1	1	1	1.0	0.0
25-40 years	92	1	1	1	1	1	1.0	0.0
41-64 years	7,339	1	1	1	1	56	1.2	3.1
≥ 65 years	32,230	1	1	1	1	84	1.6	4.8
Osilodrostat	5,007	1	28	30	30	140	30.1	12.6
0-17 years	27	11	26	26	30	46	27.5	5.4

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	241	2	30	30	30	30	29.2	3.5
25-40 years	761	1	30	30	30	90	31.5	13.7
41-64 years	2,011	1	30	30	30	90	29.8	11.4
≥ 65 years	1,967	1	26	30	30	140	30.1	14.1
Ozanimod	34,362	1	30	30	30	300	31.5	13.1
0-17 years	68	9	30	30	30	60	29.9	4.6
18-24 years	1,563	1	30	30	30	97	30.6	11.0
25-40 years	9,167	1	30	30	30	180	30.7	11.7
41-64 years	19,590	1	30	30	30	300	31.3	12.8
≥ 65 years	3,974	1	30	30	30	127	34.1	17.4
Selumetinib	7,896	1	30	30	30	120	33.6	12.5
0-17 years	4,866	1	30	30	30	120	33.5	12.5
18-24 years	1,130	1	30	30	30	90	34.4	13.0
25-40 years	1,118	1	30	30	30	90	32.1	10.7
41-64 years	690	1	30	30	30	90	35.4	14.0
≥ 65 years	92	8	30	30	30	60	31.8	9.6
Tucatinib	19,217	1	30	30	30	300	30.3	8.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	25	30	30	30	30	29.4	1.7
25-40 years	*****	1	30	30	30	300	29.8	10.0
41-64 years	11,088	1	30	30	30	90	30.3	8.1
≥ 65 years	6,193	1	30	30	30	120	30.5	8.0
Pemigatinib	4,456	1	21	21	21	63	19.7	4.5
0-17 years	*****	14	14	14	14	14	14.0	0.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	14	21	21	42	17.9	4.7
41-64 years	1,617	1	14	21	21	30	19.0	4.1
≥ 65 years	2,597	1	21	21	21	63	20.4	4.6

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sacituzumab Govitecan-hziy	106,585	1	1	1	1	28	1.1	1.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	19	1	1	1	1	1	1.0	0.0
25-40 years	4,062	1	1	1	1	21	1.1	1.5
41-64 years	33,785	1	1	1	1	28	1.1	1.6
≥ 65 years	68,719	1	1	1	1	28	1.1	1.2
Opicapone	33,733	1	30	30	30	150	39.0	23.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	90	90	50.0	34.6
25-40 years	*****	5	30	30	30	90	35.7	20.2
41-64 years	5,031	1	30	30	30	120	37.9	23.1
≥ 65 years	28,562	1	30	30	30	150	39.2	24.1
Capmatinib	10,790	1	28	28	28	112	27.3	5.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	24	11	22	28	28	30	24.5	6.1
41-64 years	1,398	1	28	28	28	84	26.6	5.1
≥ 65 years	9,368	1	28	28	28	112	27.4	5.3
Selpercatinib	9,172	1	30	30	30	180	29.4	9.4
0-17 years	67	11	28	30	30	60	28.9	11.5
18-24 years	107	1	30	30	30	30	27.5	6.1
25-40 years	598	1	27	30	30	80	26.6	7.9
41-64 years	3,234	1	30	30	30	99	28.2	8.4
≥ 65 years	5,166	1	30	30	30	180	30.6	10.0
Ripretinib	4,192	1	30	30	30	300	29.9	7.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	5	30	30	30	45	29.5	5.6

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	1,352	1	30	30	30	300	30.1	9.4
≥ 65 years	2,653	1	30	30	30	90	29.9	5.5
Fluoroestradiol F18	2,216	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	540	1	1	1	1	1	1.0	0.0
≥ 65 years	1,630	1	1	1	1	1	1.0	0.0
Artesunate	14	1	1	1	1	42	3.9	11.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	22	42	11.3	20.5
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	1,497	1	1	1	1	180	12.1	39.4
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	244	1	1	1	1	180	8.8	32.4
41-64 years	628	1	1	1	1	180	12.4	40.7
≥ 65 years	596	1	1	1	1	180	13.6	41.5
Lurbinectedin	35,503	1	1	1	1	21	1.2	1.8
0-17 years	*****	1	1	1	1	1	1.0	NaN

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	92	1	1	1	1	1	1.0	0.0
41-64 years	7,874	1	1	1	1	21	1.3	2.3
≥ 65 years	27,525	1	1	1	1	21	1.1	1.7
Triheptanoin	1,901	1	29	30	30	90	28.2	5.8
0-17 years	1,316	1	29	30	30	90	27.9	6.0
18-24 years	206	3	28	30	30	33	27.9	4.1
25-40 years	99	2	29	30	30	33	28.0	5.3
41-64 years	79	2	30	30	30	90	30.3	7.6
≥ 65 years	201	4	30	30	30	90	29.6	5.4

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Avapritinib</i>	664	110	16.6%	147	22.1%	307	46.2%	70	10.5%	30	4.5%
<i>Teprotumumab-Trbw</i>	6,680	6,035	90.3%	*****	*****	488	7.3%	*****	*****	0	0.0%
<i>Tazemetostat</i>	502	106	21.1%	130	25.9%	204	40.6%	43	8.6%	19	3.8%
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	64,418	11,006	17.1%	15,975	24.8%	21,784	33.8%	9,529	14.8%	6,124	9.5%
<i>Eptinezumab-ijmr</i>	18,234	16,762	91.9%	458	2.5%	690	3.8%	226	1.2%	98	0.5%
<i>Amisulpride</i>	7,951	7,951	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rimegepant</i>	269,018	89,666	33.3%	73,040	27.2%	82,052	30.5%	19,684	7.3%	4,576	1.7%
<i>Isatuximab</i>	2,843	2,457	86.4%	317	11.2%	46	1.6%	*****	*****	*****	*****
<i>Osilodrostat</i>	539	75	13.9%	111	20.6%	212	39.3%	87	16.1%	54	10.0%
<i>Ozanimod</i>	3,587	391	10.9%	619	17.3%	1,495	41.7%	748	20.9%	334	9.3%
<i>Selumetinib</i>	944	105	11.1%	156	16.5%	424	44.9%	197	20.9%	62	6.6%
<i>Tucatinib</i>	3,007	568	18.9%	838	27.9%	1,180	39.2%	300	10.0%	121	4.0%
<i>Pemigatinib</i>	551	111	20.1%	155	28.1%	231	41.9%	42	7.6%	12	2.2%
<i>Sacituzumab Govitecan-hziy</i>	9,669	9,000	93.1%	616	6.4%	*****	*****	*****	*****	*****	*****
<i>Opicapone</i>	4,543	1,015	22.3%	936	20.6%	1,320	29.1%	714	15.7%	558	12.3%
<i>Capmatinib</i>	1,700	396	23.3%	436	25.6%	671	39.5%	148	8.7%	49	2.9%
<i>Selpercatinib</i>	924	161	17.4%	174	18.8%	324	35.1%	172	18.6%	93	10.1%
<i>Ripretinib</i>	616	115	18.7%	160	26.0%	241	39.1%	77	12.5%	23	3.7%
<i>Fluoroestradiol F18</i>	1,791	1,791	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Artesunate</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Inebilizumab-cdon</i>	471	419	89.0%	*****	*****	27	5.7%	14	3.0%	*****	*****
<i>Lurbinectedin</i>	7,968	7,869	98.8%	77	1.0%	22	0.3%	0	0.0%	0	0.0%
<i>Triheptanoin</i>	182	21	11.5%	23	12.6%	88	48.4%	36	19.8%	14	7.7%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	664	1	60	140	270	1,440	207.6	220.7
<i>Teprotumumab-Trbw</i>	6,680	1	5	8	8	588	19.4	42.7
<i>Tazemetostat</i>	502	4	52	120	240	1,386	185.1	213.4
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	64,418	1	60	150	360	1,722	268.1	300.1
<i>Eptinezumab-jjmr</i>	18,234	1	1	3	6	1,710	25.0	99.9
<i>Amisulpride</i>	7,951	1	1	1	1	4	1.0	0.2
<i>Rimegepant</i>	269,018	1	30	60	168	1,752	133.9	173.1
<i>Isatuximab</i>	2,843	1	5	9	19	963	20.9	55.9
<i>Osilodrostat</i>	539	2	61	155	387	1,550	280.1	302.5
<i>Ozanimod</i>	3,587	1	90	208	432	1,611	301.3	290.1
<i>Selumetinib</i>	944	2	90	207	392	1,582	281.0	272.0
<i>Tucatinib</i>	3,007	1	60	120	240	1,562	193.8	224.2
<i>Pemigatinib</i>	551	2	42	101	210	1,545	159.5	179.6
<i>Sacituzumab Govitecan-hziy</i>	9,669	1	4	7	14	962	12.0	20.7
<i>Opicapone</i>	4,543	1	56	148	420	1,621	289.3	328.6
<i>Capmatinib</i>	1,700	3	43	98	224	1,484	173.0	202.0
<i>Selpercatinib</i>	924	1	60	180	416	1,583	292.1	313.9
<i>Ripretinib</i>	616	1	60	120	254	1,484	203.6	237.5
<i>Fluoroestradiol F18</i>	1,791	1	1	1	1	8	1.2	0.7
<i>Artesunate</i>	*****	1	1	1	8	42	7.9	15.3
<i>Flortaucipir F18</i>	*****	1	1	1	1	1	1.0	0.0
<i>Inebilizumab-cdon</i>	471	1	2	3	5	929	38.3	126.4
<i>Lurbinectedin</i>	7,968	1	2	3	6	336	5.2	10.8
<i>Triheptanoin</i>	182	3	91	224	383	1,438	294.2	281.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	664	110	100.0%	147	100.0%	307	100.0%	70	100.0%	30	100.0%
Female	360	54	49.1%	81	55.1%	165	53.7%	*****	*****	*****	*****
Male	304	56	50.9%	66	44.9%	142	46.3%	*****	*****	*****	*****
Teprotumumab-Trbw	6,680	6,035	100.0%	*****	*****	488	100.0%	*****	*****	0	NaN
Female	5,155	4,667	77.3%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	1,525	1,368	22.7%	*****	*****	*****	*****	*****	*****	0	NaN
Tazemetostat	502	106	100.0%	130	100.0%	204	100.0%	43	100.0%	19	100.0%
Female	230	46	43.4%	49	37.7%	109	53.4%	*****	*****	*****	*****
Male	272	60	56.6%	81	62.3%	95	46.6%	*****	*****	*****	*****
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	64,418	11,006	100.0%	15,975	100.0%	21,784	100.0%	9,529	100.0%	6,124	100.0%
Female	37,906	6,850	62.2%	9,635	60.3%	12,540	57.6%	5,432	57.0%	3,449	56.3%
Male	26,512	4,156	37.8%	6,340	39.7%	9,244	42.4%	4,097	43.0%	2,675	43.7%
Eptinezumab-jjmr	18,234	16,762	100.0%	458	100.0%	690	100.0%	226	100.0%	98	100.0%
Female	15,341	14,105	84.1%	382	83.4%	581	84.2%	190	84.1%	83	84.7%
Male	2,893	2,657	15.9%	76	16.6%	109	15.8%	36	15.9%	15	15.3%
Amisulpride	7,951	7,951	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	6,312	6,312	79.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	1,639	1,639	20.6%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	269,018	89,666	100.0%	73,040	100.0%	82,052	100.0%	19,684	100.0%	4,576	100.0%
Female	229,890	75,044	83.7%	62,446	85.5%	71,223	86.8%	17,185	87.3%	3,992	87.2%
Male	39,128	14,622	16.3%	10,594	14.5%	10,829	13.2%	2,499	12.7%	584	12.8%
Isatuximab	2,843	2,457	100.0%	317	100.0%	46	100.0%	*****	*****	*****	*****
Female	1,362	1,197	48.7%	133	42.0%	*****	*****	*****	*****	0	0.0%
Male	1,481	1,260	51.3%	184	58.0%	*****	*****	*****	*****	*****	*****

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Osilodrostat	539	75	100.0%	111	100.0%	212	100.0%	87	100.0%	54	100.0%
Female	413	57	76.0%	89	80.2%	158	74.5%	69	79.3%	40	74.1%
Male	126	18	24.0%	22	19.8%	54	25.5%	18	20.7%	14	25.9%
Ozanimod	3,587	391	100.0%	619	100.0%	1,495	100.0%	748	100.0%	334	100.0%
Female	2,281	251	64.2%	386	62.4%	939	62.8%	467	62.4%	238	71.3%
Male	1,306	140	35.8%	233	37.6%	556	37.2%	281	37.6%	96	28.7%
Selumetinib	944	105	100.0%	156	100.0%	424	100.0%	197	100.0%	62	100.0%
Female	462	47	44.8%	79	50.6%	222	52.4%	86	43.7%	28	45.2%
Male	482	58	55.2%	77	49.4%	202	47.6%	111	56.3%	34	54.8%
Tucatinib	3,007	568	100.0%	838	100.0%	1,180	100.0%	300	100.0%	121	100.0%
Female	2,863	535	94.2%	787	93.9%	*****	*****	*****	*****	*****	*****
Male	144	33	5.8%	51	6.1%	*****	*****	*****	*****	*****	*****
Pemigatinib	551	111	100.0%	155	100.0%	231	100.0%	42	100.0%	12	100.0%
Female	324	57	51.4%	86	55.5%	146	63.2%	*****	*****	*****	*****
Male	227	54	48.6%	69	44.5%	85	36.8%	*****	*****	*****	*****
Sacituzumab Govitecan-hziy	9,669	9,000	100.0%	616	100.0%	*****	*****	*****	*****	*****	*****
Female	8,395	7,784	86.5%	*****	*****	*****	*****	*****	*****	*****	*****
Male	1,274	1,216	13.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
Opicapone	4,543	1,015	100.0%	936	100.0%	1,320	100.0%	714	100.0%	558	100.0%
Female	1,749	456	44.9%	382	40.8%	498	37.7%	238	33.3%	175	31.4%
Male	2,794	559	55.1%	554	59.2%	822	62.3%	476	66.7%	383	68.6%
Capmatinib	1,700	396	100.0%	436	100.0%	671	100.0%	148	100.0%	49	100.0%
Female	952	229	57.8%	233	53.4%	365	54.4%	97	65.5%	28	57.1%
Male	748	167	42.2%	203	46.6%	306	45.6%	51	34.5%	21	42.9%
Selpercatinib	924	161	100.0%	174	100.0%	324	100.0%	172	100.0%	93	100.0%
Female	464	92	57.1%	90	51.7%	148	45.7%	92	53.5%	42	45.2%
Male	460	69	42.9%	84	48.3%	176	54.3%	80	46.5%	51	54.8%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Ripretinib	616	115	100.0%	160	100.0%	241	100.0%	77	100.0%	23	100.0%
Female	291	59	51.3%	70	43.8%	119	49.4%	*****	*****	*****	*****
Male	325	56	48.7%	90	56.3%	122	50.6%	*****	*****	*****	*****
Fluoroestradiol F18	1,791	1,791	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	1,715	1,715	95.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	76	76	4.2%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	471	419	100.0%	*****	*****	27	100.0%	14	100.0%	*****	*****
Female	404	363	86.6%	*****	*****	*****	*****	*****	*****	*****	*****
Male	67	56	13.4%	*****	*****	*****	*****	*****	*****	*****	*****
Lurbinectedin	7,968	7,869	100.0%	77	100.0%	22	100.0%	0	NaN	0	NaN
Female	3,988	3,926	49.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,980	3,943	50.1%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	182	21	100.0%	23	100.0%	88	100.0%	36	100.0%	14	100.0%
Female	91	*****	*****	11	47.8%	46	52.3%	16	44.4%	*****	*****
Male	91	*****	*****	12	52.2%	42	47.7%	20	55.6%	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	664	1	60	140	270	1,440	207.6	220.7
Female	360	3	60	145	277	1,440	220.6	241.8
Male	304	1	60	127	254	1,112	192.3	192.1
Teprotumumab-Trbw	6,680	1	5	8	8	588	19.4	42.7
Female	5,155	1	5	8	8	336	18.9	40.8
Male	1,525	1	5	8	8	588	21.1	48.8
Tazemetostat	502	4	52	120	240	1,386	185.1	213.4
Female	230	7	60	120	242	1,338	187.2	193.8
Male	272	4	46	90	227	1,386	183.4	229.1
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	64,418	1	60	150	360	1,722	268.1	300.1
Female	37,906	1	60	136	360	1,700	260.2	296.0
Male	26,512	1	68	163	381	1,722	279.3	305.6
Eptinezumab-jjmr	18,234	1	1	3	6	1,710	25.0	99.9
Female	15,341	1	1	3	6	1,710	24.9	99.7
Male	2,893	1	1	3	6	1,212	25.2	101.1
Amisulpride	7,951	1	1	1	1	4	1.0	0.2
Female	6,312	1	1	1	1	4	1.0	0.2
Male	1,639	1	1	1	1	3	1.0	0.1
Rimegepant	269,018	1	30	60	168	1,752	133.9	173.1
Female	229,890	1	30	62	173	1,752	135.8	174.3
Male	39,128	1	30	60	150	1,510	122.7	165.3
Isatuximab	2,843	1	5	9	19	963	20.9	55.9
Female	1,362	1	5	9	18	652	20.8	55.9
Male	1,481	1	5	10	20	963	21.0	56.0

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Osilodrostat	539	2	61	155	387	1,550	280.1	302.5
Female	413	2	62	150	390	1,422	276.4	296.9
Male	126	8	60	190	384	1,550	292.1	321.1
Ozanimod	3,587	1	90	208	432	1,611	301.3	290.1
Female	2,281	1	90	210	442	1,611	309.7	301.0
Male	1,306	1	89	204	416	1,440	286.6	269.4
Selumetinib	944	2	90	207	392	1,582	281.0	272.0
Female	462	2	90	180	360	1,582	269.4	262.5
Male	482	2	86	214	415	1,563	292.1	280.5
Tucatinib	3,007	1	60	120	240	1,562	193.8	224.2
Female	2,863	1	60	120	240	1,562	196.9	226.6
Male	144	3	36	90	150	1,017	132.4	158.3
Pemigatinib	551	2	42	101	210	1,545	159.5	179.6
Female	324	6	45	115	220	1,545	170.1	190.6
Male	227	2	35	84	198	987	144.4	161.8
Sacituzumab Govitecan-hziy	9,669	1	4	7	14	962	12.0	20.7
Female	8,395	1	4	8	15	962	12.4	21.6
Male	1,274	1	2	6	12	210	9.5	12.8
Opicapone	4,543	1	56	148	420	1,621	289.3	328.6
Female	1,749	2	30	120	348	1,560	257.6	313.3
Male	2,794	1	60	154	456	1,621	309.2	336.4
Capmatinib	1,700	3	43	98	224	1,484	173.0	202.0
Female	952	3	40	101	226	1,484	179.6	208.5
Male	748	3	47	96	222	1,409	164.6	193.2
Selpercatinib	924	1	60	180	416	1,583	292.1	313.9
Female	464	1	57	169	417	1,583	284.2	307.5
Male	460	1	62	180	416	1,520	300.2	320.3

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ripretinib	616	1	60	120	254	1,484	203.6	237.5
Female	291	5	56	120	248	1,484	199.7	238.5
Male	325	1	60	120	270	1,445	207.0	236.9
Fluoroestradiol F18	1,791	1	1	1	1	8	1.2	0.7
Female	1,715	1	1	1	1	8	1.2	0.7
Male	76	1	1	1	1	3	1.1	0.4
Artesunate	*****	1	1	1	8	42	7.9	15.3
Female	*****	1	1	5	25	42	13.0	19.6
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	471	1	2	3	5	929	38.3	126.4
Female	404	1	2	3	5	929	34.5	118.2
Male	67	1	2	3	8	915	61.3	166.8
Lurbinectedin	7,968	1	2	3	6	336	5.2	10.8
Female	3,988	1	2	3	6	293	5.7	12.7
Male	3,980	1	2	3	6	336	4.7	8.3
Triheptanoin	182	3	91	224	383	1,438	294.2	281.4
Female	91	3	90	222	360	1,140	272.7	242.8
Male	91	13	91	227	390	1,438	315.8	315.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	664	110	100.0%	147	100.0%	307	100.0%	70	100.0%	30	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	207	31	28.2%	42	28.6%	88	28.7%	*****	*****	*****	*****
≥ 65 years	388	67	60.9%	88	59.9%	189	61.6%	32	45.7%	12	40.0%
Teprotumumab-Trbw	6,680	6,035	100.0%	155	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	629	604	10.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,472	2,286	37.9%	*****	*****	143	29.3%	*****	*****	0	NaN
≥ 65 years	3,502	3,074	50.9%	*****	*****	326	66.8%	*****	*****	0	NaN
Tazemetostat	502	106	100.0%	130	100.0%	204	100.0%	43	100.0%	19	100.0%
0-17 years	21	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	18	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	49	*****	*****	14	10.8%	20	9.8%	*****	*****	*****	*****
41-64 years	101	24	22.6%	27	20.8%	36	17.6%	*****	*****	*****	*****
≥ 65 years	313	63	59.4%	80	61.5%	131	64.2%	*****	*****	*****	*****
Lactitol	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	64,418	11,006	100.0%	15,975	100.0%	21,784	100.0%	9,529	100.0%	6,124	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	11	0.1%	*****	*****	*****	*****	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	932	171	1.6%	221	1.4%	*****	*****	*****	*****	46	0.8%
41-64 years	18,628	2,889	26.2%	4,483	28.1%	6,779	31.1%	2,819	29.6%	1,658	27.1%
≥ 65 years	44,816	7,937	72.1%	11,260	70.5%	14,624	67.1%	6,575	69.0%	4,420	72.2%
Eptinezumab-jjmr	18,234	16,762	100.0%	458	100.0%	690	100.0%	226	100.0%	98	100.0%
0-17 years	37	37	0.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	638	604	3.6%	11	2.4%	*****	*****	*****	*****	*****	*****
25-40 years	3,097	2,864	17.1%	81	17.7%	*****	*****	*****	*****	*****	*****
41-64 years	8,482	7,702	45.9%	227	49.6%	362	52.5%	135	59.7%	56	57.1%
≥ 65 years	5,980	5,555	33.1%	139	30.3%	201	29.1%	60	26.5%	25	25.5%
Amisulpride	7,951	7,951	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	43	43	0.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	204	204	2.6%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	1,258	1,258	15.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	2,849	2,849	35.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,597	3,597	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	269,018	89,666	100.0%	73,040	100.0%	82,052	100.0%	19,684	100.0%	4,576	100.0%
0-17 years	1,686	628	0.7%	492	0.7%	466	0.6%	88	0.4%	12	0.3%
18-24 years	15,447	5,937	6.6%	4,440	6.1%	4,219	5.1%	744	3.8%	107	2.3%
25-40 years	72,809	24,126	26.9%	20,131	27.6%	22,600	27.5%	4,929	25.0%	1,023	22.4%
41-64 years	134,194	40,737	45.4%	35,804	49.0%	43,588	53.1%	11,290	57.4%	2,775	60.6%
≥ 65 years	44,882	18,238	20.3%	12,173	16.7%	11,179	13.6%	2,633	13.4%	659	14.4%
Isatuximab	2,843	2,457	100.0%	317	100.0%	46	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	568	505	20.6%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	2,262	1,939	78.9%	*****	*****	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Osilodrostat	539	75	100.0%	111	100.0%	212	100.0%	87	100.0%	54	100.0%
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	81	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	221	*****	*****	51	45.9%	88	41.5%	38	43.7%	*****	*****
≥ 65 years	214	42	56.0%	40	36.0%	77	36.3%	30	34.5%	25	46.3%
Ozanimod	3,587	391	100.0%	619	100.0%	1,495	100.0%	748	100.0%	334	100.0%
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	*****	18	4.6%	*****	*****	*****	*****	37	4.9%	*****	*****
25-40 years	1,000	115	29.4%	166	26.8%	444	29.7%	196	26.2%	79	23.7%
41-64 years	1,933	191	48.8%	335	54.1%	784	52.4%	424	56.7%	199	59.6%
≥ 65 years	467	67	17.1%	88	14.2%	176	11.8%	91	12.2%	45	13.5%
Selumetinib	944	105	100.0%	156	100.0%	424	100.0%	197	100.0%	62	100.0%
0-17 years	565	57	54.3%	88	56.4%	242	57.1%	144	73.1%	34	54.8%
18-24 years	138	18	17.1%	17	10.9%	68	16.0%	23	11.7%	12	19.4%
25-40 years	124	*****	*****	22	14.1%	61	14.4%	*****	*****	*****	*****
41-64 years	98	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	19	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Tucatinib	3,007	568	100.0%	838	100.0%	1,180	100.0%	300	100.0%	121	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	54	9.5%	*****	*****	*****	*****	34	11.3%	*****	*****
41-64 years	1,667	296	52.1%	455	54.3%	676	57.3%	164	54.7%	76	62.8%
≥ 65 years	1,023	218	38.4%	*****	*****	375	31.8%	102	34.0%	*****	*****
Pemigatinib	551	111	100.0%	155	100.0%	231	100.0%	42	100.0%	12	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	17	7.4%	*****	*****	0	0.0%
41-64 years	190	40	36.0%	*****	*****	85	36.8%	*****	*****	*****	*****
≥ 65 years	326	60	54.1%	104	67.1%	129	55.8%	*****	*****	*****	*****
Sacituzumab Govitecan-hziy	9,669	9,000	100.0%	616	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	13	2.1%	*****	*****	0	0.0%	0	0.0%
41-64 years	3,216	3,012	33.5%	185	30.0%	*****	*****	0	0.0%	*****	*****
≥ 65 years	6,017	5,568	61.9%	418	67.9%	*****	*****	*****	*****	0	0.0%
Opicapone	4,543	1,015	100.0%	936	100.0%	1,320	100.0%	714	100.0%	558	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	632	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	3,896	898	88.5%	800	85.5%	1,115	84.5%	614	86.0%	469	84.1%
Capmatinib	1,700	396	100.0%	436	100.0%	671	100.0%	148	100.0%	49	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	70	16.1%	*****	*****	17	11.5%	*****	*****
≥ 65 years	1,446	341	86.1%	*****	*****	563	83.9%	131	88.5%	*****	*****
Selpercatinib	924	161	100.0%	174	100.0%	324	100.0%	172	100.0%	93	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	67	14	8.7%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	295	*****	*****	60	34.5%	116	35.8%	58	33.7%	*****	*****
≥ 65 years	541	112	69.6%	99	56.9%	174	53.7%	98	57.0%	58	62.4%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Ripretinib	616	115	100.0%	160	100.0%	241	100.0%	77	100.0%	23	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	198	*****	*****	*****	*****	74	30.7%	*****	*****	*****	*****
≥ 65 years	396	78	67.8%	99	61.9%	*****	*****	49	63.6%	*****	*****
Fluoroestradiol F18	1,791	1,791	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	445	445	24.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,304	1,304	72.8%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	471	419	100.0%	*****	*****	27	100.0%	14	100.0%	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	88	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	187	165	39.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	184	160	38.2%	*****	*****	13	48.1%	*****	*****	*****	*****
Lurbinectedin	7,968	7,869	100.0%	77	100.0%	22	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,856	1,831	23.3%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	6,074	6,000	76.2%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	182	21	100.0%	23	100.0%	88	100.0%	36	100.0%	14	100.0%
0-17 years	119	*****	*****	*****	*****	60	68.2%	*****	*****	*****	*****
18-24 years	24	*****	*****	*****	*****	12	13.6%	*****	*****	*****	*****
25-40 years	20	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	664	1	60	140	270	1,440	207.6	220.7
0-17 years	*****	1	26	63	180	204	94.8	91.8
18-24 years	*****	30	60	103	232	342	145.3	120.0
25-40 years	*****	11	63	132	263	1,004	210.2	225.7
41-64 years	207	3	60	162	334	1,440	253.3	270.0
≥ 65 years	388	3	60	120	252	1,179	185.6	187.7
Teprotumumab-Trbw	6,680	1	5	8	8	588	19.4	42.7
0-17 years	*****	3	4	8	16	168	39.8	71.8
18-24 years	*****	1	4	8	8	176	12.7	28.4
25-40 years	629	1	4	7	8	175	10.7	24.9
41-64 years	2,472	1	5	8	8	504	16.4	37.3
≥ 65 years	3,502	1	5	8	8	588	23.1	48.3
Tazemetostat	502	4	52	120	240	1,386	185.1	213.4
0-17 years	21	7	30	118	240	510	147.0	137.4
18-24 years	18	23	60	102	232	570	165.4	162.0
25-40 years	49	4	57	114	210	840	180.3	202.5
41-64 years	101	4	43	90	238	1,319	190.2	233.2
≥ 65 years	313	4	60	120	240	1,386	188.0	215.9
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	64,418	1	60	150	360	1,722	268.1	300.1
0-17 years	*****	1	1	76	150	150	75.5	105.4
18-24 years	*****	3	59	148	343	711	196.8	175.7
25-40 years	932	1	60	137	290	1,580	224.1	247.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	18,628	1	63	152	360	1,722	266.1	290.1
≥ 65 years	44,816	1	60	146	360	1,712	269.9	305.2
Eptinezumab-jjmr	18,234	1	1	3	6	1,710	25.0	99.9
0-17 years	37	1	2	3	6	18	4.3	3.8
18-24 years	638	1	1	2	5	732	13.5	53.7
25-40 years	3,097	1	1	3	6	1,124	21.7	89.1
41-64 years	8,482	1	1	3	7	1,710	29.4	113.2
≥ 65 years	5,980	1	2	3	7	1,348	21.7	88.4
Amisulpride	7,951	1	1	1	1	4	1.0	0.2
0-17 years	43	1	1	1	1	1	1.0	0.0
18-24 years	204	1	1	1	1	2	1.0	0.1
25-40 years	1,258	1	1	1	1	3	1.0	0.2
41-64 years	2,849	1	1	1	1	4	1.0	0.2
≥ 65 years	3,597	1	1	1	1	4	1.0	0.1
Rimegepant	269,018	1	30	60	168	1,752	133.9	173.1
0-17 years	1,686	1	30	60	127	1,320	108.1	141.2
18-24 years	15,447	1	30	60	126	1,571	106.3	137.7
25-40 years	72,809	1	30	60	160	1,576	129.0	164.7
41-64 years	134,194	1	30	75	184	1,752	146.5	183.4
≥ 65 years	44,882	1	30	54	128	1,522	114.8	162.9
Isatuximab	2,843	1	5	9	19	963	20.9	55.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	8	12	12	7.0	5.6
25-40 years	*****	1	7	8	14	16	9.2	4.8
41-64 years	568	1	5	9	18	635	15.8	33.0
≥ 65 years	2,262	1	5	9	19	963	22.2	60.4
Osilodrostat	539	2	61	155	387	1,550	280.1	302.5
0-17 years	*****	742	742	742	742	742	742.0	NaN

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	32	112	213	468	1,315	320.2	303.3
25-40 years	81	8	84	180	421	1,494	295.7	313.9
41-64 years	221	3	60	169	367	1,550	271.4	279.7
≥ 65 years	214	2	58	141	384	1,422	276.9	320.7
Ozanimod	3,587	1	90	208	432	1,611	301.3	290.1
0-17 years	*****	59	150	238	320	1,269	407.2	491.5
18-24 years	*****	4	90	169	367	1,291	263.0	248.8
25-40 years	1,000	2	90	195	404	1,611	281.8	272.7
41-64 years	1,933	1	90	219	457	1,492	317.3	298.3
≥ 65 years	467	1	67	180	420	1,349	290.4	300.7
Selumetinib	944	2	90	207	392	1,582	281.0	272.0
0-17 years	565	2	90	222	420	1,576	288.9	257.7
18-24 years	138	11	90	183	375	1,474	281.7	286.2
25-40 years	124	3	74	183	338	1,582	289.0	329.0
41-64 years	98	9	60	156	344	1,462	249.3	268.2
≥ 65 years	19	30	58	120	210	480	153.8	131.7
Tucatinib	3,007	1	60	120	240	1,562	193.8	224.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	55	55	60	150	150	88.3	53.5
25-40 years	*****	1	60	117	240	1,532	182.9	200.8
41-64 years	1,667	1	60	120	250	1,562	201.8	230.5
≥ 65 years	1,023	1	55	92	228	1,528	184.4	220.5
Pemigatinib	551	2	42	101	210	1,545	159.5	179.6
0-17 years	*****	28	28	28	28	28	28.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	17	21	91	204	397	126.4	106.9
41-64 years	190	2	42	115	203	1,029	161.7	172.7
≥ 65 years	326	6	42	86	219	1,545	162.1	189.5

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Sacituzumab Govitecan-hziy	9,669	1	4	7	14	962	12.0	20.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	7	11	11	6.3	5.0
25-40 years	*****	1	3	7	12	340	10.6	19.9
41-64 years	3,216	1	4	7	14	962	11.8	23.8
≥ 65 years	6,017	1	4	7	15	525	12.2	18.9
Opicapone	4,543	1	56	148	420	1,621	289.3	328.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	150	150	150	150	150	150.0	NaN
25-40 years	*****	30	39	153	443	1,230	349.4	424.7
41-64 years	632	2	60	150	442	1,621	301.8	341.5
≥ 65 years	3,896	1	50	141	420	1,483	287.1	326.1
Capmatinib	1,700	3	43	98	224	1,484	173.0	202.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	27	79	140	209	83.9	69.8
41-64 years	*****	3	51	98	219	891	150.7	153.4
≥ 65 years	1,446	3	43	102	224	1,484	177.2	209.3
Selpercatinib	924	1	60	180	416	1,583	292.1	313.9
0-17 years	*****	11	98	248	382	470	241.9	168.4
18-24 years	*****	1	30	150	210	971	226.4	281.1
25-40 years	67	1	52	135	330	1,124	237.3	255.1
41-64 years	295	2	75	225	409	1,560	309.4	307.8
≥ 65 years	541	1	56	162	445	1,583	291.9	325.7
Ripretinib	616	1	60	120	254	1,484	203.6	237.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	210	210	210	210	210	210.0	NaN
25-40 years	*****	22	84	155	314	764	253.1	240.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	198	1	60	120	262	1,405	205.3	241.8
≥ 65 years	396	5	59	120	248	1,484	200.0	235.8
Fluoroestradiol F18	1,791	1	1	1	1	8	1.2	0.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	2	1.1	0.3
41-64 years	445	1	1	1	1	7	1.2	0.7
≥ 65 years	1,304	1	1	1	1	8	1.3	0.7
Artesunate	*****	1	1	1	8	42	7.9	15.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	8	8	8	8	8	8.0	NaN
41-64 years	*****	1	1	1	22	42	11.3	20.5
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	471	1	2	3	5	929	38.3	126.4
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	2	5	6	2.5	1.9
25-40 years	88	1	2	3	4	929	24.4	107.9
41-64 years	187	1	2	3	6	915	41.5	135.7
≥ 65 years	184	1	2	3	6	736	44.1	128.7
Lurbinectedin	7,968	1	2	3	6	336	5.2	10.8
0-17 years	*****	1	1	1	1	1	1.0	NaN

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	1	2	2	4	6	2.8	2.2
25-40 years	*****	1	1	2	4	12	2.8	2.5
41-64 years	1,856	1	2	3	5	336	5.4	14.4
≥ 65 years	6,074	1	2	3	6	233	5.2	9.4
Triheptanoin	182	3	91	224	383	1,438	294.2	281.4
0-17 years	119	9	115	238	407	1,433	308.4	265.9
18-24 years	24	3	58	219	335	829	239.5	199.6
25-40 years	20	13	30	106	210	430	138.5	124.1
41-64 years	*****	20	46	150	420	1,140	299.0	387.7
≥ 65 years	*****	30	132	350	921	1,438	540.3	497.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Avapritinib</i>	1,835	968	52.8%	512	27.9%	317	17.3%	*****	*****	*****	*****
<i>Teprotumumab-Trbw</i>	41,418	40,544	97.9%	579	1.4%	*****	*****	*****	*****	0	0.0%
<i>Tazemetostat</i>	1,332	730	54.8%	374	28.1%	210	15.8%	*****	*****	*****	*****
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	177,944	72,960	41.0%	67,096	37.7%	31,823	17.9%	4,734	2.7%	1,331	0.7%
<i>Eptinezumab-jjmr</i>	69,651	66,745	95.8%	2,072	3.0%	754	1.1%	61	0.1%	19	0.0%
<i>Amisulpride</i>	8,169	8,169	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rimegepant</i>	969,518	769,908	79.4%	143,560	14.8%	49,972	5.2%	5,217	0.5%	861	0.1%
<i>Isatuximab</i>	38,229	38,119	99.7%	57	0.1%	40	0.1%	*****	*****	*****	*****
<i>Osilodrostat</i>	1,573	785	49.9%	418	26.6%	290	18.4%	59	3.8%	21	1.3%
<i>Ozanimod</i>	10,496	4,871	46.4%	2,843	27.1%	2,235	21.3%	419	4.0%	128	1.2%
<i>Selumetinib</i>	2,931	1,644	56.1%	681	23.2%	476	16.2%	88	3.0%	42	1.4%
<i>Tucatinib</i>	7,783	4,242	54.5%	2,208	28.4%	1,163	14.9%	132	1.7%	38	0.5%
<i>Pemigatinib</i>	1,929	1,237	64.1%	481	24.9%	198	10.3%	*****	*****	*****	*****
<i>Sacituzumab Govitecan-hziy</i>	106,014	105,922	99.9%	73	0.1%	19	0.0%	0	0.0%	0	0.0%
<i>Opicapone</i>	12,408	5,813	46.8%	3,545	28.6%	2,412	19.4%	438	3.5%	200	1.6%
<i>Capmatinib</i>	4,548	2,627	57.8%	1,143	25.1%	727	16.0%	38	0.8%	13	0.3%
<i>Selpercatinib</i>	3,096	1,699	54.9%	803	25.9%	467	15.1%	91	2.9%	36	1.2%
<i>Ripretinib</i>	1,797	969	53.9%	526	29.3%	272	15.1%	30	1.7%	0	0.0%
<i>Fluoroestradiol F18</i>	2,216	2,216	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Artesunate</i>	14	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Inebilizumab-cdon</i>	1,460	1,373	94.0%	*****	*****	59	4.0%	*****	*****	0	0.0%
<i>Lurbinectedin</i>	35,276	35,208	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Triheptanoin</i>	734	457	62.3%	161	21.9%	95	12.9%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	1,835	1	30	30	90	1,138	75.1	97.2
<i>Teprotumumab-Trbw</i>	41,418	1	1	1	1	588	3.1	14.1
<i>Tazemetostat</i>	1,332	1	30	30	90	1,017	69.8	80.7
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	177,944	1	30	60	90	1,722	97.0	124.5
<i>Eptinezumab-jjmr</i>	69,651	1	1	1	1	1,530	6.5	33.6
<i>Amisulpride</i>	8,169	1	1	1	1	2	1.0	0.0
<i>Rimegepant</i>	969,518	1	15	30	30	1,560	37.2	58.5
<i>Isatuximab</i>	38,229	1	1	1	1	963	1.6	11.9
<i>Osilodrostat</i>	1,573	1	30	31	90	1,550	96.0	147.3
<i>Ozanimod</i>	10,496	1	30	40	106	1,435	103.0	148.1
<i>Selumetinib</i>	2,931	1	30	30	90	1,576	90.5	149.4
<i>Tucatinib</i>	7,783	1	30	30	77	1,562	74.9	106.7
<i>Pemigatinib</i>	1,929	2	14	21	42	1,146	45.6	66.5
<i>Sacituzumab Govitecan-hziy</i>	106,014	1	1	1	1	294	1.1	2.6
<i>Opicapone</i>	12,408	1	30	60	90	1,428	105.9	156.8
<i>Capmatinib</i>	4,548	1	28	28	70	1,092	64.7	81.2
<i>Selpercatinib</i>	3,096	1	30	30	90	1,372	87.2	140.4
<i>Ripretinib</i>	1,797	1	30	30	90	720	69.8	79.1
<i>Fluoroestradiol F18</i>	2,216	1	1	1	1	1	1.0	0.0
<i>Artesunate</i>	14	1	1	1	1	42	3.9	11.0
<i>Flortaucipir F18</i>	*****	1	1	1	1	1	1.0	0.0
<i>Inebilizumab-cdon</i>	1,460	1	1	1	1	718	12.4	51.8
<i>Lurbinectedin</i>	35,276	1	1	1	1	293	1.2	3.3
<i>Triheptanoin</i>	734	1	30	30	60	1,433	73.0	122.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	1,835	968	100.0%	512	100.0%	317	100.0%	*****	*****	*****	*****
Female	1,038	543	56.1%	290	56.6%	182	57.4%	*****	*****	*****	*****
Male	797	425	43.9%	222	43.4%	135	42.6%	*****	*****	*****	*****
Teprotumumab-Trbw	41,418	40,544	100.0%	579	100.0%	*****	*****	*****	*****	0	NaN
Female	31,918	31,269	77.1%	419	72.4%	*****	*****	0	0.0%	0	NaN
Male	9,500	9,275	22.9%	160	27.6%	*****	*****	*****	*****	0	NaN
Tazemetostat	1,332	730	100.0%	374	100.0%	210	100.0%	*****	*****	*****	*****
Female	614	346	47.4%	163	43.6%	*****	*****	*****	*****	*****	*****
Male	718	384	52.6%	211	56.4%	*****	*****	*****	*****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	177,944	72,960	100.0%	67,096	100.0%	31,823	100.0%	4,734	100.0%	1,331	100.0%
Female	104,067	43,903	60.2%	38,619	57.6%	18,154	57.0%	2,670	56.4%	721	54.2%
Male	73,877	29,057	39.8%	28,477	42.4%	13,669	43.0%	2,064	43.6%	610	45.8%
Eptinezumab-jjmr	69,651	66,745	100.0%	2,072	100.0%	754	100.0%	*****	*****	*****	*****
Female	59,136	56,693	84.9%	1,753	84.6%	622	82.5%	*****	*****	*****	*****
Male	10,515	10,052	15.1%	319	15.4%	132	17.5%	*****	*****	*****	*****
Amisulpride	8,169	8,169	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	6,503	6,503	79.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	1,666	1,666	20.4%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	969,518	769,908	100.0%	143,560	100.0%	49,972	100.0%	5,217	100.0%	861	100.0%
Female	842,478	669,816	87.0%	124,262	86.6%	43,169	86.4%	4,482	85.9%	749	87.0%
Male	127,040	100,092	13.0%	19,298	13.4%	6,803	13.6%	735	14.1%	112	13.0%
Isatuximab	38,229	38,119	100.0%	57	100.0%	40	100.0%	*****	*****	*****	*****
Female	17,304	17,260	45.3%	17	29.8%	*****	*****	*****	*****	*****	*****
Male	20,925	20,859	54.7%	40	70.2%	*****	*****	*****	*****	*****	*****
Osilodrostat	1,573	785	100.0%	418	100.0%	290	100.0%	59	100.0%	21	100.0%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	1,259	645	82.2%	337	80.6%	217	74.8%	*****	*****	*****	*****
Male	314	140	17.8%	81	19.4%	73	25.2%	*****	*****	*****	*****
Ozanimod	10,496	4,871	100.0%	2,843	100.0%	2,235	100.0%	419	100.0%	128	100.0%
Female	6,851	3,192	65.5%	1,840	64.7%	1,464	65.5%	263	62.8%	92	71.9%
Male	3,645	1,679	34.5%	1,003	35.3%	771	34.5%	156	37.2%	36	28.1%
Selumetinib	2,931	1,644	100.0%	681	100.0%	476	100.0%	88	100.0%	42	100.0%
Female	1,427	801	48.7%	348	51.1%	222	46.6%	39	44.3%	17	40.5%
Male	1,504	843	51.3%	333	48.9%	254	53.4%	49	55.7%	25	59.5%
Tucatinib	7,783	4,242	100.0%	2,208	100.0%	1,163	100.0%	132	100.0%	38	100.0%
Female	7,476	4,055	95.6%	2,132	96.6%	*****	*****	*****	*****	*****	*****
Male	307	187	4.4%	76	3.4%	*****	*****	*****	*****	*****	*****
Pemigatinib	1,929	1,237	100.0%	481	100.0%	198	100.0%	*****	*****	*****	*****
Female	1,180	738	59.7%	306	63.6%	*****	*****	*****	*****	*****	*****
Male	749	499	40.3%	175	36.4%	*****	*****	*****	*****	0	0.0%
Sacituzumab Govitecan-hziy	106,014	105,922	100.0%	73	100.0%	19	100.0%	0	NaN	0	NaN
Female	94,426	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	11,588	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Opicapone	12,408	5,813	100.0%	3,545	100.0%	2,412	100.0%	438	100.0%	200	100.0%
Female	4,383	2,168	37.3%	1,173	33.1%	824	34.2%	147	33.6%	71	35.5%
Male	8,025	3,645	62.7%	2,372	66.9%	1,588	65.8%	291	66.4%	129	64.5%
Capmatinib	4,548	2,627	100.0%	1,143	100.0%	727	100.0%	38	100.0%	13	100.0%
Female	2,582	1,489	56.7%	640	56.0%	422	58.0%	*****	*****	*****	*****
Male	1,966	1,138	43.3%	503	44.0%	305	42.0%	*****	*****	*****	*****
Selpercatinib	3,096	1,699	100.0%	803	100.0%	467	100.0%	91	100.0%	36	100.0%
Female	1,480	805	47.4%	372	46.3%	240	51.4%	47	51.6%	16	44.4%
Male	1,616	894	52.6%	431	53.7%	227	48.6%	44	48.4%	20	55.6%
Ripretinib	1,797	969	100.0%	526	100.0%	272	100.0%	30	100.0%	0	NaN
Female	924	521	53.8%	269	51.1%	*****	*****	*****	*****	0	NaN
Male	873	448	46.2%	257	48.9%	*****	*****	*****	*****	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Fluoroestradiol F18	2,216	2,216	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,134	2,134	96.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	82	82	3.7%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	14	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	1,460	1,373	100.0%	*****	*****	59	100.0%	*****	*****	0	NaN
Female	1,248	*****	*****	*****	*****	46	78.0%	*****	*****	0	NaN
Male	212	*****	*****	*****	*****	13	22.0%	*****	*****	0	NaN
Lurbinectedin	35,276	35,208	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	18,386	18,341	52.1%	*****	*****	*****	*****	0	NaN	0	NaN
Male	16,890	16,867	47.9%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	734	457	100.0%	161	100.0%	95	100.0%	*****	*****	*****	*****
Female	365	229	50.1%	83	51.6%	*****	*****	*****	*****	*****	*****
Male	369	228	49.9%	78	48.4%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	1,835	1	30	30	90	1,138	75.1	97.2
Female	1,038	1	30	30	90	1,138	76.5	104.1
Male	797	1	30	30	90	872	73.3	87.5
Teprotumumab-Trbw	41,418	1	1	1	1	588	3.1	14.1
Female	31,918	1	1	1	1	249	3.0	13.6
Male	9,500	1	1	1	1	588	3.4	15.4
Tazemetostat	1,332	1	30	30	90	1,017	69.8	80.7
Female	614	1	30	30	74	1,017	70.1	85.7
Male	718	1	30	30	90	570	69.5	76.2
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	177,944	1	30	60	90	1,722	97.0	124.5
Female	104,067	1	30	60	90	1,614	94.8	121.9
Male	73,877	1	30	60	90	1,722	100.2	128.1
Eptinezumab-jjmr	69,651	1	1	1	1	1,530	6.5	33.6
Female	59,136	1	1	1	1	1,530	6.5	33.3
Male	10,515	1	1	1	1	1,176	6.9	35.5
Amisulpride	8,169	1	1	1	1	2	1.0	0.0
Female	6,503	1	1	1	1	2	1.0	0.0
Male	1,666	1	1	1	1	1	1.0	0.0
Rimegepant	969,518	1	15	30	30	1,560	37.2	58.5
Female	842,478	1	15	30	30	1,560	37.1	58.3
Male	127,040	1	15	30	30	1,355	37.8	59.5
Isatuximab	38,229	1	1	1	1	963	1.6	11.9
Female	17,304	1	1	1	1	626	1.6	13.6
Male	20,925	1	1	1	1	963	1.5	10.2

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Osilodrostat	1,573	1	30	31	90	1,550	96.0	147.3
Female	1,259	1	30	30	90	1,244	90.7	134.2
Male	314	1	30	53	120	1,550	117.2	189.9
Ozanimod	10,496	1	30	40	106	1,435	103.0	148.1
Female	6,851	1	30	37	104	1,435	103.1	150.4
Male	3,645	1	30	46	107	1,350	102.7	143.7
Selumetinib	2,931	1	30	30	90	1,576	90.5	149.4
Female	1,427	1	30	30	90	1,576	87.2	144.1
Male	1,504	1	30	30	90	1,474	93.6	154.2
Tucatinib	7,783	1	30	30	77	1,562	74.9	106.7
Female	7,476	1	30	30	82	1,562	75.4	107.6
Male	307	3	30	30	60	957	62.1	81.2
Pemigatinib	1,929	2	14	21	42	1,146	45.6	66.5
Female	1,180	4	14	21	44	1,146	46.7	70.0
Male	749	2	14	21	42	483	43.8	60.7
Sacituzumab Govitecan-hziy	106,014	1	1	1	1	294	1.1	2.6
Female	94,426	1	1	1	1	294	1.1	2.7
Male	11,588	1	1	1	1	147	1.0	1.8
Opicapone	12,408	1	30	60	90	1,428	105.9	156.8
Female	4,383	1	30	38	90	1,428	102.8	157.2
Male	8,025	1	30	60	91	1,380	107.7	156.6
Capmatinib	4,548	1	28	28	70	1,092	64.7	81.2
Female	2,582	1	28	28	70	1,092	66.2	84.3
Male	1,966	3	28	28	61	860	62.6	77.0
Selpercatinib	3,096	1	30	30	90	1,372	87.2	140.4
Female	1,480	1	30	30	90	1,320	89.1	143.4
Male	1,616	1	30	30	88	1,372	85.5	137.6

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ripretinib	1,797	1	30	30	90	720	69.8	79.1
Female	924	5	30	30	60	630	62.9	68.0
Male	873	1	30	30	90	720	77.1	88.8
Fluoroestradiol F18	2,216	1	1	1	1	1	1.0	0.0
Female	2,134	1	1	1	1	1	1.0	0.0
Male	82	1	1	1	1	1	1.0	0.0
Artesunate	14	1	1	1	1	42	3.9	11.0
Female	*****	1	1	1	1	42	4.7	12.4
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	1,460	1	1	1	1	718	12.4	51.8
Female	1,248	1	1	1	1	718	11.2	49.0
Male	212	1	1	1	1	554	19.4	65.3
Lurbinectedin	35,276	1	1	1	1	293	1.2	3.3
Female	18,386	1	1	1	1	293	1.2	3.9
Male	16,890	1	1	1	1	126	1.1	2.5
Triheptanoin	734	1	30	30	60	1,433	73.0	122.2
Female	365	1	30	30	60	1,020	68.0	110.1
Male	369	1	30	30	60	1,433	77.9	133.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	1,835	968	100.0%	512	100.0%	317	100.0%	*****	*****	*****	*****
0-17 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	155	79	8.2%	50	9.8%	*****	*****	*****	*****	*****	*****
41-64 years	663	371	38.3%	160	31.3%	113	35.6%	*****	*****	*****	*****
≥ 65 years	985	500	51.7%	292	57.0%	178	56.2%	*****	*****	*****	*****
Teprotumumab-Trbw	41,418	40,544	100.0%	579	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	17	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	419	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	3,654	3,623	8.9%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	15,338	15,084	37.2%	177	30.6%	77	26.2%	0	0.0%	0	NaN
≥ 65 years	21,990	21,409	52.8%	375	64.8%	*****	*****	*****	*****	0	NaN
Tazemetostat	1,332	730	100.0%	374	100.0%	210	100.0%	*****	*****	*****	*****
0-17 years	42	22	3.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	51	30	4.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	121	52	7.1%	51	13.6%	*****	*****	*****	*****	0	0.0%
41-64 years	287	170	23.3%	73	19.5%	*****	*****	*****	*****	*****	*****
≥ 65 years	831	456	62.5%	226	60.4%	138	65.7%	11	64.7%	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	177,944	72,960	100.0%	67,096	100.0%	31,823	100.0%	4,734	100.0%	1,331	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	36	0.1%	*****	*****	*****	*****	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	2,672	1,286	1.8%	950	1.4%	382	1.2%	*****	*****	*****	*****
41-64 years	53,906	23,379	32.0%	19,975	29.8%	8,875	27.9%	*****	*****	*****	*****
≥ 65 years	121,277	48,260	66.1%	46,135	68.8%	22,549	70.9%	3,371	71.2%	962	72.3%
Eptinezumab-jjmr	69,651	66,745	100.0%	2,072	100.0%	754	100.0%	61	100.0%	19	100.0%
0-17 years	143	143	0.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	2,113	2,059	3.1%	36	1.7%	18	2.4%	0	0.0%	0	0.0%
25-40 years	11,007	10,573	15.8%	319	15.4%	102	13.5%	*****	*****	*****	*****
41-64 years	31,803	30,200	45.2%	1,130	54.5%	432	57.3%	*****	*****	*****	*****
≥ 65 years	24,585	23,770	35.6%	587	28.3%	202	26.8%	*****	*****	*****	*****
Amisulpride	8,169	8,169	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	43	43	0.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	206	206	2.5%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	1,302	1,302	15.9%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	2,947	2,947	36.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,671	3,671	44.9%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	969,518	769,908	100.0%	143,560	100.0%	49,972	100.0%	5,217	100.0%	861	100.0%
0-17 years	5,190	4,158	0.5%	786	0.5%	217	0.4%	*****	*****	*****	*****
18-24 years	46,273	37,458	4.9%	6,503	4.5%	2,087	4.2%	*****	*****	*****	*****
25-40 years	260,482	209,570	27.2%	36,780	25.6%	12,629	25.3%	1,308	25.1%	195	22.6%
41-64 years	520,417	411,144	53.4%	77,762	54.2%	28,057	56.1%	2,951	56.6%	503	58.4%
≥ 65 years	137,156	107,578	14.0%	21,729	15.1%	6,982	14.0%	726	13.9%	141	16.4%
Isatuximab	38,229	38,119	100.0%	57	100.0%	40	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	21	21	0.1%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	92	92	0.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	7,211	7,198	18.9%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	30,905	30,808	80.8%	*****	*****	*****	*****	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Osilodrostat	1,573	785	100.0%	418	100.0%	290	100.0%	59	100.0%	21	100.0%
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	27	3.4%	18	4.3%	*****	*****	*****	*****	0	0.0%
25-40 years	244	126	16.1%	61	14.6%	*****	*****	*****	*****	*****	*****
41-64 years	629	330	42.0%	157	37.6%	112	38.6%	*****	*****	*****	*****
≥ 65 years	633	302	38.5%	182	43.5%	119	41.0%	*****	*****	*****	*****
Ozanimod	10,496	4,871	100.0%	2,843	100.0%	2,235	100.0%	419	100.0%	128	100.0%
0-17 years	18	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	501	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	3,017	1,485	30.5%	775	27.3%	642	28.7%	*****	*****	*****	*****
41-64 years	5,773	2,642	54.2%	1,584	55.7%	1,221	54.6%	239	57.0%	87	68.0%
≥ 65 years	1,187	486	10.0%	337	11.9%	287	12.8%	65	15.5%	12	9.4%
Selumetinib	2,931	1,644	100.0%	681	100.0%	476	100.0%	88	100.0%	42	100.0%
0-17 years	1,838	1,047	63.7%	420	61.7%	286	60.1%	61	69.3%	24	57.1%
18-24 years	398	213	13.0%	93	13.7%	75	15.8%	*****	*****	*****	*****
25-40 years	422	249	15.1%	92	13.5%	*****	*****	11	12.5%	*****	*****
41-64 years	233	118	7.2%	*****	*****	43	9.0%	*****	*****	*****	*****
≥ 65 years	40	17	1.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
Tucatinib	7,783	4,242	100.0%	2,208	100.0%	1,163	100.0%	132	100.0%	38	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	108	9.3%	*****	*****	*****	*****
41-64 years	4,287	2,332	55.0%	1,172	53.1%	672	57.8%	85	64.4%	26	68.4%
≥ 65 years	2,623	1,413	33.3%	779	35.3%	383	32.9%	*****	*****	*****	*****
Pemigatinib	1,929	1,237	100.0%	481	100.0%	198	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	15	3.1%	11	5.6%	0	0.0%	0	0.0%
41-64 years	704	459	37.1%	168	34.9%	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,107	686	55.5%	298	62.0%	*****	*****	*****	*****	*****	*****
Sacituzumab Govitecan-hziy	106,014	105,922	100.0%	73	100.0%	19	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	19	19	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	4,023	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	33,533	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	68,439	68,396	64.6%	*****	*****	*****	*****	0	NaN	0	NaN
Opicapone	12,408	5,813	100.0%	3,545	100.0%	2,412	100.0%	438	100.0%	200	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	23	0.4%	14	0.4%	*****	*****	*****	*****	0	0.0%
41-64 years	1,846	849	14.6%	560	15.8%	*****	*****	*****	*****	27	13.5%
≥ 65 years	10,510	4,941	85.0%	2,971	83.8%	2,058	85.3%	367	83.8%	173	86.5%
Capmatinib	4,548	2,627	100.0%	1,143	100.0%	727	100.0%	38	100.0%	13	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	586	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	3,947	2,273	86.5%	997	87.2%	632	86.9%	*****	*****	*****	*****
Selpercatinib	3,096	1,699	100.0%	803	100.0%	467	100.0%	91	100.0%	36	100.0%
0-17 years	23	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	43	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	261	175	10.3%	57	7.1%	*****	*****	*****	*****	*****	*****
41-64 years	1,040	564	33.2%	268	33.4%	165	35.3%	*****	*****	*****	*****
≥ 65 years	1,729	916	53.9%	466	58.0%	272	58.2%	52	57.1%	23	63.9%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ripretinib	1,797	969	100.0%	526	100.0%	272	100.0%	30	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	576	313	32.3%	165	31.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,130	603	62.2%	333	63.3%	175	64.3%	19	63.3%	0	NaN
Fluoroestradiol F18	2,216	2,216	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	540	540	24.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,630	1,630	73.6%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	14	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	1,460	1,373	100.0%	*****	*****	59	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	241	230	16.8%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	613	577	42.0%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	577	537	39.1%	*****	*****	29	49.2%	*****	*****	0	NaN
Lurbinectedin	35,276	35,208	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	92	92	0.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	7,807	7,787	22.1%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	27,365	27,317	77.6%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	734	457	100.0%	161	100.0%	95	100.0%	*****	*****	*****	*****
0-17 years	468	276	60.4%	106	65.8%	70	73.7%	*****	*****	*****	*****
18-24 years	96	68	14.9%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	60	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	32	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 65 years	78	46	10.1%	18	11.2%	*****	*****	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	1,835	1	30	30	90	1,138	75.1	97.2
0-17 years	11	1	15	28	60	120	43.1	40.6
18-24 years	21	12	30	30	60	180	55.3	42.6
25-40 years	155	8	30	30	86	1,004	76.0	115.9
41-64 years	663	1	30	30	90	1,138	79.1	112.7
≥ 65 years	985	1	30	30	90	1,057	73.1	83.0
Teprotumumab-Trbw	41,418	1	1	1	1	588	3.1	14.1
0-17 years	17	1	1	1	1	168	11.7	40.4
18-24 years	419	1	1	1	1	105	2.2	8.9
25-40 years	3,654	1	1	1	1	168	1.8	8.5
41-64 years	15,338	1	1	1	1	249	2.6	11.7
≥ 65 years	21,990	1	1	1	1	588	3.7	16.2
Tazemetostat	1,332	1	30	30	90	1,017	69.8	80.7
0-17 years	42	7	30	30	90	360	73.5	76.5
18-24 years	51	14	30	30	60	300	58.4	53.8
25-40 years	121	4	30	60	90	510	73.0	75.6
41-64 years	287	4	30	30	60	1,017	66.9	91.3
≥ 65 years	831	1	30	30	90	630	70.8	79.2
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	177,944	1	30	60	90	1,722	97.0	124.5
0-17 years	*****	1	1	30	120	120	50.3	62.1
18-24 years	*****	1	30	69	90	561	91.5	93.8
25-40 years	2,672	1	30	52	90	1,200	78.2	93.5

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	53,906	1	30	60	90	1,722	92.0	119.3
≥ 65 years	121,277	1	30	60	90	1,614	99.7	127.3
Eptinezumab-jjmr	69,651	1	1	1	1	1,530	6.5	33.6
0-17 years	143	1	1	1	1	17	1.1	1.3
18-24 years	2,113	1	1	1	1	360	4.1	20.1
25-40 years	11,007	1	1	1	1	863	6.1	30.7
41-64 years	31,803	1	1	1	1	1,530	7.8	38.6
≥ 65 years	24,585	1	1	1	1	867	5.3	28.6
Amisulpride	8,169	1	1	1	1	2	1.0	0.0
0-17 years	43	1	1	1	1	1	1.0	0.0
18-24 years	206	1	1	1	1	1	1.0	0.0
25-40 years	1,302	1	1	1	1	1	1.0	0.0
41-64 years	2,947	1	1	1	1	2	1.0	0.0
≥ 65 years	3,671	1	1	1	1	1	1.0	0.0
Rimegepant	969,518	1	15	30	30	1,560	37.2	58.5
0-17 years	5,190	1	15	30	30	920	35.1	50.8
18-24 years	46,273	1	15	30	30	1,110	35.5	50.8
25-40 years	260,482	1	15	30	30	1,424	36.1	56.0
41-64 years	520,417	1	15	30	30	1,560	37.8	60.2
≥ 65 years	137,156	1	15	30	30	1,328	37.6	59.1
Isatuximab	38,229	1	1	1	1	963	1.6	11.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	21	1	1	1	1	1	1.0	0.0
25-40 years	92	1	1	1	1	1	1.0	0.0
41-64 years	7,211	1	1	1	1	626	1.2	8.3
≥ 65 years	30,905	1	1	1	1	963	1.6	12.6
Osilodrostat	1,573	1	30	31	90	1,550	96.0	147.3
0-17 years	*****	742	742	742	742	742	742.0	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	5	30	60	120	510	106.7	119.5
25-40 years	244	1	30	30	90	909	98.2	149.5
41-64 years	629	1	30	30	90	1,550	95.3	156.8
≥ 65 years	633	1	30	40	90	1,244	93.6	137.1
Ozanimod	10,496	1	30	40	106	1,435	103.0	148.1
0-17 years	18	29	30	30	90	810	113.1	197.4
18-24 years	501	1	30	35	90	1,231	95.5	147.9
25-40 years	3,017	1	30	36	91	1,417	93.4	129.8
41-64 years	5,773	1	30	46	109	1,435	106.3	156.4
≥ 65 years	1,187	1	30	60	146	1,153	114.3	148.4
Selumetinib	2,931	1	30	30	90	1,576	90.5	149.4
0-17 years	1,838	1	30	30	86	1,576	88.8	144.3
18-24 years	398	2	30	30	90	1,474	97.7	159.4
25-40 years	422	3	30	30	90	1,440	84.9	145.7
41-64 years	233	3	30	30	90	1,462	104.8	184.1
≥ 65 years	40	11	30	58	90	240	73.1	58.7
Tucatinib	7,783	1	30	30	77	1,562	74.9	106.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	55	90	44.2	24.6
25-40 years	*****	1	30	30	60	1,532	66.3	95.8
41-64 years	4,287	1	30	30	90	1,562	78.5	113.6
≥ 65 years	2,623	1	30	30	60	1,498	71.9	97.9
Pemigatinib	1,929	2	14	21	42	1,146	45.6	66.5
0-17 years	*****	28	28	28	28	28	28.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	14	21	21	294	36.7	51.8
41-64 years	704	2	14	21	42	651	43.6	59.6
≥ 65 years	1,107	2	14	21	42	1,146	47.7	71.8

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sacituzumab Govitecan-hziy	106,014	1	1	1	1	294	1.1	2.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	19	1	1	1	1	1	1.0	0.0
25-40 years	4,023	1	1	1	1	63	1.1	2.0
41-64 years	33,533	1	1	1	1	231	1.1	3.1
≥ 65 years	68,439	1	1	1	1	294	1.1	2.4
Opicapone	12,408	1	30	60	90	1,428	105.9	156.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	150	150	150	150	150	150.0	NaN
25-40 years	*****	5	30	60	120	600	95.9	109.1
41-64 years	1,846	1	30	60	90	1,428	103.3	154.1
≥ 65 years	10,510	1	30	60	90	1,380	106.4	157.5
Capmatinib	4,548	1	28	28	70	1,092	64.7	81.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	15	14	14	28	30	179	39.1	42.4
41-64 years	586	3	28	28	60	813	63.5	77.5
≥ 65 years	3,947	1	28	28	71	1,092	64.9	81.9
Selpercatinib	3,096	1	30	30	90	1,372	87.2	140.4
0-17 years	23	11	30	50	90	451	84.1	102.9
18-24 years	43	1	30	30	30	600	68.4	126.5
25-40 years	261	1	30	30	60	1,124	60.9	107.6
41-64 years	1,040	2	30	30	90	1,165	87.8	135.3
≥ 65 years	1,729	1	30	30	90	1,372	91.3	148.0
Ripretinib	1,797	1	30	30	90	720	69.8	79.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	90	42.0	26.8
25-40 years	*****	5	30	30	60	630	61.8	78.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	576	1	30	30	75	619	70.6	81.1
≥ 65 years	1,130	1	30	30	90	720	70.1	78.3
Fluoroestradiol F18	2,216	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	540	1	1	1	1	1	1.0	0.0
≥ 65 years	1,630	1	1	1	1	1	1.0	0.0
Artesunate	14	1	1	1	1	42	3.9	11.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	22	42	11.3	20.5
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	1,460	1	1	1	1	718	12.4	51.8
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	241	1	1	1	1	360	8.9	40.8
41-64 years	613	1	1	1	1	718	12.7	56.7
≥ 65 years	577	1	1	1	1	613	14.1	51.6
Lurbinectedin	35,276	1	1	1	1	293	1.2	3.3
0-17 years	*****	1	1	1	1	1	1.0	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	92	1	1	1	1	1	1.0	0.0
41-64 years	7,807	1	1	1	1	293	1.3	5.1
≥ 65 years	27,365	1	1	1	1	126	1.2	2.6
Triheptanoin	734	1	30	30	60	1,433	73.0	122.2
0-17 years	468	1	30	30	68	1,433	78.4	131.2
18-24 years	96	3	30	30	56	829	59.9	104.0
25-40 years	60	11	30	30	32	268	46.2	46.4
41-64 years	32	2	30	30	60	1,020	74.8	175.2
≥ 65 years	78	4	30	30	70	570	76.2	98.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Avapritinib</i>	664	325	48.9%	182	27.4%	136	20.5%	*****	*****	*****	*****
<i>Teprotumumab-Trbw</i>	6,680	6,349	95.0%	188	2.8%	*****	*****	*****	*****	0	0.0%
<i>Tazemetostat</i>	502	268	53.4%	136	27.1%	*****	*****	*****	*****	*****	*****
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	64,418	25,138	39.0%	24,188	37.5%	12,074	18.7%	2,252	3.5%	766	1.2%
<i>Eptinezumab-jjmr</i>	18,234	17,062	93.6%	813	4.5%	325	1.8%	*****	*****	*****	*****
<i>Amisulpride</i>	7,951	7,951	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rimegepant</i>	269,018	207,967	77.3%	40,769	15.2%	17,433	6.5%	2,431	0.9%	418	0.2%
<i>Isatuximab</i>	2,843	2,802	98.6%	15	0.5%	*****	*****	*****	*****	*****	*****
<i>Osilodrostat</i>	539	214	39.7%	141	26.2%	133	24.7%	35	6.5%	16	3.0%
<i>Ozanimod</i>	3,587	1,381	38.5%	961	26.8%	942	26.3%	229	6.4%	74	2.1%
<i>Selumetinib</i>	944	430	45.6%	198	21.0%	224	23.7%	62	6.6%	30	3.2%
<i>Tucatinib</i>	3,007	1,544	51.3%	857	28.5%	525	17.5%	61	2.0%	20	0.7%
<i>Pemigatinib</i>	551	293	53.2%	186	33.8%	*****	*****	*****	*****	0	0.0%
<i>Sacituzumab Govitecan-hziy</i>	9,669	9,645	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Opicapone</i>	4,543	2,148	47.3%	1,173	25.8%	881	19.4%	214	4.7%	127	2.8%
<i>Capmatinib</i>	1,700	902	53.1%	427	25.1%	341	20.1%	*****	*****	*****	*****
<i>Selpercatinib</i>	924	462	50.0%	232	25.1%	169	18.3%	44	4.8%	17	1.8%
<i>Ripretinib</i>	616	320	51.9%	181	29.4%	104	16.9%	11	1.8%	0	0.0%
<i>Fluoroestradiol F18</i>	1,791	1,791	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Artesunate</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Inebilizumab-cdon</i>	471	447	94.9%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Lurbinectedin</i>	7,968	7,937	99.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Triheptanoin</i>	182	106	58.2%	37	20.3%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	664	1	30	46	90	1,138	85.9	116.0
<i>Teprotumumab-Trbw</i>	6,680	1	1	1	1	588	6.5	24.7
<i>Tazemetostat</i>	502	4	30	30	90	1,017	74.8	92.2
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	64,418	1	30	71	90	1,722	108.3	146.5
<i>Eptinezumab-jjmr</i>	18,234	1	1	1	1	1,530	9.7	42.6
<i>Amisulpride</i>	7,951	1	1	1	1	2	1.0	0.0
<i>Rimegepant</i>	269,018	1	16	30	30	1,560	43.0	71.4
<i>Isatuximab</i>	2,843	1	1	1	1	963	4.3	33.1
<i>Osilodrostat</i>	539	2	30	60	150	1,550	136.8	195.2
<i>Ozanimod</i>	3,587	1	30	60	150	1,435	128.4	180.8
<i>Selumetinib</i>	944	2	30	60	150	1,576	137.8	210.2
<i>Tucatinib</i>	3,007	1	30	30	90	1,562	82.8	119.1
<i>Pemigatinib</i>	551	2	21	21	63	441	52.7	62.9
<i>Sacituzumab Govitecan-hziy</i>	9,669	1	1	1	1	210	1.3	5.0
<i>Opicapone</i>	4,543	1	30	60	120	1,428	123.8	191.0
<i>Capmatinib</i>	1,700	3	28	28	84	1,092	75.2	98.4
<i>Selpercatinib</i>	924	1	30	31	90	1,145	110.0	173.0
<i>Ripretinib</i>	616	1	30	30	90	720	72.3	79.1
<i>Fluoroestradiol F18</i>	1,791	1	1	1	1	1	1.0	0.0
<i>Artesunate</i>	*****	1	1	1	1	42	6.9	15.5
<i>Flortaucipir F18</i>	*****	1	1	1	1	1	1.0	0.0
<i>Inebilizumab-cdon</i>	471	1	1	1	1	718	11.9	54.0
<i>Lurbinectedin</i>	7,968	1	1	1	1	293	1.4	5.2
<i>Triheptanoin</i>	182	1	30	30	90	1,433	99.6	183.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	664	325	100.0%	182	100.0%	136	100.0%	*****	*****	*****	*****
Female	360	166	51.1%	105	57.7%	*****	*****	*****	*****	*****	*****
Male	304	159	48.9%	77	42.3%	*****	*****	*****	*****	*****	*****
Teprotumumab-Trbw	6,680	6,349	100.0%	188	100.0%	*****	*****	*****	*****	0	NaN
Female	5,155	4,906	77.3%	137	72.9%	*****	*****	0	0.0%	0	NaN
Male	1,525	1,443	22.7%	51	27.1%	*****	*****	*****	*****	0	NaN
Tazemetostat	502	268	100.0%	136	100.0%	*****	*****	*****	*****	*****	*****
Female	230	127	47.4%	50	36.8%	*****	*****	*****	*****	*****	*****
Male	272	141	52.6%	86	63.2%	*****	*****	*****	*****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	64,418	25,138	100.0%	24,188	100.0%	12,074	100.0%	2,252	100.0%	766	100.0%
Female	37,906	15,297	60.9%	14,091	58.3%	6,861	56.8%	1,244	55.2%	413	53.9%
Male	26,512	9,841	39.1%	10,097	41.7%	5,213	43.2%	1,008	44.8%	353	46.1%
Eptinezumab-jjmr	18,234	17,062	100.0%	813	100.0%	325	100.0%	*****	*****	*****	*****
Female	15,341	14,366	84.2%	677	83.3%	*****	*****	*****	*****	*****	*****
Male	2,893	2,696	15.8%	136	16.7%	*****	*****	*****	*****	*****	*****
Amisulpride	7,951	7,951	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	6,312	6,312	79.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	1,639	1,639	20.6%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	269,018	207,967	100.0%	40,769	100.0%	17,433	100.0%	2,431	100.0%	418	100.0%
Female	229,890	177,735	85.5%	34,800	85.4%	14,921	85.6%	2,075	85.4%	359	85.9%
Male	39,128	30,232	14.5%	5,969	14.6%	2,512	14.4%	356	14.6%	59	14.1%
Isatuximab	2,843	2,802	100.0%	15	100.0%	*****	*****	*****	*****	*****	*****
Female	1,362	1,342	47.9%	*****	*****	*****	*****	*****	*****	0	0.0%
Male	1,481	1,460	52.1%	*****	*****	*****	*****	*****	*****	*****	*****
Osilodrostat	539	214	100.0%	141	100.0%	133	100.0%	35	100.0%	16	100.0%
Female	413	162	75.7%	114	80.9%	99	74.4%	*****	*****	*****	*****
Male	126	52	24.3%	27	19.1%	34	25.6%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Ozanimod	3,587	1,381	100.0%	961	100.0%	942	100.0%	229	100.0%	74	100.0%
Female	2,281	892	64.6%	604	62.9%	596	63.3%	139	60.7%	50	67.6%
Male	1,306	489	35.4%	357	37.1%	346	36.7%	90	39.3%	24	32.4%
Selumetinib	944	430	100.0%	198	100.0%	224	100.0%	62	100.0%	30	100.0%
Female	462	209	48.6%	105	53.0%	106	47.3%	28	45.2%	14	46.7%
Male	482	221	51.4%	93	47.0%	118	52.7%	34	54.8%	16	53.3%
Tucatinib	3,007	1,544	100.0%	857	100.0%	525	100.0%	61	100.0%	20	100.0%
Female	2,863	1,465	94.9%	818	95.4%	*****	*****	*****	*****	20	100.0%
Male	144	79	5.1%	39	4.6%	*****	*****	*****	*****	0	0.0%
Pemigatinib	551	293	100.0%	186	100.0%	*****	*****	*****	*****	0	NaN
Female	324	164	56.0%	120	64.5%	*****	*****	*****	*****	0	NaN
Male	227	129	44.0%	66	35.5%	*****	*****	*****	*****	0	NaN
Sacituzumab Govitecan-hziy	9,669	9,645	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	8,395	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,274	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Opicapone	4,543	2,148	100.0%	1,173	100.0%	881	100.0%	214	100.0%	127	100.0%
Female	1,749	858	39.9%	441	37.6%	342	38.8%	66	30.8%	42	33.1%
Male	2,794	1,290	60.1%	732	62.4%	539	61.2%	148	69.2%	85	66.9%
Capmatinib	1,700	902	100.0%	427	100.0%	341	100.0%	*****	*****	*****	*****
Female	952	517	57.3%	237	55.5%	180	52.8%	*****	*****	*****	*****
Male	748	385	42.7%	190	44.5%	161	47.2%	*****	*****	*****	*****
Selpercatinib	924	462	100.0%	232	100.0%	169	100.0%	44	100.0%	17	100.0%
Female	464	243	52.6%	104	44.8%	84	49.7%	*****	*****	*****	*****
Male	460	219	47.4%	128	55.2%	85	50.3%	*****	*****	*****	*****
Ripretinib	616	320	100.0%	181	100.0%	104	100.0%	11	100.0%	0	NaN
Female	291	168	52.5%	75	41.4%	*****	*****	*****	*****	0	NaN
Male	325	152	47.5%	106	58.6%	*****	*****	*****	*****	0	NaN
Fluoroestradiol F18	1,791	1,791	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	1,715	1,715	95.8%	0	NaN	0	NaN	0	NaN	0	NaN
Male	76	76	4.2%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	471	447	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	404	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	67	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Lurbinectedin	7,968	7,937	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	3,988	3,972	50.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	3,980	3,965	50.0%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	182	106	100.0%	37	100.0%	*****	*****	*****	*****	*****	*****
Female	91	56	52.8%	18	48.6%	*****	*****	*****	*****	*****	*****
Male	91	50	47.2%	19	51.4%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	664	1	30	46	90	1,138	85.9	116.0
Female	360	3	30	59	90	1,138	91.0	132.3
Male	304	1	30	30	90	789	79.8	92.9
Teprotumumab-Trbw	6,680	1	1	1	1	588	6.5	24.7
Female	5,155	1	1	1	1	249	6.4	23.5
Male	1,525	1	1	1	1	588	7.1	28.3
Tazemetostat	502	4	30	30	90	1,017	74.8	92.2
Female	230	7	30	30	90	1,017	83.3	111.4
Male	272	4	30	30	78	535	67.6	71.5
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	64,418	1	30	71	90	1,722	108.3	146.5
Female	37,906	1	30	60	90	1,614	104.7	142.1
Male	26,512	1	30	89	90	1,722	113.4	152.4
Eptinezumab-jjmr	18,234	1	1	1	1	1,530	9.7	42.6
Female	15,341	1	1	1	1	1,530	9.5	42.3
Male	2,893	1	1	1	1	1,176	10.3	44.4
Amisulpride	7,951	1	1	1	1	2	1.0	0.0
Female	6,312	1	1	1	1	2	1.0	0.0
Male	1,639	1	1	1	1	1	1.0	0.0
Rimegepant	269,018	1	16	30	30	1,560	43.0	71.4
Female	229,890	1	16	30	30	1,560	43.0	71.5
Male	39,128	1	16	30	30	1,335	42.8	70.7
Isatuximab	2,843	1	1	1	1	963	4.3	33.1
Female	1,362	1	1	1	1	449	4.7	34.4
Male	1,481	1	1	1	1	963	3.9	31.9
Osilodrostat	539	2	30	60	150	1,550	136.8	195.2
Female	413	2	30	60	150	1,244	130.7	176.1

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	126	8	30	60	150	1,550	156.5	247.4
Ozanimod	3,587	1	30	60	150	1,435	128.4	180.8
Female	2,281	1	30	59	150	1,435	127.9	184.5
Male	1,306	1	30	60	150	1,344	129.3	174.3
Selumetinib	944	2	30	60	150	1,576	137.8	210.2
Female	462	2	30	60	122	1,576	133.8	207.6
Male	482	2	30	60	157	1,474	141.6	212.8
Tucatinib	3,007	1	30	30	90	1,562	82.8	119.1
Female	2,863	1	30	30	90	1,562	83.7	121.0
Male	144	3	30	30	60	450	65.6	68.5
Pemigatinib	551	2	21	21	63	441	52.7	62.9
Female	324	6	21	28	63	431	52.3	60.9
Male	227	2	21	21	56	441	53.4	65.8
Sacituzumab Govitecan-hziy	9,669	1	1	1	1	210	1.3	5.0
Female	8,395	1	1	1	1	210	1.3	5.1
Male	1,274	1	1	1	1	147	1.3	5.0
Opicapone	4,543	1	30	60	120	1,428	123.8	191.0
Female	1,749	2	30	42	120	1,428	116.5	181.9
Male	2,794	1	30	60	120	1,380	128.4	196.4
Capmatinib	1,700	3	28	28	84	1,092	75.2	98.4
Female	952	3	28	28	84	1,092	75.0	100.9
Male	748	3	28	29	84	860	75.5	95.2
Selpercatinib	924	1	30	31	90	1,145	110.0	173.0
Female	464	1	30	30	93	1,145	116.2	194.8
Male	460	1	30	56	90	1,036	103.7	147.7
Ripretinib	616	1	30	30	90	720	72.3	79.1
Female	291	5	30	30	60	540	64.8	70.0
Male	325	1	30	55	90	720	79.0	85.9
Fluoroestradiol F18	1,791	1	1	1	1	1	1.0	0.0

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	1,715	1	1	1	1	1	1.0	0.0
Male	76	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	1	42	6.9	15.5
Female	*****	1	1	1	22	42	11.3	20.5
Male	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	471	1	1	1	1	718	11.9	54.0
Female	404	1	1	1	1	718	10.0	47.8
Male	67	1	1	1	1	554	23.4	81.5
Lurbinectedin	7,968	1	1	1	1	293	1.4	5.2
Female	3,988	1	1	1	1	293	1.5	6.2
Male	3,980	1	1	1	1	111	1.3	3.9
Triheptanoin	182	1	30	30	90	1,433	99.6	183.6
Female	91	1	30	30	90	1,020	93.1	161.0
Male	91	13	30	30	90	1,433	106.1	204.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	664	325	100.0%	182	100.0%	136	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	56	24	7.4%	20	11.0%	*****	*****	0	0.0%	*****	*****
41-64 years	207	101	31.1%	54	29.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	388	193	59.4%	105	57.7%	*****	*****	*****	*****	*****	*****
Teprotumumab-Trbw	6,680	6,349	100.0%	188	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	629	613	9.7%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,472	2,386	37.6%	54	28.7%	32	22.5%	0	0.0%	0	NaN
≥ 65 years	3,502	3,278	51.6%	121	64.4%	*****	*****	*****	*****	0	NaN
Tazemetostat	502	268	100.0%	136	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	49	23	8.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	101	57	21.3%	27	19.9%	*****	*****	*****	*****	*****	*****
≥ 65 years	313	166	61.9%	78	57.4%	*****	*****	*****	*****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	64,418	25,138	100.0%	24,188	100.0%	12,074	100.0%	2,252	100.0%	766	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	17	0.1%	*****	*****	0	0.0%	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	932	411	1.6%	328	1.4%	*****	*****	27	1.2%	*****	*****
41-64 years	18,628	7,565	30.1%	6,850	28.3%	*****	*****	637	28.3%	*****	*****
≥ 65 years	44,816	17,145	68.2%	16,993	70.3%	8,535	70.7%	1,588	70.5%	555	72.5%
Eptinezumab-jjmr	18,234	17,062	100.0%	813	100.0%	325	100.0%	*****	*****	*****	*****
0-17 years	37	37	0.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	638	616	3.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	3,097	2,923	17.1%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	8,482	7,876	46.2%	401	49.3%	186	57.2%	*****	*****	*****	*****
≥ 65 years	5,980	5,610	32.9%	268	33.0%	*****	*****	*****	*****	*****	*****
Amisulpride	7,951	7,951	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	43	43	0.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	204	204	2.6%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	1,258	1,258	15.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	2,849	2,849	35.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,597	3,597	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	269,018	207,967	100.0%	40,769	100.0%	17,433	100.0%	2,431	100.0%	418	100.0%
0-17 years	1,686	1,334	0.6%	236	0.6%	101	0.6%	*****	*****	*****	*****
18-24 years	15,447	12,250	5.9%	2,211	5.4%	872	5.0%	*****	*****	*****	*****
25-40 years	72,809	56,778	27.3%	10,682	26.2%	4,589	26.3%	659	27.1%	101	24.2%
41-64 years	134,194	102,385	49.2%	20,789	51.0%	9,419	54.0%	1,356	55.8%	245	58.6%
≥ 65 years	44,882	35,220	16.9%	6,851	16.8%	2,452	14.1%	*****	*****	*****	*****
Isatuximab	2,843	2,802	100.0%	*****	*****	17	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	568	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	2,262	2,225	79.4%	*****	*****	*****	*****	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Osilodrostat	539	214	100.0%	141	100.0%	133	100.0%	35	100.0%	16	100.0%
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	81	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	221	92	43.0%	61	43.3%	49	36.8%	*****	*****	*****	*****
≥ 65 years	214	96	44.9%	50	35.5%	50	37.6%	*****	*****	*****	*****
Ozanimod	3,587	1,381	100.0%	961	100.0%	942	100.0%	229	100.0%	74	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	*****	*****
18-24 years	*****	*****	*****	45	4.7%	*****	*****	*****	*****	*****	*****
25-40 years	1,000	416	30.1%	253	26.3%	261	27.7%	53	23.1%	17	23.0%
41-64 years	1,933	721	52.2%	523	54.4%	507	53.8%	136	59.4%	46	62.2%
≥ 65 years	467	165	11.9%	140	14.6%	125	13.3%	*****	*****	*****	*****
Selumetinib	944	430	100.0%	198	100.0%	224	100.0%	62	100.0%	30	100.0%
0-17 years	565	261	60.7%	117	59.1%	123	54.9%	46	74.2%	18	60.0%
18-24 years	138	55	12.8%	31	15.7%	*****	*****	*****	*****	*****	*****
25-40 years	124	66	15.3%	20	10.1%	*****	*****	*****	*****	*****	*****
41-64 years	98	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	19	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Tucatinib	3,007	1,544	100.0%	857	100.0%	525	100.0%	61	100.0%	20	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	50	9.5%	*****	*****	*****	*****
41-64 years	1,667	824	53.4%	468	54.6%	317	60.4%	*****	*****	*****	*****
≥ 65 years	1,023	543	35.2%	305	35.6%	158	30.1%	*****	*****	*****	*****
Pemigatinib	551	293	100.0%	186	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	190	101	34.5%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	326	169	57.7%	124	66.7%	*****	*****	*****	*****	0	NaN
Sacituzumab Govitecan-hziy	9,669	9,645	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	3,216	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	6,017	6,003	62.2%	*****	*****	*****	*****	0	NaN	0	NaN
Opicapone	4,543	2,148	100.0%	1,173	100.0%	881	100.0%	214	100.0%	127	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	632	*****	*****	*****	*****	*****	*****	34	15.9%	17	13.4%
≥ 65 years	3,896	1,858	86.5%	996	84.9%	752	85.4%	180	84.1%	110	86.6%
Capmatinib	1,700	902	100.0%	427	100.0%	341	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	50	14.7%	*****	*****	0	0.0%
≥ 65 years	1,446	761	84.4%	368	86.2%	291	85.3%	*****	*****	*****	*****
Selpercatinib	924	462	100.0%	232	100.0%	169	100.0%	44	100.0%	17	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	67	43	9.3%	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	295	133	28.8%	68	29.3%	68	40.2%	*****	*****	*****	*****
≥ 65 years	541	272	58.9%	147	63.4%	89	52.7%	*****	*****	*****	*****
Ripretinib	616	320	100.0%	181	100.0%	104	100.0%	11	100.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	198	102	31.9%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	396	201	62.8%	127	70.2%	*****	*****	*****	*****	0	NaN
Fluoroestradiol F18	1,791	1,791	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	445	445	24.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,304	1,304	72.8%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Flortaucipir F18	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Inebilizumab-cdon	471	447	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	88	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	187	173	38.7%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	184	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Lurbinectedin	7,968	7,937	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	1,856	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	6,074	6,051	76.2%	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	182	106	100.0%	37	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	119	65	61.3%	26	70.3%	*****	*****	*****	*****	*****	*****
18-24 years	24	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	20	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	664	1	30	46	90	1,138	85.9	116.0
0-17 years	*****	1	15	28	42	120	41.2	46.6
18-24 years	*****	30	30	45	120	180	75.0	60.0
25-40 years	56	11	30	59	90	1,004	95.2	164.0
41-64 years	207	3	30	45	104	1,138	93.6	134.2
≥ 65 years	388	3	30	43	90	1,057	81.3	97.2
Teprotumumab-Trbw	6,680	1	1	1	1	588	6.5	24.7
0-17 years	*****	1	1	1	16	168	37.4	73.3
18-24 years	*****	1	1	1	1	84	4.8	14.0
25-40 years	629	1	1	1	1	168	3.7	16.7
41-64 years	2,472	1	1	1	1	249	4.8	18.8
≥ 65 years	3,502	1	1	1	1	588	8.3	29.1
Tazemetostat	502	4	30	30	90	1,017	74.8	92.2
0-17 years	21	7	30	30	60	210	61.2	58.9
18-24 years	18	23	30	45	60	180	62.8	47.4
25-40 years	49	4	30	46	60	210	54.5	38.2
41-64 years	101	4	30	30	71	1,017	81.7	131.1
≥ 65 years	313	4	30	30	90	630	77.3	86.4
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	64,418	1	30	71	90	1,722	108.3	146.5
0-17 years	*****	1	1	16	30	30	15.5	20.5
18-24 years	*****	3	30	76	90	360	88.7	85.5
25-40 years	932	1	30	60	90	1,002	90.1	109.3

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	18,628	1	30	60	90	1,722	104.5	142.5
≥ 65 years	44,816	1	30	82	90	1,614	110.2	148.7
Eptinezumab-jjmr	18,234	1	1	1	1	1,530	9.7	42.6
0-17 years	37	1	1	1	1	2	1.0	0.2
18-24 years	638	1	1	1	1	270	5.4	24.3
25-40 years	3,097	1	1	1	1	507	8.3	35.2
41-64 years	8,482	1	1	1	1	1,530	11.3	50.1
≥ 65 years	5,980	1	1	1	1	810	8.6	35.7
Amisulpride	7,951	1	1	1	1	2	1.0	0.0
0-17 years	43	1	1	1	1	1	1.0	0.0
18-24 years	204	1	1	1	1	1	1.0	0.0
25-40 years	1,258	1	1	1	1	1	1.0	0.0
41-64 years	2,849	1	1	1	1	2	1.0	0.0
≥ 65 years	3,597	1	1	1	1	1	1.0	0.0
Rimegepant	269,018	1	16	30	30	1,560	43.0	71.4
0-17 years	1,686	1	16	30	30	920	40.4	64.6
18-24 years	15,447	1	16	30	30	1,110	39.5	59.0
25-40 years	72,809	1	16	30	30	1,421	42.3	69.8
41-64 years	134,194	1	16	30	30	1,560	44.9	75.5
≥ 65 years	44,882	1	16	30	30	1,328	39.9	64.7
Isatuximab	2,843	1	1	1	1	963	4.3	33.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	568	1	1	1	1	112	1.7	6.9
≥ 65 years	2,262	1	1	1	1	963	4.9	36.9
Osilodrostat	539	2	30	60	150	1,550	136.8	195.2
0-17 years	*****	742	742	742	742	742	742.0	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	*****	30	60	105	246	510	167.2	144.2
25-40 years	81	8	30	87	150	909	166.4	209.8
41-64 years	221	3	30	60	138	1,550	130.2	200.8
≥ 65 years	214	2	30	59	139	1,244	126.3	183.6
Ozanimod	3,587	1	30	60	150	1,435	128.4	180.8
0-17 years	*****	30	30	30	118	810	203.6	341.1
18-24 years	*****	4	30	60	123	916	112.2	152.4
25-40 years	1,000	2	30	57	144	1,417	119.8	171.0
41-64 years	1,933	1	30	60	156	1,435	134.8	191.3
≥ 65 years	467	1	30	60	160	1,049	125.8	163.1
Selumetinib	944	2	30	60	150	1,576	137.8	210.2
0-17 years	565	2	30	60	150	1,576	140.7	211.2
18-24 years	138	7	30	60	175	1,474	137.7	203.1
25-40 years	124	3	30	30	120	1,323	115.4	180.9
41-64 years	98	9	30	60	180	1,462	160.7	260.4
≥ 65 years	19	30	30	60	120	240	77.0	62.4
Tucatinib	3,007	1	30	30	90	1,562	82.8	119.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	55	55	38.3	14.4
25-40 years	*****	1	30	30	75	1,532	78.3	131.6
41-64 years	1,667	1	30	38	90	1,562	90.5	130.8
≥ 65 years	1,023	1	30	30	80	1,110	71.9	90.9
Pemigatinib	551	2	21	21	63	441	52.7	62.9
0-17 years	*****	28	28	28	28	28	28.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	18	21	42	294	53.4	67.9
41-64 years	190	2	21	25	63	431	56.3	66.9
≥ 65 years	326	6	21	23	63	441	50.7	60.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sacituzumab Govitecan-hziy	9,669	1	1	1	1	210	1.3	5.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	23	1.1	1.5
41-64 years	3,216	1	1	1	1	210	1.4	6.0
≥ 65 years	6,017	1	1	1	1	168	1.3	4.6
Opicapone	4,543	1	30	60	120	1,428	123.8	191.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	150	150	150	150	150	150.0	NaN
25-40 years	*****	30	30	60	60	270	68.6	63.8
41-64 years	632	1	30	60	120	1,428	127.7	200.8
≥ 65 years	3,896	1	30	60	120	1,380	123.4	189.7
Capmatinib	1,700	3	28	28	84	1,092	75.2	98.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	20	27	28	56	79	38.3	21.3
41-64 years	*****	3	28	28	84	560	74.3	89.7
≥ 65 years	1,446	3	28	28	84	1,092	75.6	100.0
Selpercatinib	924	1	30	31	90	1,145	110.0	173.0
0-17 years	*****	11	30	98	248	451	151.6	154.1
18-24 years	*****	1	30	30	30	150	36.5	37.0
25-40 years	67	1	30	30	60	1,124	68.9	143.2
41-64 years	295	2	30	60	150	1,115	130.5	184.3
≥ 65 years	541	1	30	30	90	1,145	105.1	170.8
Ripretinib	616	1	30	30	90	720	72.3	79.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	22	30	30	30	270	58.0	61.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	198	1	30	30	90	510	76.0	79.9
≥ 65 years	396	5	30	30	90	720	71.3	79.6
Fluoroestradiol F18	1,791	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	445	1	1	1	1	1	1.0	0.0
≥ 65 years	1,304	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	1	42	6.9	15.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	22	42	11.3	20.5
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Flortaucipir F18	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Inebilizumab-cdon	471	1	1	1	1	718	11.9	54.0
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	88	1	1	1	1	235	8.3	31.2
41-64 years	187	1	1	1	1	718	18.4	77.9
≥ 65 years	184	1	1	1	1	180	7.7	27.7
Lurbinectedin	7,968	1	1	1	1	293	1.4	5.2
0-17 years	*****	1	1	1	1	1	1.0	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	1,856	1	1	1	1	293	1.5	8.0
≥ 65 years	6,074	1	1	1	1	126	1.3	4.0
Triheptanoin	182	1	30	30	90	1,433	99.6	183.6
0-17 years	119	1	30	30	90	1,433	101.7	184.6
18-24 years	24	3	30	30	46	829	97.5	190.6
25-40 years	20	13	30	30	41	268	56.4	65.1
41-64 years	*****	20	30	75	135	1,020	190.0	338.6
≥ 65 years	*****	14	30	30	60	570	94.0	160.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Avapritinib</i>	1,171	643	54.9%	330	28.2%	181	15.5%	*****	*****	*****	*****
<i>Teprotumumab-Trbw</i>	34,738	34,195	98.4%	391	1.1%	152	0.4%	0	0.0%	0	0.0%
<i>Tazemetostat</i>	830	462	55.7%	238	28.7%	*****	*****	*****	*****	0	0.0%
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	113,526	47,822	42.1%	42,908	37.8%	19,749	17.4%	2,482	2.2%	565	0.5%
<i>Eptinezumab-jjmr</i>	51,417	49,683	96.6%	1,259	2.4%	429	0.8%	35	0.1%	11	0.0%
<i>Amisulpride</i>	218	218	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rimegepant</i>	700,500	561,941	80.2%	102,791	14.7%	32,539	4.6%	2,786	0.4%	443	0.1%
<i>Isatuximab</i>	35,386	35,317	99.8%	42	0.1%	*****	*****	*****	*****	0	0.0%
<i>Osilodrostat</i>	1,034	571	55.2%	277	26.8%	157	15.2%	*****	*****	*****	*****
<i>Ozanimod</i>	6,909	3,490	50.5%	1,882	27.2%	1,293	18.7%	190	2.8%	54	0.8%
<i>Selumetinib</i>	1,987	1,214	61.1%	483	24.3%	252	12.7%	26	1.3%	12	0.6%
<i>Tucatinib</i>	4,776	2,698	56.5%	1,351	28.3%	638	13.4%	71	1.5%	18	0.4%
<i>Pemigatinib</i>	1,378	944	68.5%	295	21.4%	*****	*****	*****	*****	*****	*****
<i>Sacituzumab Govitecan-hziy</i>	96,345	96,277	99.9%	57	0.1%	11	0.0%	0	0.0%	0	0.0%
<i>Opicapone</i>	7,865	3,665	46.6%	2,372	30.2%	1,531	19.5%	224	2.8%	73	0.9%
<i>Capmatinib</i>	2,848	1,725	60.6%	716	25.1%	386	13.6%	*****	*****	*****	*****
<i>Selpercatinib</i>	2,172	1,237	57.0%	571	26.3%	298	13.7%	47	2.2%	19	0.9%
<i>Ripretinib</i>	1,181	649	55.0%	345	29.2%	168	14.2%	19	1.6%	0	0.0%
<i>Fluoroestradiol F18</i>	425	425	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Artesunate</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Inebilizumab-cdon</i>	989	926	93.6%	*****	*****	44	4.4%	*****	*****	0	0.0%
<i>Lurbinectedin</i>	27,308	27,271	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Triheptanoin</i>	552	351	63.6%	124	22.5%	66	12.0%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	1,171	1	30	30	80	872	69.0	84.2
<i>Teprotumumab-Trbw</i>	34,738	1	1	1	1	210	2.5	10.8
<i>Tazemetostat</i>	830	1	30	30	79	570	66.8	72.8
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	113,526	1	30	60	90	1,521	90.7	109.6
<i>Eptinezumab-jjmr</i>	51,417	1	1	1	1	1,392	5.4	29.7
<i>Amisulpride</i>	218	1	1	1	1	1	1.0	0.0
<i>Rimegepant</i>	700,500	1	15	30	30	1,527	34.9	52.6
<i>Isatuximab</i>	35,386	1	1	1	1	626	1.3	8.0
<i>Osilodrostat</i>	1,034	1	30	30	84	1,136	74.7	108.9
<i>Ozanimod</i>	6,909	1	30	30	90	1,350	89.8	125.9
<i>Selumetinib</i>	1,987	1	30	30	60	1,440	68.1	101.8
<i>Tucatinib</i>	4,776	1	30	30	60	1,498	69.9	97.7
<i>Pemigatinib</i>	1,378	2	14	21	42	1,146	42.7	67.7
<i>Sacituzumab Govitecan-hziy</i>	96,345	1	1	1	1	294	1.1	2.2
<i>Opicapone</i>	7,865	1	30	60	90	1,375	95.6	132.1
<i>Capmatinib</i>	2,848	1	28	28	56	813	58.4	68.2
<i>Selpercatinib</i>	2,172	1	30	30	73	1,372	77.5	122.7
<i>Ripretinib</i>	1,181	1	30	30	60	675	68.5	79.1
<i>Fluoroestradiol F18</i>	425	1	1	1	1	1	1.0	0.0
<i>Artesunate</i>	*****	1	1	1	1	1	1.0	0.0
<i>Flortaucipir F18</i>	0	-	-	-	-	-	-	-
<i>Inebilizumab-cdon</i>	989	1	1	1	1	613	12.6	50.7
<i>Lurbinectedin</i>	27,308	1	1	1	1	147	1.1	2.5
<i>Triheptanoin</i>	552	1	30	30	60	978	64.2	92.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	1,171	643	100.0%	330	100.0%	181	100.0%	*****	*****	*****	*****
Female	678	377	58.6%	185	56.1%	*****	*****	*****	*****	*****	*****
Male	493	266	41.4%	145	43.9%	*****	*****	*****	*****	*****	*****
Teprotumumab-Trbw	34,738	34,195	100.0%	391	100.0%	152	100.0%	0	NaN	0	NaN
Female	26,763	26,363	77.1%	282	72.1%	118	77.6%	0	NaN	0	NaN
Male	7,975	7,832	22.9%	109	27.9%	34	22.4%	0	NaN	0	NaN
Tazemetostat	830	462	100.0%	238	100.0%	*****	*****	*****	*****	0	NaN
Female	384	219	47.4%	113	47.5%	*****	*****	*****	*****	0	NaN
Male	446	243	52.6%	125	52.5%	*****	*****	*****	*****	0	NaN
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	113,526	47,822	100.0%	42,908	100.0%	19,749	100.0%	2,482	100.0%	565	100.0%
Female	66,161	28,606	59.8%	24,528	57.2%	11,293	57.2%	1,426	57.5%	308	54.5%
Male	47,365	19,216	40.2%	18,380	42.8%	8,456	42.8%	1,056	42.5%	257	45.5%
Eptinezumab-jjmr	51,417	49,683	100.0%	1,259	100.0%	429	100.0%	*****	*****	*****	*****
Female	43,795	42,327	85.2%	1,076	85.5%	*****	*****	*****	*****	*****	*****
Male	7,622	7,356	14.8%	183	14.5%	*****	*****	*****	*****	*****	*****
Amisulpride	218	218	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	191	191	87.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	27	27	12.4%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	700,500	561,941	100.0%	102,791	100.0%	32,539	100.0%	2,786	100.0%	443	100.0%
Female	612,588	492,081	87.6%	89,462	87.0%	28,248	86.8%	2,407	86.4%	390	88.0%
Male	87,912	69,860	12.4%	13,329	13.0%	4,291	13.2%	379	13.6%	53	12.0%
Isatuximab	35,386	35,317	100.0%	42	100.0%	*****	*****	*****	*****	0	NaN
Female	15,942	15,918	45.1%	*****	*****	*****	*****	*****	*****	0	NaN
Male	19,444	19,399	54.9%	*****	*****	*****	*****	*****	*****	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Osilodrostat	1,034	571	100.0%	277	100.0%	157	100.0%	*****	*****	*****	*****
Female	846	483	84.6%	223	80.5%	*****	*****	*****	*****	*****	*****
Male	188	88	15.4%	54	19.5%	*****	*****	*****	*****	*****	*****
Ozanimod	6,909	3,490	100.0%	1,882	100.0%	1,293	100.0%	190	100.0%	54	100.0%
Female	4,570	2,300	65.9%	1,236	65.7%	868	67.1%	124	65.3%	42	77.8%
Male	2,339	1,190	34.1%	646	34.3%	425	32.9%	66	34.7%	12	22.2%
Selumetinib	1,987	1,214	100.0%	483	100.0%	252	100.0%	*****	*****	*****	*****
Female	965	592	48.8%	243	50.3%	116	46.0%	*****	*****	*****	*****
Male	1,022	622	51.2%	240	49.7%	136	54.0%	*****	*****	*****	*****
Tucatinib	4,776	2,698	100.0%	1,351	100.0%	638	100.0%	71	100.0%	18	100.0%
Female	4,613	2,590	96.0%	1,314	97.3%	*****	*****	*****	*****	*****	*****
Male	163	108	4.0%	37	2.7%	*****	*****	*****	*****	*****	*****
Pemigatinib	1,378	944	100.0%	295	100.0%	*****	*****	*****	*****	*****	*****
Female	856	574	60.8%	186	63.1%	*****	*****	*****	*****	*****	*****
Male	522	370	39.2%	109	36.9%	*****	*****	*****	*****	0	0.0%
Sacituzumab Govitecan-hziy	96,345	96,277	100.0%	57	100.0%	11	100.0%	0	NaN	0	NaN
Female	86,031	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	10,314	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Opicapone	7,865	3,665	100.0%	2,372	100.0%	1,531	100.0%	224	100.0%	73	100.0%
Female	2,634	1,310	35.7%	732	30.9%	482	31.5%	81	36.2%	29	39.7%
Male	5,231	2,355	64.3%	1,640	69.1%	1,049	68.5%	143	63.8%	44	60.3%
Capmatinib	2,848	1,725	100.0%	716	100.0%	386	100.0%	*****	*****	*****	*****
Female	1,630	972	56.3%	403	56.3%	*****	*****	*****	*****	*****	*****
Male	1,218	753	43.7%	313	43.7%	*****	*****	*****	*****	*****	*****
Selpercatinib	2,172	1,237	100.0%	571	100.0%	298	100.0%	47	100.0%	19	100.0%
Female	1,016	562	45.4%	268	46.9%	156	52.3%	*****	*****	*****	*****
Male	1,156	675	54.6%	303	53.1%	142	47.7%	*****	*****	*****	*****
Ripretinib	1,181	649	100.0%	345	100.0%	168	100.0%	19	100.0%	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	633	353	54.4%	194	56.2%	*****	*****	*****	*****	0	NaN
Male	548	296	45.6%	151	43.8%	*****	*****	*****	*****	0	NaN
Fluoroestradiol F18	425	425	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Inebilizumab-cdon	989	926	100.0%	*****	*****	44	100.0%	*****	*****	0	NaN
Female	844	794	85.7%	*****	*****	*****	*****	*****	*****	0	NaN
Male	145	132	14.3%	*****	*****	*****	*****	*****	*****	0	NaN
Lurbinectedin	27,308	27,271	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	14,398	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	12,910	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Triheptanoin	552	351	100.0%	124	100.0%	66	100.0%	*****	*****	*****	*****
Female	274	173	49.3%	65	52.4%	*****	*****	*****	*****	*****	*****
Male	278	178	50.7%	59	47.6%	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	1,171	1	30	30	80	872	69.0	84.2
Female	678	1	30	30	72	789	68.8	84.6
Male	493	1	30	30	81	872	69.4	83.8
Teprotumumab-Trbw	34,738	1	1	1	1	210	2.5	10.8
Female	26,763	1	1	1	1	210	2.4	10.6
Male	7,975	1	1	1	1	168	2.7	11.2
Tazemetostat	830	1	30	30	79	570	66.8	72.8
Female	384	1	30	30	60	510	62.3	64.5
Male	446	1	30	30	90	570	70.6	79.1
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	113,526	1	30	60	90	1,521	90.7	109.6
Female	66,161	1	30	60	90	1,521	89.1	108.2
Male	47,365	1	30	60	90	1,474	92.9	111.6
Eptinezumab-jjmr	51,417	1	1	1	1	1,392	5.4	29.7
Female	43,795	1	1	1	1	1,392	5.4	29.4
Male	7,622	1	1	1	1	953	5.7	31.4
Amisulpride	218	1	1	1	1	1	1.0	0.0
Female	191	1	1	1	1	1	1.0	0.0
Male	27	1	1	1	1	1	1.0	0.0
Rimegepant	700,500	1	15	30	30	1,527	34.9	52.6
Female	612,588	1	14	30	30	1,527	34.8	52.4
Male	87,912	1	15	30	30	1,355	35.5	53.7
Isatuximab	35,386	1	1	1	1	626	1.3	8.0
Female	15,942	1	1	1	1	626	1.4	9.9
Male	19,444	1	1	1	1	348	1.3	5.9
Osilodrostat	1,034	1	30	30	84	1,136	74.7	108.9
Female	846	1	28	30	80	1,136	71.1	102.5

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	188	1	30	40	90	1,084	90.9	133.1
Ozanimod	6,909	1	30	30	90	1,350	89.8	125.9
Female	4,570	1	30	30	90	1,241	90.8	128.4
Male	2,339	1	30	30	90	1,350	87.8	121.0
Selumetinib	1,987	1	30	30	60	1,440	68.1	101.8
Female	965	1	30	30	60	1,440	64.9	92.5
Male	1,022	1	30	30	60	1,037	71.0	109.8
Tucatinib	4,776	1	30	30	60	1,498	69.9	97.7
Female	4,613	1	30	30	60	1,498	70.3	98.0
Male	163	3	30	30	60	957	59.0	91.1
Pemigatinib	1,378	2	14	21	42	1,146	42.7	67.7
Female	856	4	14	21	42	1,146	44.6	73.0
Male	522	2	14	21	42	483	39.6	57.8
Sacituzumab Govitecan-hziy	96,345	1	1	1	1	294	1.1	2.2
Female	86,031	1	1	1	1	294	1.1	2.4
Male	10,314	1	1	1	1	63	1.0	0.7
Opicapone	7,865	1	30	60	90	1,375	95.6	132.1
Female	2,634	1	30	35	90	1,375	93.7	137.7
Male	5,231	1	30	60	90	1,355	96.6	129.2
Capmatinib	2,848	1	28	28	56	813	58.4	68.2
Female	1,630	1	28	28	56	813	61.1	72.5
Male	1,218	4	28	28	56	768	54.7	62.0
Selpercatinib	2,172	1	30	30	73	1,372	77.5	122.7
Female	1,016	1	30	30	90	1,320	76.7	110.2
Male	1,156	1	30	30	60	1,372	78.2	132.7
Ripretinib	1,181	1	30	30	60	675	68.5	79.1
Female	633	5	30	30	60	630	62.0	67.1
Male	548	1	30	30	90	675	75.9	90.6
Fluoroestradiol F18	425	1	1	1	1	1	1.0	0.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Se

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Inebilizumab-cdon	989	1	1	1	1	613	12.6	50.7
Female	844	1	1	1	1	613	11.8	49.6
Male	145	1	1	1	1	360	17.5	56.5
Lurbinectedin	27,308	1	1	1	1	147	1.1	2.5
Female	14,398	1	1	1	1	147	1.2	3.0
Male	12,910	1	1	1	1	126	1.1	1.9
Triheptanoin	552	1	30	30	60	978	64.2	92.2
Female	274	1	30	30	60	709	59.6	85.7
Male	278	1	30	30	60	978	68.6	98.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	1,171	643	100.0%	330	100.0%	181	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	99	55	8.6%	30	9.1%	*****	*****	*****	*****	0	0.0%
41-64 years	456	270	42.0%	106	32.1%	*****	*****	*****	*****	*****	*****
≥ 65 years	597	307	47.7%	187	56.7%	*****	*****	*****	*****	*****	*****
Teprotumumab-Trbw	34,738	34,195	100.0%	391	100.0%	152	100.0%	0	NaN	0	NaN
0-17 years	12	12	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	347	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	3,025	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	12,866	12,698	37.1%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	18,488	18,131	53.0%	254	65.0%	103	67.8%	0	NaN	0	NaN
Tazemetostat	830	462	100.0%	238	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	33	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	72	29	6.3%	29	12.2%	*****	*****	*****	*****	0	NaN
41-64 years	186	113	24.5%	46	19.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	518	290	62.8%	148	62.2%	*****	*****	*****	*****	0	NaN
Lactitol	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	113,526	47,822	100.0%	42,908	100.0%	19,749	100.0%	2,482	100.0%	565	100.0%
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	18	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	1,740	875	1.8%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	35,278	15,814	33.1%	13,125	30.6%	5,506	27.9%	*****	*****	*****	*****
≥ 65 years	76,461	31,115	65.1%	29,142	67.9%	14,014	71.0%	1,783	71.8%	407	72.0%
Eptinezumab-jjmr	51,417	49,683	100.0%	1,259	100.0%	429	100.0%	35	100.0%	11	100.0%
0-17 years	106	106	0.2%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	1,475	1,443	2.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	7,910	7,650	15.4%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	23,321	22,324	44.9%	729	57.9%	246	57.3%	*****	*****	*****	*****
≥ 65 years	18,605	18,160	36.6%	319	25.3%	109	25.4%	*****	*****	*****	*****
Amisulpride	218	218	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	98	98	45.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	74	74	33.9%	0	NaN	0	NaN	0	NaN	0	NaN
Rimegepant	700,500	561,941	100.0%	102,791	100.0%	32,539	100.0%	2,786	100.0%	443	100.0%
0-17 years	3,504	2,824	0.5%	550	0.5%	116	0.4%	14	0.5%	0	0.0%
18-24 years	30,826	25,208	4.5%	4,292	4.2%	1,215	3.7%	99	3.6%	12	2.7%
25-40 years	187,673	152,792	27.2%	26,098	25.4%	8,040	24.7%	649	23.3%	94	21.2%
41-64 years	386,223	308,759	54.9%	56,973	55.4%	18,638	57.3%	1,595	57.3%	258	58.2%
≥ 65 years	92,274	72,358	12.9%	14,878	14.5%	4,530	13.9%	429	15.4%	79	17.8%
Isatuximab	35,386	35,317	100.0%	42	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	18	18	0.1%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	82	82	0.2%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	6,643	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	28,643	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Osilodrostat	1,034	571	100.0%	277	100.0%	157	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	44	25	4.4%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	163	102	17.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	408	238	41.7%	96	34.7%	63	40.1%	*****	*****	*****	*****
≥ 65 years	419	206	36.1%	132	47.7%	69	43.9%	*****	*****	*****	*****
Ozanimod	6,909	3,490	100.0%	1,882	100.0%	1,293	100.0%	190	100.0%	54	100.0%
0-17 years	13	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	319	*****	*****	*****	*****	36	2.8%	*****	*****	*****	*****
25-40 years	2,017	1,069	30.6%	522	27.7%	381	29.5%	*****	*****	*****	*****
41-64 years	3,840	1,921	55.0%	1,061	56.4%	714	55.2%	103	54.2%	41	75.9%
≥ 65 years	720	321	9.2%	197	10.5%	162	12.5%	*****	*****	*****	*****
Selumetinib	1,987	1,214	100.0%	483	100.0%	252	100.0%	26	100.0%	12	100.0%
0-17 years	1,273	786	64.7%	303	62.7%	163	64.7%	*****	*****	*****	*****
18-24 years	260	158	13.0%	62	12.8%	*****	*****	*****	*****	*****	*****
25-40 years	298	183	15.1%	72	14.9%	*****	*****	*****	*****	*****	*****
41-64 years	135	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Tucatinib	4,776	2,698	100.0%	1,351	100.0%	638	100.0%	71	100.0%	18	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	58	9.1%	*****	*****	0	0.0%
41-64 years	2,620	1,508	55.9%	704	52.1%	355	55.6%	*****	*****	*****	*****
≥ 65 years	1,600	870	32.2%	474	35.1%	225	35.3%	*****	*****	*****	*****
Pemigatinib	1,378	944	100.0%	295	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	83	69	7.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	514	358	37.9%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	781	517	54.8%	174	59.0%	*****	*****	*****	*****	*****	*****
Sacituzumab Govitecan-hziy	96,345	96,277	100.0%	57	100.0%	11	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	16	16	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	3,590	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	30,317	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	62,422	62,393	64.8%	*****	*****	*****	*****	0	NaN	0	NaN
Opicapone	7,865	3,665	100.0%	2,372	100.0%	1,531	100.0%	224	100.0%	73	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	37	17	0.5%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,214	565	15.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	6,614	3,083	84.1%	1,975	83.3%	1,306	85.3%	*****	*****	*****	*****
Capmatinib	2,848	1,725	100.0%	716	100.0%	386	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	87	12.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	2,501	1,512	87.7%	629	87.8%	341	88.3%	*****	*****	*****	*****
Selpercatinib	2,172	1,237	100.0%	571	100.0%	298	100.0%	47	100.0%	19	100.0%
0-17 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	30	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	194	132	10.7%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	745	431	34.8%	200	35.0%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,188	644	52.1%	319	55.9%	183	61.4%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ripretinib	1,181	649	100.0%	345	100.0%	168	100.0%	19	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	378	211	32.5%	112	32.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	734	402	61.9%	206	59.7%	*****	*****	*****	*****	0	NaN
Fluoroestradiol F18	425	425	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	326	326	76.7%	0	NaN	0	NaN	0	NaN	0	NaN
Artesunate	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Inebilizumab-cdon	989	926	100.0%	*****	*****	44	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	17	17	1.8%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	153	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	426	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	393	359	38.8%	*****	*****	*****	*****	*****	*****	0	NaN
Lurbinectedin	27,308	27,271	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	5,951	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	21,291	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Triheptanoin	552	351	100.0%	124	100.0%	66	100.0%	*****	*****	*****	*****
0-17 years	349	211	60.1%	80	64.5%	*****	*****	*****	*****	*****	*****
18-24 years	72	51	14.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	40	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	24	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	67	40	11.4%	15	12.1%	*****	*****	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	1,171	1	30	30	80	872	69.0	84.2
0-17 years	*****	11	21	29	60	118	44.7	39.5
18-24 years	*****	12	30	30	60	90	43.2	22.7
25-40 years	99	8	30	30	60	450	65.1	75.3
41-64 years	456	1	30	30	60	789	72.5	100.9
≥ 65 years	597	1	30	30	86	872	67.8	71.8
Teprotumumab-Trbw	34,738	1	1	1	1	210	2.5	10.8
0-17 years	12	1	1	1	1	1	1.0	0.0
18-24 years	347	1	1	1	1	105	1.7	7.3
25-40 years	3,025	1	1	1	1	133	1.5	5.4
41-64 years	12,866	1	1	1	1	210	2.2	9.7
≥ 65 years	18,488	1	1	1	1	168	2.8	12.1
Tazemetostat	830	1	30	30	79	570	66.8	72.8
0-17 years	21	20	30	60	90	360	85.8	90.6
18-24 years	33	14	30	30	60	300	56.0	57.6
25-40 years	72	25	30	60	90	510	85.6	91.0
41-64 years	186	13	30	30	60	449	58.9	58.3
≥ 65 years	518	1	30	30	90	570	66.9	74.3
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	113,526	1	30	60	90	1,521	90.7	109.6
0-17 years	*****	120	120	120	120	120	120.0	NaN
18-24 years	*****	1	30	63	90	561	94.0	101.4
25-40 years	1,740	1	30	30	90	1,200	71.8	83.2

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	35,278	1	30	60	90	1,416	85.3	104.4
≥ 65 years	76,461	1	30	60	90	1,521	93.6	112.4
Eptinezumab-jjmr	51,417	1	1	1	1	1,392	5.4	29.7
0-17 years	106	1	1	1	1	17	1.2	1.6
18-24 years	1,475	1	1	1	1	360	3.5	18.0
25-40 years	7,910	1	1	1	1	863	5.3	28.7
41-64 years	23,321	1	1	1	1	1,392	6.6	33.3
≥ 65 years	18,605	1	1	1	1	867	4.2	25.9
Amisulpride	218	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	98	1	1	1	1	1	1.0	0.0
≥ 65 years	74	1	1	1	1	1	1.0	0.0
Rimegepant	700,500	1	15	30	30	1,527	34.9	52.6
0-17 years	3,504	1	15	30	30	630	32.6	42.4
18-24 years	30,826	1	15	30	30	955	33.5	46.0
25-40 years	187,673	1	13	30	30	1,424	33.6	49.4
41-64 years	386,223	1	14	30	30	1,527	35.3	53.7
≥ 65 years	92,274	1	15	30	30	1,289	36.4	56.2
Isatuximab	35,386	1	1	1	1	626	1.3	8.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	18	1	1	1	1	1	1.0	0.0
25-40 years	82	1	1	1	1	1	1.0	0.0
41-64 years	6,643	1	1	1	1	626	1.2	8.4
≥ 65 years	28,643	1	1	1	1	595	1.4	7.9
Osilodrostat	1,034	1	30	30	84	1,136	74.7	108.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	44	5	30	30	90	450	76.5	92.9
25-40 years	163	1	30	30	60	602	64.3	91.0
41-64 years	408	1	28	30	78	1,136	76.4	122.9
≥ 65 years	419	1	30	36	90	827	76.9	102.2
Ozanimod	6,909	1	30	30	90	1,350	89.8	125.9
0-17 years	13	29	30	30	80	429	78.3	108.2
18-24 years	319	1	30	30	72	1,231	86.0	144.7
25-40 years	2,017	1	30	30	90	994	80.3	101.1
41-64 years	3,840	1	30	30	90	1,350	91.9	133.2
≥ 65 years	720	1	30	60	120	1,153	106.8	137.6
Selumetinib	1,987	1	30	30	60	1,440	68.1	101.8
0-17 years	1,273	1	30	30	60	1,037	65.7	92.5
18-24 years	260	2	30	30	60	1,021	76.4	125.7
25-40 years	298	3	30	30	60	1,440	72.2	126.5
41-64 years	135	3	30	30	60	600	64.3	75.3
≥ 65 years	21	11	30	56	90	210	69.5	56.6
Tucatinib	4,776	1	30	30	60	1,498	69.9	97.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	90	90	50.0	34.6
25-40 years	*****	2	30	30	60	602	59.4	66.7
41-64 years	2,620	1	30	30	60	1,276	70.8	100.4
≥ 65 years	1,600	3	30	30	60	1,498	71.9	102.1
Pemigatinib	1,378	2	14	21	42	1,146	42.7	67.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	83	3	14	14	21	287	29.9	42.2
41-64 years	514	2	14	21	42	651	39.0	56.0
≥ 65 years	781	2	14	21	42	1,146	46.5	76.1

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sacituzumab Govitecan-hziy	96,345	1	1	1	1	294	1.1	2.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	1	1	1	1	1	1.0	0.0
25-40 years	3,590	1	1	1	1	63	1.1	2.0
41-64 years	30,317	1	1	1	1	231	1.1	2.7
≥ 65 years	62,422	1	1	1	1	294	1.1	2.0
Opicapone	7,865	1	30	60	90	1,375	95.6	132.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	37	5	30	60	135	600	106.3	121.0
41-64 years	1,214	1	30	57	90	1,140	90.6	121.2
≥ 65 years	6,614	1	30	60	90	1,375	96.5	134.0
Capmatinib	2,848	1	28	28	56	813	58.4	68.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	21	28	179	39.9	56.6
41-64 years	*****	6	28	28	56	813	55.7	66.3
≥ 65 years	2,501	1	28	28	56	768	58.8	68.5
Selpercatinib	2,172	1	30	30	73	1,372	77.5	122.7
0-17 years	15	12	30	30	60	120	48.1	28.1
18-24 years	30	15	30	30	60	600	82.3	148.2
25-40 years	194	5	30	30	60	795	58.1	92.5
41-64 years	745	2	30	30	60	1,165	70.8	105.5
≥ 65 years	1,188	1	30	30	90	1,372	85.1	135.9
Ripretinib	1,181	1	30	30	60	675	68.5	79.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	60	90	45.0	30.0
25-40 years	*****	5	30	30	60	630	63.0	84.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	378	2	30	30	60	619	67.7	81.6
≥ 65 years	734	1	30	30	83	675	69.5	77.7
Fluoroestradiol F18	425	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	326	1	1	1	1	1	1.0	0.0
Artesunate	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Inebilizumab-cdon	989	1	1	1	1	613	12.6	50.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	1	1	1	1	1	1.0	0.0
25-40 years	153	1	1	1	1	360	9.3	45.5
41-64 years	426	1	1	1	1	360	10.2	44.1
≥ 65 years	393	1	1	1	1	613	17.1	59.4
Lurbinectedin	27,308	1	1	1	1	147	1.1	2.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	5,951	1	1	1	1	147	1.2	3.8
≥ 65 years	21,291	1	1	1	1	84	1.1	2.1
Triheptanoin	552	1	30	30	60	978	64.2	92.2
0-17 years	349	1	30	30	60	978	70.5	106.2
18-24 years	72	3	30	30	57	288	47.3	45.6
25-40 years	40	11	30	30	32	201	41.1	33.3
41-64 years	24	2	30	30	30	90	36.3	17.5
≥ 65 years	67	4	30	30	80	450	73.3	85.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	1,171	1	3	6	14	760	25.2	71.2
<i>Teprotumumab-Trbw</i>	34,738	1	20	20	20	1,437	27.3	54.0
<i>Tazemetostat</i>	830	1	3	5	16	360	17.8	40.1
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	113,526	1	3	8	25	1,382	29.3	72.4
<i>Eptinezumab-jjmr</i>	51,417	1	83	90	94	1,625	94.4	53.7
<i>Amisulpride</i>	218	1	46	118	204	592	143.4	117.5
<i>Rimegepant</i>	700,500	1	9	23	53	1,608	49.0	85.6
<i>Isatuximab</i>	35,386	1	12	13	13	1,040	14.1	19.8
<i>Osilodrostat</i>	1,034	1	3	7	19	776	20.9	49.3
<i>Ozanimod</i>	6,909	1	2	5	13	1,201	14.8	41.2
<i>Selumetinib</i>	1,987	1	3	7	18	1,275	19.8	59.1
<i>Tucatinib</i>	4,776	1	3	7	18	1,028	20.4	53.8
<i>Pemigatinib</i>	1,378	1	3	7	11	526	12.4	29.5
<i>Sacituzumab Govitecan-hziy</i>	96,345	1	6	13	13	1,044	11.8	14.1
<i>Opicapone</i>	7,865	1	3	6	18	1,145	23.0	61.5
<i>Capmatinib</i>	2,848	1	3	7	19	907	19.4	47.7
<i>Selpercatinib</i>	2,172	1	3	7	18	846	19.1	48.1
<i>Ripretinib</i>	1,181	1	3	6	15	479	17.1	36.9
<i>Fluoroestradiol F18</i>	425	3	100	139	209	1,273	176.6	120.8
<i>Artesunate</i>	*****	1	5	6	11	18	7.7	5.4
<i>Flortaucipir F18</i>	0	-	-	-	-	-	-	-
<i>Inebilizumab-cdon</i>	989	1	15	176	184	742	133.6	93.9
<i>Lurbinctedin</i>	27,308	1	20	20	21	622	23.1	12.5
<i>Triheptanoin</i>	552	1	4	8	19	1,118	21.5	59.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	1,171	1	3	6	14	760	25.2	71.2
Female	678	1	2	5	13	760	26.3	76.0
Male	493	1	3	6	16	698	23.7	63.9
Teprotumumab-Trbw	34,738	1	20	20	20	1,437	27.3	54.0
Female	26,763	1	20	20	20	1,437	27.3	54.2
Male	7,975	1	20	20	20	1,309	27.2	53.5
Tazemetostat	830	1	3	5	16	360	17.8	40.1
Female	384	1	3	6	17	351	19.1	44.8
Male	446	1	2	5	15	360	16.6	35.5
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	113,526	1	3	8	25	1,382	29.3	72.4
Female	66,161	1	3	9	26	1,331	30.7	75.4
Male	47,365	1	3	8	23	1,382	27.3	68.1
Eptinezumab-jjmr	51,417	1	83	90	94	1,625	94.4	53.7
Female	43,795	1	83	90	94	1,625	94.4	53.8
Male	7,622	1	83	90	93	1,280	94.5	53.5
Amisulpride	218	1	46	118	204	592	143.4	117.5
Female	191	1	48	118	202	592	144.9	119.3
Male	27	7	27	104	227	370	132.7	105.2
Rimegepant	700,500	1	9	23	53	1,608	49.0	85.6
Female	612,588	1	9	23	53	1,608	49.0	85.2
Male	87,912	1	8	21	52	1,570	49.4	88.4
Isatuximab	35,386	1	12	13	13	1,040	14.1	19.8
Female	15,942	1	12	13	13	994	14.1	21.6
Male	19,444	1	13	13	13	1,040	14.0	18.3
Osilodrostat	1,034	1	3	7	19	776	20.9	49.3

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	846	1	3	7	18	585	19.7	44.8
Male	188	1	3	9	23	776	26.2	65.8
Ozanimod	6,909	1	2	5	13	1,201	14.8	41.2
Female	4,570	1	3	6	14	1,201	15.4	42.4
Male	2,339	1	2	5	12	859	13.8	38.9
Selumetinib	1,987	1	3	7	18	1,275	19.8	59.1
Female	965	1	4	7	19	1,275	21.9	68.3
Male	1,022	1	3	7	18	1,029	17.9	48.7
Tucatinib	4,776	1	3	7	18	1,028	20.4	53.8
Female	4,613	1	3	7	18	1,028	20.6	54.5
Male	163	1	3	8	17	292	14.4	27.3
Pemigatinib	1,378	1	3	7	11	526	12.4	29.5
Female	856	1	3	7	12	526	13.1	31.3
Male	522	1	3	7	9	338	11.4	26.2
Sacituzumab Govitecan-hziy	96,345	1	6	13	13	1,044	11.8	14.1
Female	86,031	1	6	13	13	1,044	11.8	13.6
Male	10,314	1	6	13	13	909	12.0	17.6
Opicapone	7,865	1	3	6	18	1,145	23.0	61.5
Female	2,634	1	3	6	18	1,145	25.8	77.0
Male	5,231	1	3	6	19	776	21.6	51.9
Capmatinib	2,848	1	3	7	19	907	19.4	47.7
Female	1,630	1	3	7	19	907	18.0	40.3
Male	1,218	1	3	8	19	846	21.3	56.1
Selpercatinib	2,172	1	3	7	18	846	19.1	48.1
Female	1,016	1	3	7	18	846	19.9	48.7
Male	1,156	1	3	7	18	765	18.4	47.6
Ripretinib	1,181	1	3	6	15	479	17.1	36.9
Female	633	1	3	7	18	479	17.7	35.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	548	1	2	5	13	332	16.3	38.5
Fluoroestradiol F18	425	3	100	139	209	1,273	176.6	120.8
Female	*****	3	100	139	209	1,273	177.2	121.4
Male	*****	34	125	140	183	183	134.2	55.3
Artesunate	*****	1	5	6	11	18	7.7	5.4
Female	*****	1	5	6	11	18	7.7	5.4
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Inebilizumab-cdon	989	1	15	176	184	742	133.6	93.9
Female	844	1	16	179	184	742	134.6	92.7
Male	145	1	14	167	182	727	127.6	101.1
Lurbinectedin	27,308	1	20	20	21	622	23.1	12.5
Female	14,398	1	20	20	21	622	23.1	12.7
Male	12,910	1	20	20	21	364	23.1	12.2
Triheptanoin	552	1	4	8	19	1,118	21.5	59.6
Female	274	1	4	10	21	1,118	26.4	80.0
Male	278	1	3	7	16	201	16.6	26.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	1,171	1	3	6	14	760	25.2	71.2
0-17 years	*****	1	1	4	7	14	5.2	5.0
18-24 years	*****	1	5	6	11	254	28.5	68.7
25-40 years	99	1	3	5	15	551	21.9	67.6
41-64 years	456	1	3	6	13	624	19.2	55.5
≥ 65 years	597	1	2	6	16	760	30.4	81.8
Teprotumumab-Trbw	34,738	1	20	20	20	1,437	27.3	54.0
0-17 years	12	18	20	20	23	27	21.3	2.6
18-24 years	347	3	20	20	22	629	28.1	46.3
25-40 years	3,025	1	20	20	21	795	24.9	32.1
41-64 years	12,866	1	20	20	21	1,369	26.8	49.5
≥ 65 years	18,488	1	20	20	20	1,437	28.0	59.8
Tazemetostat	830	1	3	5	16	360	17.8	40.1
0-17 years	21	1	2	5	20	116	20.1	33.1
18-24 years	33	1	2	8	18	54	12.8	14.2
25-40 years	72	1	2	5	12	261	16.6	38.6
41-64 years	186	1	2	6	15	242	12.6	23.3
≥ 65 years	518	1	3	5	17	360	20.0	45.9
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	113,526	1	3	8	25	1,382	29.3	72.4
0-17 years	*****	26	26	26	26	26	26.0	NaN
18-24 years	*****	1	7	15	64	373	50.8	82.1
25-40 years	1,740	1	3	9	26	963	29.9	68.7
41-64 years	35,278	1	3	8	25	1,382	29.7	73.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	76,461	1	3	8	25	1,331	29.0	71.9
Eptinezumab-jjmr	51,417	1	83	90	94	1,625	94.4	53.7
0-17 years	106	1	83	90	94	1,183	103.4	117.9
18-24 years	1,475	1	83	90	96	1,163	95.6	58.8
25-40 years	7,910	1	83	90	94	1,172	93.9	55.7
41-64 years	23,321	1	83	90	94	1,625	93.9	55.9
≥ 65 years	18,605	1	84	90	93	1,245	95.1	48.9
Amisulpride	218	1	46	118	204	592	143.4	117.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	142	142	211	279	279	210.5	96.9
25-40 years	*****	4	52	100	195	552	132.3	114.8
41-64 years	98	2	55	136	213	522	156.3	121.3
≥ 65 years	74	1	41	105	195	592	131.2	114.1
Rimegepant	700,500	1	9	23	53	1,608	49.0	85.6
0-17 years	3,504	1	8	23	56	1,327	52.8	92.1
18-24 years	30,826	1	10	26	60	1,509	53.3	87.4
25-40 years	187,673	1	9	23	51	1,608	46.9	81.6
41-64 years	386,223	1	9	22	52	1,574	47.8	83.3
≥ 65 years	92,274	1	8	23	60	1,529	56.8	100.3
Isatuximab	35,386	1	12	13	13	1,040	14.1	19.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	18	5	6	13	13	21	10.5	4.4
25-40 years	82	6	6	13	13	63	12.5	8.4
41-64 years	6,643	1	12	13	13	994	14.3	20.9
≥ 65 years	28,643	1	12	13	13	1,040	14.0	19.6
Osilodrostat	1,034	1	3	7	19	776	20.9	49.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	44	1	3	7	17	370	23.9	57.9
25-40 years	163	1	4	7	17	579	19.0	49.5

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	408	1	4	9	23	776	25.9	63.4
≥ 65 years	419	1	2	6	18	223	16.4	27.3
Ozanimod	6,909	1	2	5	13	1,201	14.8	41.2
0-17 years	13	1	2	5	6	22	5.6	5.5
18-24 years	319	1	2	6	14	468	16.5	40.9
25-40 years	2,017	1	3	6	13	916	14.5	41.1
41-64 years	3,840	1	2	5	12	1,201	14.8	43.5
≥ 65 years	720	1	3	6	15	315	15.1	27.4
Selumetinib	1,987	1	3	7	18	1,275	19.8	59.1
0-17 years	1,273	1	3	7	18	1,029	17.5	46.4
18-24 years	260	1	4	7	18	1,275	29.2	109.5
25-40 years	298	1	3	6	21	630	20.5	51.8
41-64 years	135	1	4	9	24	284	22.5	42.6
≥ 65 years	21	1	4	12	22	120	18.0	25.6
Tucatinib	4,776	1	3	7	18	1,028	20.4	53.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	7	28	33	33	22.7	13.8
25-40 years	*****	1	3	6	14	801	19.5	59.1
41-64 years	2,620	1	3	7	19	1,028	20.8	52.9
≥ 65 years	1,600	1	3	7	18	967	19.9	53.4
Pemigatinib	1,378	1	3	7	11	526	12.4	29.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	83	1	4	7	10	66	9.0	9.5
41-64 years	514	1	4	7	11	526	12.5	32.7
≥ 65 years	781	1	3	7	11	387	12.7	28.6
Sacituzumab Govitecan-hziy	96,345	1	6	13	13	1,044	11.8	14.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	6	6	13	20	22	12.6	6.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	3,590	1	6	13	13	155	11.7	9.2
41-64 years	30,317	1	6	13	13	671	11.9	13.1
≥ 65 years	62,422	1	6	13	13	1,044	11.7	14.7
Opicapone	7,865	1	3	6	18	1,145	23.0	61.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	37	1	2	4	9	704	32.2	116.8
41-64 years	1,214	1	2	6	16	977	20.0	57.7
≥ 65 years	6,614	1	3	7	19	1,145	23.5	61.7
Capmatinib	2,848	1	3	7	19	907	19.4	47.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	9	14	18	22	13.3	6.2
41-64 years	*****	1	3	7	15	219	14.5	24.7
≥ 65 years	2,501	1	3	7	20	907	20.1	50.0
Selpercatinib	2,172	1	3	7	18	846	19.1	48.1
0-17 years	15	2	4	7	11	44	9.7	10.4
18-24 years	30	2	6	16	42	591	43.3	106.5
25-40 years	194	1	3	8	23	765	21.3	59.6
41-64 years	745	1	3	6	15	372	15.8	33.3
≥ 65 years	1,188	1	3	7	19	846	20.4	51.6
Ripretinib	1,181	1	3	6	15	479	17.1	36.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	14	31	42	18.5	16.9
25-40 years	*****	1	5	10	23	282	24.2	42.8
41-64 years	378	1	3	6	15	298	14.9	30.2
≥ 65 years	734	1	2	6	15	479	17.5	39.4
Fluoroestradiol F18	425	3	100	139	209	1,273	176.6	120.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	47	130	172	174	109.3	80.7
41-64 years	*****	34	95	132	209	1,273	171.8	141.1
≥ 65 years	326	39	104	140	209	709	178.8	114.6
Artesunate	*****	1	5	6	11	18	7.7	5.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	5	6	11	18	7.7	5.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Inebilizumab-cdon	989	1	15	176	184	742	133.6	93.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	12	18	176	181	191	129.5	77.1
25-40 years	153	3	13	175	183	727	125.4	99.6
41-64 years	426	1	18	175	183	742	136.0	90.5
≥ 65 years	393	1	15	178	184	660	134.3	96.1
Lurbinectedin	27,308	1	20	20	21	622	23.1	12.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	22	55	60	31.9	17.7
25-40 years	*****	18	20	20	23	48	23.6	7.5
41-64 years	5,951	1	20	20	21	276	23.2	10.3
≥ 65 years	21,291	1	20	20	21	622	23.1	13.0
Triheptanoin	552	1	4	8	19	1,118	21.5	59.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
0-17 years	349	1	3	8	18	1,118	19.5	64.5
18-24 years	72	1	4	10	22	164	21.0	31.8
25-40 years	40	3	6	18	56	310	40.3	61.0
41-64 years	24	1	7	11	16	149	19.1	31.3
≥ 65 years	67	1	2	6	13	481	21.5	61.8

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Avapritinib</i>	377	1	3	6	26	698	36.6	95.1
<i>Teprotumumab-Trbw</i>	6,093	1	20	20	20	1,369	23.7	38.3
<i>Tazemetostat</i>	274	1	3	6	18	351	22.3	49.0
<i>Lactitol</i>	0	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	33,710	1	3	10	31	1,382	38.7	95.3
<i>Eptinezumab-jjmr</i>	12,923	1	83	90	95	1,625	96.3	67.6
<i>Amisulpride</i>	203	1	49	118	206	592	145.3	118.4
<i>Rimegepant</i>	163,915	1	10	27	71	1,608	65.9	114.3
<i>Isatuximab</i>	2,592	1	6	6	7	532	9.2	17.6
<i>Osilodrostat</i>	263	1	3	10	30	776	28.6	64.3
<i>Ozanimod</i>	2,040	1	3	6	15	1,201	18.8	55.4
<i>Selumetinib</i>	563	1	4	9	22	1,275	25.7	72.6
<i>Tucatinib</i>	1,653	1	3	8	20	1,028	23.4	63.2
<i>Pemigatinib</i>	341	1	2	6	11	338	14.2	35.0
<i>Sacituzumab Govitecan-hziy</i>	8,803	1	6	6	13	269	10.4	10.1
<i>Opicapone</i>	2,310	1	3	8	22	1,145	33.5	91.0
<i>Capmatinib</i>	906	1	3	7	20	907	19.8	48.4
<i>Selpercatinib</i>	551	1	3	8	25	429	21.2	41.9
<i>Ripretinib</i>	360	1	3	6	19	479	19.5	41.3
<i>Fluoroestradiol F18</i>	251	3	111	153	238	1,273	193.6	138.0
<i>Artesunate</i>	*****	18	18	18	18	18	18.0	NaN
<i>Flortaucipir F18</i>	0	-	-	-	-	-	-	-
<i>Inebilizumab-cdon</i>	380	1	13	14	155	518	65.7	85.7
<i>Lurbinectedin</i>	6,245	1	20	20	21	298	23.0	10.8
<i>Triheptanoin</i>	133	1	4	8	19	1,118	30.2	107.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	377	1	3	6	26	698	36.6	95.1
Female	202	1	3	6	29	624	39.8	99.3
Male	175	1	3	6	21	698	33.0	90.2
Teprotumumab-Trbw	6,093	1	20	20	20	1,369	23.7	38.3
Female	4,689	1	20	20	21	1,369	23.8	38.3
Male	1,404	1	20	20	20	1,116	23.3	38.2
Tazemetostat	274	1	3	6	18	351	22.3	49.0
Female	130	1	3	7	18	351	24.9	56.7
Male	144	1	3	5	16	293	19.9	41.0
Lactitol	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Bempedoic Acid	33,710	1	3	10	31	1,382	38.7	95.3
Female	19,590	1	4	10	33	1,323	41.0	99.3
Male	14,120	1	3	9	29	1,382	35.5	89.4
Eptinezumab-jjmr	12,923	1	83	90	95	1,625	96.3	67.6
Female	10,947	1	83	90	95	1,625	96.3	68.1
Male	1,976	1	83	90	93	1,280	95.8	64.4
Amisulpride	203	1	49	118	206	592	145.3	118.4
Female	178	1	55	118	202	592	146.2	120.2
Male	25	7	34	130	227	370	138.9	106.7
Rimegepant	163,915	1	10	27	71	1,608	65.9	114.3
Female	142,010	1	10	28	71	1,608	65.7	113.7
Male	21,905	1	9	26	71	1,570	67.2	118.3
Isatuximab	2,592	1	6	6	7	532	9.2	17.6
Female	1,235	3	6	6	7	358	9.1	15.6
Male	1,357	1	6	6	7	532	9.3	19.3
Osilodrostat	263	1	3	10	30	776	28.6	64.3
Female	204	1	3	10	30	370	27.0	48.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	59	1	3	9	29	776	34.4	102.6
Ozanimod	2,040	1	3	6	15	1,201	18.8	55.4
Female	1,310	1	3	7	16	1,201	19.8	59.4
Male	730	1	2	6	14	535	17.0	47.2
Selumetinib	563	1	4	9	22	1,275	25.7	72.6
Female	273	1	4	10	23	1,275	32.7	98.1
Male	290	1	3	9	22	284	19.0	33.0
Tucatinib	1,653	1	3	8	20	1,028	23.4	63.2
Female	1,580	1	3	8	21	1,028	24.0	64.5
Male	73	1	2	5	12	58	10.2	12.2
Pemigatinib	341	1	2	6	11	338	14.2	35.0
Female	207	1	2	6	11	251	11.7	26.3
Male	134	1	2	5	12	338	18.1	45.2
Sacituzumab Govitecan-hziy	8,803	1	6	6	13	269	10.4	10.1
Female	7,675	1	6	6	13	269	10.4	9.7
Male	1,128	4	6	6	13	238	10.5	12.4
Opicapone	2,310	1	3	8	22	1,145	33.5	91.0
Female	800	1	3	8	23	1,145	42.0	120.3
Male	1,510	1	3	8	22	776	29.0	70.3
Capmatinib	906	1	3	7	20	907	19.8	48.4
Female	516	1	3	7	20	907	19.5	52.1
Male	390	1	3	8	19	532	20.2	43.1
Selpercatinib	551	1	3	8	25	429	21.2	41.9
Female	268	1	3	8	21	429	21.1	47.3
Male	283	1	3	8	27	372	21.4	36.2
Ripretinib	360	1	3	6	19	479	19.5	41.3
Female	177	1	3	8	25	479	23.9	49.7
Male	183	1	2	5	14	292	15.3	30.6
Fluoroestradiol F18	251	3	111	153	238	1,273	193.6	138.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	*****	3	111	153	242	1,273	194.5	138.7
Male	*****	34	94	168	183	183	138.3	70.9
Artesunate	*****	18	18	18	18	18	18.0	NaN
Female	*****	18	18	18	18	18	18.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Inebilizumab-cdon	380	1	13	14	155	518	65.7	85.7
Female	329	1	13	14	167	518	68.6	87.5
Male	51	1	13	13	22	308	47.1	70.9
Lurbinectedin	6,245	1	20	20	21	298	23.0	10.8
Female	3,192	1	20	20	21	174	22.8	8.9
Male	3,053	1	20	20	21	298	23.2	12.5
Triheptanoin	133	1	4	8	19	1,118	30.2	107.7
Female	68	1	5	10	23	1,118	43.8	148.2
Male	65	1	3	8	18	127	15.9	22.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	377	1	3	6	26	698	36.6	95.1
0-17 years	*****	1	4	7	11	14	7.0	5.4
18-24 years	*****	6	8	10	28	46	17.8	18.9
25-40 years	*****	1	3	5	25	551	29.0	94.9
41-64 years	124	1	3	6	27	624	35.3	94.6
≥ 65 years	212	1	2	7	27	698	39.5	97.4
Teprotumumab-Trbw	6,093	1	20	20	20	1,369	23.7	38.3
0-17 years	*****	20	20	20	20	20	20.0	0.0
18-24 years	*****	3	20	20	22	124	23.1	14.5
25-40 years	568	1	20	20	21	397	23.7	24.0
41-64 years	2,271	1	20	20	21	1,369	24.8	44.4
≥ 65 years	3,187	1	20	20	20	1,116	22.9	36.0
Tazemetostat	274	1	3	6	18	351	22.3	49.0
0-17 years	*****	1	3	9	46	103	26.1	34.9
18-24 years	*****	1	2	3	12	54	10.9	17.2
25-40 years	27	1	2	4	12	261	26.0	57.3
41-64 years	55	1	2	5	18	107	15.5	23.7
≥ 65 years	174	1	3	7	18	351	24.2	55.0
Lactitol	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Bempedoic Acid	33,710	1	3	10	31	1,382	38.7	95.3
0-17 years	*****	26	26	26	26	26	26.0	NaN
18-24 years	*****	1	9	20	97	373	61.0	89.3
25-40 years	506	1	3	11	36	963	38.2	86.7
41-64 years	10,314	1	4	10	32	1,382	39.0	94.5

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	22,867	1	3	10	31	1,321	38.6	95.9
Eptinezumab-jjmr	12,923	1	83	90	95	1,625	96.3	67.6
0-17 years	27	14	83	90	94	1,183	128.2	211.5
18-24 years	417	1	83	90	97	1,163	101.6	85.3
25-40 years	2,133	1	83	90	95	1,172	93.8	52.1
41-64 years	5,958	1	83	90	96	1,625	96.6	72.5
≥ 65 years	4,388	1	84	90	94	1,245	96.4	63.5
Amisulpride	203	1	49	118	206	592	145.3	118.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	142	142	211	279	279	210.5	96.9
25-40 years	*****	4	55	104	206	552	137.4	115.1
41-64 years	88	2	64	141	214	522	159.9	122.6
≥ 65 years	71	1	41	106	195	592	130.3	114.9
Rimegepant	163,915	1	10	27	71	1,608	65.9	114.3
0-17 years	992	1	9	28	73	1,327	66.2	113.9
18-24 years	8,613	1	11	32	77	1,509	67.0	106.8
25-40 years	44,753	1	10	27	66	1,608	60.8	105.7
41-64 years	85,670	1	10	27	69	1,574	64.2	111.5
≥ 65 years	23,887	1	10	30	89	1,500	81.3	138.5
Isatuximab	2,592	1	6	6	7	532	9.2	17.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	5	5	6	6	6	5.5	0.7
25-40 years	*****	6	6	6	7	19	8.0	4.2
41-64 years	519	1	6	6	12	271	10.2	16.8
≥ 65 years	2,062	2	6	6	7	532	9.0	17.9
Osilodrostat	263	1	3	10	30	776	28.6	64.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	4	10	47	370	59.9	118.0
25-40 years	*****	1	4	8	26	103	20.5	25.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	114	1	3	12	30	776	36.2	85.6
≥ 65 years	104	1	3	8	24	156	20.5	30.1
Ozanimod	2,040	1	3	6	15	1,201	18.8	55.4
0-17 years	*****	1	1	5	7	9	4.6	3.6
18-24 years	*****	1	2	6	13	303	13.7	31.8
25-40 years	571	1	3	6	14	916	18.7	58.5
41-64 years	1,120	1	3	6	16	1,201	19.7	59.1
≥ 65 years	235	1	3	7	15	315	17.2	34.5
Selumetinib	563	1	4	9	22	1,275	25.7	72.6
0-17 years	352	1	4	8	19	543	19.8	45.5
18-24 years	76	1	3	9	26	1,275	46.4	156.9
25-40 years	78	1	5	13	30	278	27.5	46.8
41-64 years	46	1	3	10	45	284	34.1	59.4
≥ 65 years	11	1	4	14	29	120	22.9	34.0
Tucatinib	1,653	1	3	8	20	1,028	23.4	63.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	28	31	33	33	30.5	3.5
25-40 years	*****	1	3	6	16	425	18.8	41.1
41-64 years	906	1	3	8	21	1,028	22.9	58.0
≥ 65 years	547	1	4	8	20	967	25.8	76.7
Pemigatinib	341	1	2	6	11	338	14.2	35.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	1	1	4	12	66	8.8	14.6
41-64 years	120	1	2	6	14	251	16.0	38.2
≥ 65 years	202	1	2	5	10	338	13.7	34.4
Sacituzumab Govitecan-hziy	8,803	1	6	6	13	269	10.4	10.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	13	13	18	22	22	17.5	6.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	*****	1	6	6	13	97	11.3	10.8
41-64 years	2,939	1	6	6	13	118	10.7	8.7
≥ 65 years	5,470	1	6	6	13	269	10.2	10.7
Opicapone	2,310	1	3	8	22	1,145	33.5	91.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	2	4	14	704	86.0	232.0
41-64 years	*****	1	3	7	21	977	30.2	88.7
≥ 65 years	1,969	1	3	8	22	1,145	33.8	90.3
Capmatinib	906	1	3	7	20	907	19.8	48.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	4	5	17	17	8.7	7.2
41-64 years	*****	1	4	7	15	150	14.9	23.3
≥ 65 years	772	1	3	7	20	907	20.7	51.5
Selpercatinib	551	1	3	8	25	429	21.2	41.9
0-17 years	*****	12	12	18	44	44	24.7	17.0
18-24 years	*****	4	7	14	36	98	26.6	33.1
25-40 years	41	1	3	8	24	106	18.7	23.9
41-64 years	185	1	3	7	16	372	19.3	41.3
≥ 65 years	314	1	3	8	26	429	22.5	44.5
Ripretinib	360	1	3	6	19	479	19.5	41.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	4	4	4	4	4.0	NaN
25-40 years	*****	3	6	13	29	84	23.2	25.3
41-64 years	114	1	3	5	16	292	16.2	34.1
≥ 65 years	230	1	2	6	21	479	21.0	45.3
Fluoroestradiol F18	251	3	111	153	238	1,273	193.6	138.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	47	130	172	174	109.3	80.7
41-64 years	*****	34	104	139	251	1,273	196.5	175.0
≥ 65 years	192	39	111	157	238	709	194.5	126.5
Artesunate	*****	18	18	18	18	18	18.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	18	18	18	18	18	18.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Flortaucipir F18	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Inebilizumab-cdon	380	1	13	14	155	518	65.7	85.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	12	13	14	18	181	42.0	68.1
25-40 years	*****	3	13	13	138	308	62.8	84.5
41-64 years	154	1	13	15	167	374	66.8	84.4
≥ 65 years	152	1	13	14	158	518	66.9	88.6
Lurbinectedin	6,245	1	20	20	21	298	23.0	10.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	20	20	22	26	26	22.7	3.1
25-40 years	*****	20	20	20	34	48	26.7	10.3
41-64 years	1,436	1	20	20	22	174	23.3	10.7
≥ 65 years	4,787	1	20	20	21	298	22.9	10.9
Triheptanoin	133	1	4	8	19	1,118	30.2	107.7

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
0-17 years	92	1	4	9	15	1,118	28.4	117.5
18-24 years	17	2	4	6	23	60	15.6	19.3
25-40 years	*****	3	12	25	43	234	45.9	72.2
41-64 years	*****	1	3	9	13	19	8.8	6.6
≥ 65 years	*****	2	3	4	32	481	74.6	158.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025^{1,2}

Censoring Reason									
		End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Avapritinib</i>	1,835	1,807	98.5%	0	0.0%	341	18.6%	258	14.1%
<i>Teprotumumab-Trbw</i>	41,418	41,416	100.0%	0	0.0%	174	0.4%	134	0.3%
<i>Tazemetostat</i>	1,332	1,299	97.5%	0	0.0%	130	9.8%	85	6.4%
<i>Lactitol</i>	0	-	-	-	-	-	-	-	-
<i>Bempedoic Acid</i>	177,944	177,556	99.8%	0	0.0%	29,786	16.7%	21,297	12.0%
<i>Eptinezumab-jjmr</i>	69,651	69,644	100.0%	0	0.0%	775	1.1%	555	0.8%
<i>Amisulpride</i>	8,169	8,169	100.0%	0	0.0%	17	0.2%	20	0.2%
<i>Rimegepant</i>	969,518	969,235	100.0%	0	0.0%	70,721	7.3%	43,286	4.5%
<i>Isatuximab</i>	38,229	38,217	100.0%	0	0.0%	62	0.2%	57	0.1%
<i>Osilodrostat</i>	1,573	1,549	98.5%	0	0.0%	293	18.6%	199	12.7%
<i>Ozanimod</i>	10,496	10,486	99.9%	0	0.0%	2,066	19.7%	1,137	10.8%
<i>Selumetinib</i>	2,931	2,924	99.8%	0	0.0%	544	18.6%	416	14.2%
<i>Tucatinib</i>	7,783	7,637	98.1%	0	0.0%	867	11.1%	495	6.4%
<i>Pemigatinib</i>	1,929	1,897	98.3%	0	0.0%	118	6.1%	74	3.8%
<i>Sacituzumab Govitecan-hziy</i>	106,014	106,009	100.0%	0	0.0%	159	0.1%	143	0.1%
<i>Opicapone</i>	12,408	12,253	98.8%	0	0.0%	1,452	11.7%	1,084	8.7%
<i>Capmatinib</i>	4,548	4,390	96.5%	0	0.0%	422	9.3%	289	6.4%
<i>Selpercatinib</i>	3,096	3,025	97.7%	0	0.0%	463	15.0%	320	10.3%
<i>Ripretinib</i>	1,797	1,752	97.5%	0	0.0%	170	9.5%	119	6.6%
<i>Fluoroestradiol F18</i>	2,216	*****	*****	0	0.0%	*****	*****	*****	*****
<i>Artesunate</i>	14	14	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Flortaucipir F18</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025^{1,2}

Censoring Reason								
	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Inebilizumab-cdon</i>	1,460	99.9%	0	0.0%	37	2.5%	25	1.7%
<i>Lurbinectedin</i>	35,276	100.0%	0	0.0%	55	0.2%	45	0.1%
<i>Triheptanoin</i>	734	99.7%	0	0.0%	116	15.8%	85	11.6%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Avapritinib		Teprotumumab-Trbw		Tazemetostat		Lactitol	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	290,664,364	N/A ¹	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event								
Had any cohort-defining claim during the query period	767	217,101,446	7,167	217,095,046	562	217,101,651	0	217,102,213
Claim recorded during specified age range	767	0	7,167	0	562	0	0	0
Episode defining index claim recorded during the query period	767	0	7,167	0	562	0	0	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	664	103	6,680	487	502	60	0	0
Met inclusion and exclusion criteria	664	0	6,680	0	502	0	0	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	664	0	6,680	0	502	0	0	0
Final cohort								
Number of members	664	N/A	6,680	N/A	502	N/A	0	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Bempedoic Acid		Eptinezumab-jjmr		Amisulpride		Rimegepant	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event								
Had any cohort-defining claim during the query period	72,878	217,029,335	20,038	217,082,175	9,043	217,093,170	309,354	216,792,859
Claim recorded during specified age range	72,878	0	20,038	0	9,043	0	309,354	0
Episode defining index claim recorded during the query period	72,878	0	20,038	0	9,043	0	309,354	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	64,418	8,460	18,234	1,804	7,951	1,092	269,018	40,336
Met inclusion and exclusion criteria	64,418	0	18,234	0	7,951	0	269,018	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	64,418	0	18,234	0	7,951	0	269,018	0
Final cohort								
Number of members	64,418	N/A	18,234	N/A	7,951	N/A	269,018	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Isatuximab		Osilodrostat		Ozanimod		Selumetinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event								
Had any cohort-defining claim during the query period	3,012	217,099,201	610	217,101,603	4,337	217,097,876	1,042	217,101,171
Claim recorded during specified age range	3,012	0	610	0	4,337	0	1,042	0
Episode defining index claim recorded during the query period	3,012	0	610	0	4,337	0	1,042	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	2,843	169	539	71	3,587	750	944	98
Met inclusion and exclusion criteria	2,843	0	539	0	3,587	0	944	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	2,843	0	539	0	3,587	0	944	0
Final cohort								
Number of members	2,843	N/A	539	N/A	3,587	N/A	944	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Tucatinib		Pemigatinib		Sacituzumab Govitecan-hziy		Opicapone	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event								
Had any cohort-defining claim during the query period	3,504	217,098,709	626	217,101,587	10,739	217,091,474	5,034	217,097,179
Claim recorded during specified age range	3,504	0	626	0	10,739	0	5,034	0
Episode defining index claim recorded during the query period	3,504	0	626	0	10,739	0	5,034	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	3,007	497	551	75	9,669	1,070	4,543	491
Met inclusion and exclusion criteria	3,007	0	551	0	9,669	0	4,543	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	3,007	0	551	0	9,669	0	4,543	0
Final cohort								
Number of members	3,007	N/A	551	N/A	9,669	N/A	4,543	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Capmatinib		Selpercatinib		Ripretinib		Fluoroestradiol F18	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event								
Had any cohort-defining claim during the query period	1,903	217,100,310	1,079	217,101,134	693	217,101,520	1,977	217,100,236
Claim recorded during specified age range	1,903	0	1,079	0	693	0	1,977	0
Episode defining index claim recorded during the query period	1,903	0	1,079	0	693	0	1,977	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,700	203	924	155	616	77	1,791	186
Met inclusion and exclusion criteria	1,700	0	924	0	616	0	1,791	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,700	0	924	0	616	0	1,791	0
Final cohort								
Number of members	1,700	N/A	924	N/A	616	N/A	1,791	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

	Artesunate		Flortaucipir F18		Inebilizumab-cdon		Lurbinectedin		Triheptanoin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements										
Enrolled at any point during the query period	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A	290,664,364	N/A
Had required coverage type (medical and/or drug coverage)	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518	217,192,846	73,471,518
Enrolled during specified age range	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916	217,186,930	5,916
Had requestable medical charts	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0	217,186,930	0
Met demographic requirements (sex, race, and Hispanic origin)	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717	217,102,213	84,717
Members with a valid index event										
Had any cohort-defining claim during the query period	*****	*****	11	217,102,202	538	217,101,675	8,821	217,093,392	211	217,102,002
Claim recorded during specified age range	*****	0	11	0	538	0	8,821	0	211	0
Episode defining index claim recorded during the query period	*****	0	11	0	538	0	8,821	0	211	0
Members with required pre-index history										
Had sufficient pre-index continuous enrollment	*****	*****	*****	*****	471	67	7,968	853	182	29
Met inclusion and exclusion criteria	*****	0	*****	0	471	0	7,968	0	182	0
Members with required post-index follow-up										
Had sufficient post-index continuous enrollment	*****	0	*****	0	471	0	7,968	0	182	0
Final cohort										
Number of members	*****	N/A	*****	N/A	471	N/A	7,968	N/A	182	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Avapritinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on January 9, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1b. Patient Entry into Study by Month for Teprotumumab-Trbw in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on January 21, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1c. Patient Entry into Study by Month for Tazemetostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on January 23, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1d. Patient Entry into Study by Month for Lactitol in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025




*The FDA approval date for this drug was on February 12, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

There was no use during the query period.


Figure 1e. Patient Entry into Study by Month for Bempedoic Acid in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on February 21, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1f. Patient Entry into Study by Month for Eptinezumab-jjmr in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on February 21, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>


Figure 1g. Patient Entry into Study by Month for Amisulpride in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on February 26, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for Rimegepant in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on February 27, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1i. Patient Entry into Study by Month for Isatuximab in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on March 2, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1j. Patient Entry into Study by Month for Osilodrostat in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on March 6, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1k. Patient Entry into Study by Month for Ozanimod in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on March 25, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1I. Patient Entry into Study by Month for Selumetinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on April 10, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1m. Patient Entry into Study by Month for Tucatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on April 17, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*


Figure 1n. Patient Entry into Study by Month for Pemigatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on April 17, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1o. Patient Entry into Study by Month for Sacituzumab Govitecan-hziy in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on April 22, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1p. Patient Entry into Study by Month for Opicapone in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on April 24, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1q. Patient Entry into Study by Month for Capmatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 6, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1r. Patient Entry into Study by Month for Selpercatinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 8, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1s. Patient Entry into Study by Month for Ripretinib in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 15, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1t. Patient Entry into Study by Month for Fluoroestradiol F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 20, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1u. Patient Entry into Study by Month for Artesunate in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 26, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1v. Patient Entry into Study by Month for Flortaucipir F18 in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on May 28, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1w. Patient Entry into Study by Month for Inebilizumab-cdon in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on June 11, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

******Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1x. Patient Entry into Study by Month for Lurbinectedin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025



*The FDA approval date for this drug was on June 15, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

Figure 1y. Patient Entry into Study by Month for Triheptanoin in the Sentinel Distributed Database from January 1, 2020 to April 30, 2025

*The FDA approval date for this drug was on June 30, 2020, as listed on the FDA website:

<https://web.archive.org/web/20240430031332/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2020>

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	01/31/2024
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	03/31/2025
DP04	01/01/2006	10/31/2024
DP05	01/01/2010	09/30/2024
DP06	01/01/2004	03/31/2024
DP07	01/01/2000	04/30/2024
DP08	01/01/2007	10/31/2024
DP09	01/01/2000	01/31/2024
DP10	01/01/2008	08/31/2024
DP11	01/01/2000	04/30/2025
DP12	01/01/2000	04/30/2024
DP13	01/01/2014	12/31/2021

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Avapritinib	
avapritinib	Ayvakit
Teprotumumab_Trbw	
teprotumumab-trbw	Tepezza
Tazemetostat	
tazemetostat hydrobromide	Tazverik
Lactitol	
LACTITOL	Pizensy
Bempedoic_Acid	
Bempedoic Acid	Nexletol
Bempedoic Acid and Ezetimibe	Nexlizet
bempedoic acid	Nexletol
bempedoic acid/ezetimibe	Nexlizet
Eptinezumab_jjmr	
eptinezumab-jjmr	Vyepti
Amisulpride	
amisulpride	Barhemsys
Rimegepant	
rimegepant sulfate	Nurtec ODT
Isatuximab	
isatuximab-irfc	Sarclisa
Osilodrostat	
osilodrostat phosphate	Isturisa
Ozanimod	
ozanimod hydrochloride	ZEPOSIA
ozanimod hydrochloride	Zeposia
ozanimod hydrochloride	Zeposia Starter Kit (28-day)
ozanimod hydrochloride	Zeposia Starter Kit (37-day)
ozanimod hydrochloride	Zeposia Starter Pack (7-day)
Selumetinib	
selumetinib sulfate	Koselugo
Tucatinib	
tucatinib	Tukysa
Pemigatinib	
pemigatinib	Pemazyre
Sacituzumab_Govitecan	
sacituzumab govitecan-hziy	Trodelvy

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Opicapone	
opicapone	Ongentys
Capmatinib	
capmatinib	TABRECTA
capmatinib hydrochloride	Tabrecta
Selpercatinib	
selpercatinib	Retevmo
Ripretinib	
ripretinib	Qinlock
Fluoroestradiol_F18	
fluoroestradiol F-18	Cerianna
Artesunate	
artesunate	artesunate
Flortaucipir_F18	
flortaucipir F-18	Tauvid
Inebilizumab_cdon	
inebilizumab-cdon	Uplizna
Lurbinectedin	
lurbinectedin	Zepzelca
Triheptanoin	
triheptanoin	Dojolvi

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Teprotumumab_Trbw			
C9061	Injection, teprotumumab-trbw, 10 mg	Procedure	HCPCS
J3241	Injection, teprotumumab-trbw, 10 mg	Procedure	HCPCS
Eptinezumab_jjmr			
C9063	Injection, eptinezumab-jjmr, 1 mg	Procedure	HCPCS
J3032	Injection, eptinezumab-jjmr, 1 mg	Procedure	HCPCS
Amisulpride			
C9153	Injection, amisulpride, 1 mg	Procedure	HCPCS
J0184	Injection, amisulpride, 1 mg	Procedure	HCPCS
Isatuximab			
J9227	Injection, isatuximab-irfc, 10 mg	Procedure	HCPCS
Sacituzumab_Govitecan			
C9066	Injection, sacituzumab govitecan-hziy, 2.5 mg	Procedure	HCPCS
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg	Procedure	HCPCS
Fluoroestradiol_F18			
A9591	Fluoroestradiol F-18, diagnostic, 1 mCi	Procedure	HCPCS
C9060	Fluoroestradiol F18, diagnostic, 1 mci	Procedure	HCPCS
Artesunate			
J0391	Injection, artesunate, 1 mg	Procedure	HCPCS
Flortaucipir_F18			
A9601	Flortaucipir F-18 injection, diagnostic, 1 mCi	Procedure	HCPCS
Inebilizumab_cdon			
J1823	Injection, inebilizumab-cdon, 1 mg	Procedure	HCPCS
XW03398	Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
XW04398	Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8	Procedure	ICD-10-PCS
Lurbinectedin			
J9223	Injection, lurbinectedin, 0.1 mg	Procedure	HCPCS
XW03387	Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	Procedure	ICD-10-PCS
XW04387	Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnesic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acute Myocardial Infarction			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Atrial Fibrillation			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Breast Cancer			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal Cancer			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depression			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Lung Cancer			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM

Obesity

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00X A	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011 A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012 A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.019 A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021 A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022 A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029 A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031 A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032 A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039 A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041 A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042 A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049 A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051 A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052 A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059 A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061 A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062 A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069 A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071 A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.072 A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079 A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08X A	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AX A	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80X A	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811 A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812 A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819 A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821 A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822 A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829 A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831 A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832 A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839 A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841 A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842 A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849 A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.851 A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852 A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859 A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861 A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862 A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869 A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871 A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872 A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879 A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88X A	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AX A	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

Non-Proprietary Name	Proprietary Name
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

Appendix F.1 Specifications Defining Parameters in this Request

Specifications for Type 5 Request: cder_mpl1r_wp310

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2020 in the Sentinel Distributed Database (SDD).

Query period: 01/01/2020 - 04/30/2025
Coverage requirement: Medical and Drug Coverage
Minimum Pre-Index Enrollment Days: 183 days
Minimum Post-Index Required Days: 0 days
Enrollment Gap: 45 days
Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Sex: M, F
Other Demographic Restrictions: n/a
Stratifications: Age group, Sex, Calendar Month (for Figures only)
Data Restrictions: None
Chart Availability Restriction Indicator: N
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: N
Drop Censor Output Indicator: Yes (Indicates if counts of episodes censored by death and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure

Scenario	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	Avapritinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
2	Teprotumumab-Trbw	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Tazemetostat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Lactitol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
5	Bempedoic Acid	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Eptinezumab-jjmr	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Amisulpride	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
8	Rimegepant	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	Isatuximab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	Osilodrostat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
11	Ozanimod	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Selumetinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	Tucatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
14	Pemigatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Sacituzumab Govitecan-hziy	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Opicapone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
17	Capmatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	Selpercatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	Ripretinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
20	Fluoroestradiol F18	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	Artesunate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	Flortaucipir F18	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F.1 Specifications Defining Parameters in this Request

Scenario	Index Exposure	Cohort definition	Exposure				Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
			Type 5 Exposure Washout Period	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap			
23	Inebilizumab-cdon	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	Lurbinectedin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	Triheptanoin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	Any	F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode.	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and CPT (Current Procedural Terminology) codes are provided by Optum360. National Drug Codes (NDCs) are checked against FirstDataBank's FDBMedKnowledge®									

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>									
Acute Myocardial Infarction	1	DX		IPP, IPS	1	-183	-1	N/A ¹	Y
Alzheimer's Disease	2	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	3	DX		Any	1	-183	-1	N/A	Y
Atrial Fibrillation	4	DX		IPP, IPS	1	-183	-1	N/A	Y
	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
Diabetes	7	DX		IP*, IS*	1	-183	-1	N/A	Y
	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	10	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
Hyperlipidemia	11	DX		IP*, IS*	1	-183	-1	N/A	Y
	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
Hypertension	14	DX		IP*, IS*	1	-183	-1	N/A	Y
	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	17	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	18	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	19	DX		Any	2	-183	-1	N/A	Y
Stroke/Transient Ischemic Attack (TIA)	20	DX		IP*	1	-183	-1	N/A	Y
	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y
Breast Cancer	23	DX		IP*, IS*	1	-183	-1	N/A	Y
	24	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A	Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	28	CC	26 or 27		1			N/A	Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A	Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	31	CC	29 or 30		1			N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
Lung Cancer	32	DX		IP*, IS*	1	-183	-1	N/A	Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	34	CC	32 or 33		1			N/A	Y
Endometrial Cancer	35	DX		IP*, IS*	1	-183	-1	N/A	Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	37	CC	35 or 36		1			N/A	Y
Acquired Hypothyroidism	38	DX		IP*, IS*,	1	-183	-1	N/A	Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	40	CC	38 or 39		1			N/A	Y
Anemia	41	DX		Any	1	-183	-1	N/A	Y
Asthma	42	DX		IP*, IS*,	1	-183	-1	N/A	Y
	43	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	44	CC	42 or 43		1			N/A	Y
Benign Prostatic Hyperplasia	45	DX		IP*, IS*,	1	-183	-1	N/A	Y
	46	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	47	CC	45 or 46		1			N/A	Y
Chronic Kidney Disease	48	DX		IP*, IS*,	1	-183	-1	N/A	Y
	49	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	50	CC	48 or 49		1			N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX		IP*, IS*,	1	-183	-1	N/A	Y
	52	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	53	CC	51 or 52		1			N/A	Y
Glaucoma	54	DX		AV*, ED*, OA*	1	-183	-1	N/A	Y
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
<i>Other</i>									
Obesity (Diagnosis or Procedure Codes)	58	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	59	RX		Any	1	-183	-1	N/A	Y
Overweight	60	DX		Any	1	-183	-1	N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (<i>only applies to RX codes</i>)	Lookback Period Date Only
Smoking (Diagnosis or Procedure Codes)	61	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	62	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	63	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	64	DX, PX		Any	1	-183	-1	N/A	Y
History of Cardiac Arrest	65	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	66	DX, PX		Any	1	-183	-1	N/A	Y
Liver Disease CCW	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or 81		1			N/A	Y

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (<i>only applies to RX codes</i>)	Lookback Period Date Only
Liver Disease Extended	83	DX		IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC	83 or 84		1			N/A	Y
	86	PX		AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC	86 and 87		1			N/A	Y
	89	PX		ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
	91	CC	89 and 90		1			N/A	Y
	92	PX		OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC	92 and 93		1			N/A	Y
	95	PX		IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y
	97	CC	95 and 96		1			N/A	Y
	98	CC	85 or 88 or 91 or 94 or 97		1			N/A	Y
		RX: Drug code DX: Diagnosis code PX: Procedure code CC: Complex covariates (multiple COVARNUM values are used to define a covariate)		IP*: inpatient hospital stays, any diagnoses IS*: non-acute institutional stays, any diagnoses ED*: emergency department encounters AV*: ambulatory visits OA*: other ambulatory visits		N: Lookback period should search for evidence of a date or an interval Y: Lookback period should search for evidence of a date only			

Appendix F.2 Specifications Defining Baseline Characteristics in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (<i>only applies to RX codes</i>)	Lookback Period Date Only

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.


¹N/A: Not Applicable

Appendix F.3 Specifications Defining Utilization Parameters in this Request

Utilization			
Medical Utilization Evaluation Period Start	Medical Utilization Evaluation Period End	Drug Utilization Evaluation Period Start	Drug Utilization Evaluation Period End
-183	-1	-183	-1

Appendix G. Design Diagrams of Cohort Entry Requirements in this Request

Cohort Design for Part 1 QF-9449¹



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² Scenarios defined on initiation of NMEs approved in 2020 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Race, Hispanic Ethnicity, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking, Liver Disease CCW, Liver Disease Extended

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date